

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Therapeutic effects of exercise interventions for patients with chronic kidney disease: an umbrella review of systematic reviews and meta-analyses

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054887
Article Type:	Original research
Date Submitted by the Author:	12-Jul-2021
Complete List of Authors:	Zhang, Fan; Long Hua Hospital, Department of Nephrology Zhang, Huachun; Long Hua Hospital, Department of Nephrology Bai, Yan; Shanghai University of Traditional Chinese Medicine, Longhua Clinical Medical College Zhao, Xing; Shanghai University of Traditional Chinese Medicine, Longhua Clinical Medical College Huang, Liuyan; Shanghai University of Traditional Chinese Medicine Wang, Weiqiong; Long Hua Hospital, Blood Purification Centre Zhou, Wenqin; Long Hua Hospital, Department of Nursing
Keywords:	Nephrology < INTERNAL MEDICINE, Rehabilitation medicine < INTERNAL MEDICINE, Chronic renal failure < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Therapeutic effects of exercise interventions for patients with chronic kidney disease: an**
4 **umbrella review of systematic reviews and meta-analyses**
5

6
7 Fan Zhang¹, Huachun Zhang², Yan Bai³, Xing Zhao³, Liuyan Huang¹, Weiqiong Wang⁴, Wenqin
8 Zhou².
9

10
11 1 Department of Nephrology, Longhua Hospital Shanghai University of Traditional Chinese
12 Medicine, ShangHai, 200032, China.
13

14
15 2 Department of Nursing, Longhua Hospital Shanghai University of Traditional Chinese
16 Medicine, ShangHai, 200032, China.
17

18
19 3 Longhua Clinical Medical College, Shanghai University of Traditional Chinese Medicine,
20 Shang Hai, 200032, China.
21

22
23 4 Blood Purification Centre, Longhua Hospital Shanghai University of Traditional Chinese
24 Medicine, ShangHai, 200032, China.
25

26 **Running Head:** Exercise for chronic kidney disease
27

28 **First author**
29

30 Fan Zhang, Department of Nephrology, No. 725, Wan Ping Nan Road, Xuhui District, Shanghai,
31 200032, P.R. China E-mail: fan_zhang1993@163.com
32

33
34 **Corresponding author**
35

36 Huachun Zhang, Department of Nursing, No. 725, Wan Ping Nan Road, Xuhui District, Shanghai,
37 200032, P.R. China, E-mail: lhhky@163.com
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective To conduct an overview of meta-analyses evaluating the impact of exercise interventions for improving health outcome in patients with chronic kidney disease (CKD).

Design An umbrella review of systematic review and meta-analyses of intervention trials was performed.

Data sources PubMed, the Web of Science, Embase, and the Cochrane Database of Systematic Reviews were searched for relevant articles.

Eligibility criteria for selecting studies Eligible meta-analyses compared the effects of usual care with and without exercise in CKD patients. Health outcomes included those related to cardiovascular risk factors, physical fitness, dialysis-related symptoms, and health-related quality of life. Systematic reviews and meta-analyses that included fewer than three RCTs or fewer than 100 participants were excluded from the analysis.

Results A total of 31 eligible systematic reviews and meta-analyses were included that assessed 120 outcomes. For physical fitness, there was a moderate effect size for cardiorespiratory fitness, muscle strength, and body composition, and a small effect size for muscle endurance. The effect sizes for cardiovascular risk factors, dialysis-related symptoms, and health-related quality of life outcomes were small. Most outcomes were scored as low or very low quality according to the Grading of Recommendations Assessment, Development and Evaluation framework.

Conclusion Exercise appears to be a safe way to affect concomitant cardiovascular risk factors, such as blood pressure, improve physical fitness and health-related quality of life, and reduce dialysis-related symptoms in CKD patients.

Ethics approval statement Ethics approval are not required as no private information from individuals is collected.

Dissemination The results will be published in a peer-reviewed journal or disseminated in relevant conferences.

Key words: Exercise, Chronic Kidney Disease, Systematic Review, Meta-Analyses

PROSPERO registration number CRD42020223591.

Strengths and limitations of this study

- 1) This overview provide a comprehensive summary of the therapeutic effects of exercise interventions for patients with chronic kidney disease.
- 2) Another strength of this overview allows us to identify the evidence base effect size are high or low.
- 3) The limitation of this overview is that language bias may exist in this review because the search strategy was limited to English.

For peer review only

INTRODUCTION

Chronic kidney disease (CKD) is a long-term condition characterized by the gradual loss of renal function over time.¹ In the past 30 years, the mortality attributed to CKD increased by 41.5%, a percentage rate that exceeds several cancers and cardiovascular diseases.² With the increasing incidence of hypertension, diabetes, and obesity, this number will continue to rise.^{3,4} CKD patients experience a high symptom burden with progressively impaired physical performance, leading to decreased kidney function, lower health-related quality of life (HRQOL), increased risk of cardiovascular events, and increased all-cause mortality.^{5,6}

Renal rehabilitation is a multifaceted intervention program. Rehabilitation consists of exercise interventions, diet control, fluid management, and psychological support to alleviate physical/mental deficiencies caused by kidney disease and renal replacement therapy, in order to improve disease prognosis and to prolong life expectancy.⁷ Since exercise is the core of renal rehabilitation, there is an increasing number of systematic reviews and meta-analyses investigating the influence of exercise on health outcomes in CKD patients.⁸ Although some researchers and guidelines recommend that healthcare providers prescribe exercise for CKD patients,⁹⁻¹² the results of meta-analyses of exercise in CKD patients are inconsistent.

This umbrella review aims to assess the therapeutic effects of exercise regarding cardiovascular risk factors, physical fitness, dialysis-related symptoms, and HRQOL in CKD patients that are summarized in systematic reviews and meta-analyses.

METHODS AND ANALYSIS

This umbrella review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.¹³ The review was prospectively registered (PROSPERO: CRD42020223591) and the protocol for this review was published.¹⁴

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Literature Search

A comprehensive search strategy was performed to identify systematic reviews and meta-analyses of CKD patients that compared usual care procedures with and without exercise interventions. PubMed, Embase, the Cochrane Database of Systematic Reviews (CDSR), and the Web of Science were searched for systematic reviews and meta-analyses from inception to March 9th, 2021. The detailed search strategy is summarized in Supplementary Table S1. The references of existing systematic reviews were also screened. Any reviews considered potentially relevant by authors were retrieved for further consideration.

Eligibility Criteria

Eligible systematic reviews and meta-analyses included those 1) where patients were diagnosed with CKD at various stages of treatment; 2) that compared exercise interventions with sham/no exercise or usual/standard care; 3) that reported outcomes on at least one of the following: cardiovascular risk factors, physical fitness, dialysis-related symptoms, and HRQOL. The methods to assess each outcome was shown in Supplement Figure S1; and 4) that were systematic reviews with meta-analysis of intervention trials (such as randomized controlled trials and quasi-experimental studies). Meta-analysis that included less than three studies or less than 100 participants were excluded. For duplicate literature, the article with most comprehensive data was selected. The language was restricted to English. Letters to the editor, trial protocols, and conference abstracts were excluded.

Study selection

Two independent authors screened all titles and abstracts compiled from the search results. Each paper was examined for appropriate eligibility criteria and a third author resolved disagreements.

Data extraction

Requisite data were extracted independently by two independent authors into a standardized format that included: 1) author, 2) publication year, 3) stage of CKD, 4) the number of included studies and participants, 5) exercise type, 6) exercise mode (intradialytic or interdialytic), 7) standardized mean difference (SMD) or mean difference (MD) with corresponding 95% confidence intervals (CI) for each outcome, 8) *P*-values, 9) *I*² values, and 10) exercise-related adverse events.

Risk of bias assessment

AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews-2) was used to assess the risk of bias among the included systematic reviews.¹⁵ This checklist contains 16 items, and each item was answered with a “yes” (1 point), “partial yes” (0.5 points), or “no” (0 points). A percentage score was calculated for each study based on the total score as the numerator and the maximum 16 points as the denominator. A meta-analysis scoring $\geq 80\%$ was classified as high quality, those scoring 40-79% as medium quality, and those scoring $< 40\%$ as low quality.¹⁶ Risk of bias assessment was performed independently by two authors, and disagreement were resolved through discussions.

Data analysis

For each outcome, the summary effect size from each meta-analysis was analyzed qualitatively based on the SMD and its 95% CI. If they were not presented as SMD in the original meta-analysis, Review Manager V.5.3 was used to convert SMD outcomes. If data could not be

converted into SMD, we contacted the authors of the meta-analysis for the data. Effects were considered small (SMD < 0.50), moderate (SMD from 0.50 to 0.79), and large (SMD ≥ 0.80).¹⁷ I^2 values were interpreted as follows: ≤25% indicate low heterogeneity, 25% < I^2 ≤ 50% indicate mild heterogeneity, 50% < I^2 ≤ 75% indicate moderate heterogeneity, and >75% indicate high heterogeneity.¹⁸

The level of evidence for each meta-analysis was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.¹⁹ The quality of evidence was assessed using five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias. Beginning with an initial score of 4 points, the score for each of these five domains was reduced accordingly: “not reported (-1)”, “serious (-1)”, “very serious (-2)”, or “neutral (0)”. Studies were rated as high (4 points), moderate (3 points), low (2 points), or very low (≤ 1 point) using the GRADE system. The GRADE assessment was conducted independently by two authors. Any differences were resolved by discussion or adjudication by a third author. The incidence of adverse events was based on the number of reported divided by the patients in the exercise group.

RESULTS

Characteristics of the meta-analyses

The search identified 2305 potential articles, of which 648 were duplicates. After reading the title and abstract, 1598 papers were excluded and 28 were excluded after full-text review resulting in 31 final studies.²⁰⁻⁵⁰ A flow diagram of the study selection illustrates the selection process (Supplement Figure S2). The detail of reasons for excluded articles were listed in Supplementary Table S2.

The 31 included systematic reviews and meta-analyses were published from September, 2011 through March, 2021. The number of included studies assessed in the articles ranged from 3 to 24 with a mean of 8 studies. The sample sizes in the studies ranged from 106 to 874 participants with a mean of 304. The characteristics of the included meta-analyses were shown in Supplement Table S3. SMD data from four papers could not be obtained from the authors and the data of their effect size was presented as MD.^{25 26 37 43}

The assessment of the methodological quality of the included meta-analyses was determined and the AMSTAR-2 scores ranged from 34.4% to 100.0% with a mean score of 68.0%. Seven (22.6%) systematic reviews were rated of high quality while 23 (74.2%) were rated of medium quality, and just one (0.3%) was rated as low quality (Supplement Table S4).

Of the GRADE evidence quality of the 120 outcomes, 1.7% (2 / 120) reported evidence of high quality, 17.5% (21 / 120) reported evidence of moderate quality, 20.0% (24 / 120) reported evidence of low quality, and 60.8% (73 / 120) reported evidence of very low quality (Supplement

Table S5).

Cardiovascular risk factor

There were 25 meta-analyses (reported in 13 articles) investigating the effect of exercise on cardiovascular risk factors (systolic and diastolic blood pressure) in CKD patients.^{23 26 29-31 37 38 40 43-46 49} Of which, the number of studies ranged from 3 to 12 with a mean of 314 participants (range from 198 to 514) were included in each meta-analysis (Table 1).

The effect of exercise on systolic blood pressure was investigated in 13 meta-analyses with a mild heterogeneity (average $I^2 = 36.1\%$),^{23 26 29-31 37 38 40 43-46 49} and 6 reported a positive statistically significant outcome.^{26 29 38 40 46 49} Of the 13 meta-analyses, 9 reported a small effect size,^{23 29-31 38 40 44 45 49} and one reported moderate.⁴⁶ GRADE assessment of quality indicated the overall evidence as being very low (10 meta-analyses^{23 26 29 30 38 40 43-46}), low (2 meta-analyses^{31 37}), and moderate (1 meta-analysis⁴⁹). See Table 1.

The effect of exercise on diastolic blood pressure was investigated in 12 meta-analyses with a mild heterogeneity (average $I^2=49.1\%$),^{23 26 29-31 37 38 40 43-45 49} and 2 reported a positive statistically significant outcome.^{38 40} Of the 12 meta-analyses, 9 reported a small effect size,^{23 29-31 38 40 44 45 49} and all were graded as low or very low quality of evidence (Table 1).

Cardiorespiratory fitness

There were 34 meta-analyses (reported in 21 articles) that investigated the effects of exercise on cardiorespiratory fitness in CKD patients using a peak oxygen uptake (18 of 34), 6-minute walk test (14 of 34), or aerobic capacity (2 of 34). The meta-analyses included a mean of 9 studies (ranging from 5 to 20) and a mean of 330 participants (ranging from 179 to 504). See Table 2.

The effect of exercise on peak oxygen consumption was investigated in 18 meta-analyses (reported in 17 articles) with a mild heterogeneity (average $I^2=42.2\%$),^{20 21 23 24 26 28 31 34-38 40 41 44 46 47} and 16 reported positive statistically significant outcomes.^{20 21 24 26 28 31 34 35 37 38 40 41 44 46 47} Of the 18 meta-analyses, 3 reported a low effect size,^{23 36 47} 9 reported a moderate effect size^{21 24 28 31 34 38 40 41 46} and 3 reported a large effect size.^{20 35 44} GRADE assessment of quality indicated the overall evidence as being very low (9 meta-analyses^{21 23 24 26 28 34 40 44 46}), low (8 meta-analyses^{20 31 35-38 41 47}), and high (1 meta-analysis³⁴). A meta-analysis that included kidney transplant recipients found no statistically significant difference in the SMD of the exercise group (0.38; 95% CI, -0.06 to 0.82; $P=0.09$).³⁶ See Table 2.

The effect of exercise on 6-minute walk test was investigated in 14 meta-analyses (reported in 13 articles) with a mild heterogeneity (average $I^2=44.9\%$),^{21 24-26 28 31 33-35 37 38 40 48} and 13 reported positive statistically significant outcomes.^{21 24-26 28 31 33-35 38 40 48} Of the 14 meta-analyses, 2 reported a small effect size,^{21 24} 5 reported a moderate effect size,^{33 34 38 40 48} and 3 reported a large effect size.^{28 31 35} GRADE assessment of quality indicated the overall evidence as being very low

1
2
3
4 (8 meta-analyses^{21 26 28 31 35 37 40}), low (4 meta-analyses^{24 34 38 48}), and moderate (2 meta-analyses²⁵
5³³). In addition, the meta-analysis by Heiwe et al (2014) showed that regular exercise had
6 significant beneficial effects on aerobic capacity.^{29 30} See Table 2.

8 **Muscle strength**

10
11 Ten meta-analyses (reported in 9 articles) investigated the effects of exercise on muscle strength in
12 CKD patients with a low heterogeneity (average $I^2 = 19.1\%$).^{22 28-30 32-35 48} The meta-analyses
13 included a mean of 7 studies (ranging from 3 to 12) and a mean of 252 participants (ranging from
14 115 to 385). See Table 3.

17
18 Muscle strength was measured using handgrip strength, lower limb muscle strength, et al. For
19 patients in 8 of 10 meta-analyses, exercise resulted in statistically significant improvements in
20 muscle strength.^{28-30 32-34 48} Of the 10 meta-analyses, 3 reported a small effect size,^{33 35 48} 5
21 reported a moderate effect size,^{28-30 32 33} and 2 reported a large effect size.^{22 34} GRADE assessment
22 of quality indicated the overall evidence as being very low (6 meta-analyses^{28-30 32 34 35}) and low (4
23 meta-analyses^{22 33 48}). See Table 3.

26 **Muscle endurance**

28
29 Nine meta-analyses (reported in 8 articles) investigated the effects of exercise on muscle
30 endurance with a mild heterogeneity (average $I^2 = 29.4\%$).^{21 29 30 33 35 37 40 48} A mean of 5 studies
31 (ranging from 3 to 7) and a mean of 238 participants (ranging from 106 to 461) were included in
32 meta-analyses (Table 4).

35
36 Muscle endurance was measured using a sit-to-stand test, timed up and go test, and walking
37 capacity exercise. Pooled effect estimates from all 9 meta-analyses suggested a beneficial effect of
38 exercise on muscle endurance in CKD patients. Power to detect a statistically significant effect
39 was reported by 7 of the 9 meta-analyses.^{21 29 33 35 40 48} Two meta-analyses reported a moderate
40 effect size and 5 reported a small effect size. GRADE assessment of quality indicated the overall
41 evidence as being very low (7 meta-analyses^{21 29 33 35 37 40 48}), low (1 meta-analyses³³) and moderate
42 (1 meta-analyses³⁰). See Table 4.

46 **Body composition**

48
49 Four meta-analyses consisting of a mean of 9 studies (ranging from 4 to 13) and a mean of 335
50 participants (ranging from 166 to 466) included body mass index as an outcome.^{23 44 46 49} There
51 was a low heterogeneity (average $I^2 = 12.0\%$) among the study outcomes (Table 5).

53
54 Of the 4 meta-analyses, 3 showed a positive statistically significant impact on body mass index
55 using exercise interventions in CKD patients.^{44 46 49} Small effect size was reported in all
56 meta-analyses. GRADE assessment of quality indicated the overall evidence as being very low (1
57 meta-analyses), low (2 meta-analyses^{44 46}) and moderate (1 meta-analyses⁴⁹). See Table 5.

Dialysis-related symptoms

Nine meta-analyses (reported in 7 articles) investigated the effect of exercise on dialysis-related symptoms in CKD patients.^{26 27 31 38 40 42 50} Each meta-analysis included a mean of 7 studies (ranging from 3 to 12 studies) and a mean of 239 participants (ranging from 139 to 370). See Table 6.

Dialysis adequacy was measured using the value of Kt/V. Six meta-analyses (reported in 5 articles) investigated the effects of exercise on Kt/V in CKD patients with a mild heterogeneity (average $I^2 = 25.7\%$).^{26 27 31 38 40} Comprehensive effect estimates from all the 6 meta-analyses with Kt/V outcomes showed that exercise had a beneficial effect. Of the 6 meta-analyses, 3 reported a small effect size^{31 38 40} and 1 reported a large effect size.²⁷ According to GRADE criteria, all meta-analyses were rated as very low quality of evidence (Table 6).

Fatigue was measured using the Rhoten Fatigue Scale, Visual Analogue Scale, and Hemodialysis Patients Fatigue Scale. The effect of exercise on fatigue was investigated in 2 meta-analyses with a low heterogeneity (average $I^2 = 23.5\%$).^{42 50} The 2 meta-analyses revealed a statistically significant effect of exercise on fatigue. Although the meta-analyses reported large effect size, the quality of evidence was low⁴² or very low⁵⁰ according to GRADE criteria (Table 6).

Just one meta-analysis investigated the effects of exercise on restless legs syndrome in CKD patients.⁴² Result showed that pooled effect estimated for restless legs syndrome with statistically significant but considerable average heterogeneity ($I^2 = 87.0\%$). According to GRADE criteria, the overall of evidence for this outcome was rated as very low (Table 6).

Health-related quality of life

Twenty-nine meta-analyses (reported in 13 articles) investigated the effect of exercise on HRQOL in CKD patients.^{22 24 28 31 32 34 36-40 48 50} Among them, nine the meta-analyses each assessed physical and mental subscale of the Short-Form Health Survey-36.^{24 28 31 34 38-40 48 50} A mean of 6 studies (ranging from 3 to 10) and a mean of 311 participants (ranging from 167 to 562) were included in each meta-analysis. The included meta-analyses had moderate heterogeneity (average $I^2 = 51.0\%$). See Table 7.

Of the 29 meta-analyses, a comprehensive effect estimate of the 28 meta-analyses shows that exercise is beneficial to the HRQOL of CKD patients, but only 12 of 29 meta-analyses reported a statistically significant outcome.^{24 31 34 36 38-40 50} There were 13 of 29 meta-analyses reporting a small effect size,^{24 28 31 34 38 40 48 50} 4 were moderate,^{28 34 36 38} and 6 were large.^{22 32 39} According to GRADE criteria, the overall of evidence for HRQOL was rated as very low (20 meta-analyses^{28 32 34 36-40 50}) or low (9 meta-analyses^{22 24 31 38 48 50}). See Table 7.

Adverse events

1
2
3 Six meta-analyses reported exercise-related adverse events.^{22 24 35 38 40 41} Of the adverse effects, the
4 most commonly reported were hypotension and cramping. Overall, the incidence of adverse
5 events was approximately 0.3%.
6
7

8 **DISCUSSION**

9

10 Several meta-analyses have been published in the area of exercise interventions in CKD patients.⁵¹
11 The findings of these meta-analyses should be assessed to determine if evidence is consistent
12 among the studies. This umbrella review included 31 eligible articles involving 120 separate
13 meta-analyses investigating the effect of exercise on the health outcomes in CKD patients. There
14 was low- or very low-quality evidence for moderate beneficial effects of exercise on
15 cardiorespiratory fitness, muscle strength, and body composition. In addition, there was very
16 low-quality evidence for small beneficial effects of exercise on muscle endurance, cardiovascular
17 risk factors, dialysis-related symptoms, and HRQOL. There were few adverse events related to
18 exercise, indicating that exercise is safe for CKD patients.
19
20
21
22
23
24

25 Cardiovascular disease is a frequent complication of CKD and is the leading cause of death in
26 CKD patients.⁵² Hypertension is an important modifiable risk factor for cardiovascular diseases
27 and progressive renal dysfunction in CKD patients.⁵³ The present overview showed that exercise
28 has a small to moderate effect on blood pressure (SMD: -0.75 to 0.04 for systolic blood pressure,
29 and SMD: -0.47 to 0.04 for diastolic blood pressure), it is an appealing strategy for blood pressure
30 control in CKD patients. However, the dose effects of exercise in the context of the cardiovascular
31 health of CKD patients should be considered. A recent cohort study found that 7.5-15 metabolic
32 equivalent-hours per week (MET-h/week) was associated with the lowest risk of cardiovascular
33 events.⁵⁴ Regrettable, the benefit of exercise on cardiovascular risk factors cannot be determined
34 because there are an insufficient number of conclusive studies that assess exercise effects on
35 overall cardiovascular health. A recent randomized controlled trial published by Graham-Brown
36 indicated that intradialytic exercise can reduce left ventricular mass and is safe, deliverable, and
37 well-tolerated.⁵⁵ Although the GRADE evidence generated was low, exercise should be
38 recommended for CKD patients, particularly those comorbid with cardiovascular disease.
39
40
41
42
43
44
45
46

47 Physical fitness is necessary for participation in activities of daily living. Exercise provided the
48 best results in improving cardiorespiratory fitness and muscle strength in CKD patients, with more
49 than a half of the meta-analyses reporting moderate or large effect sizes, regardless of the quality
50 of evidence. Cardiorespiratory fitness is considered an important independent predictor of
51 mortality and muscle strength is an important indicator of physical performance in CKD
52 patients.⁵⁶ It is well known that aerobic exercise is the “gold standard” for cardiorespiratory
53 rehabilitation⁵⁷ and resistance training for muscle strength improvement.⁵⁸ However, a
54 combination of aerobic and resistance exercises may have a more profound effect in CKD patients
55 based on the current review. Meta-analyses conducted by Andrade et al. showed that combined
56
57
58
59
60

1
2
3 training has an exert benefits in cardiorespiratory fitness in CKD patients.²⁰
4
5

6 Both sarcopenia and obesity have been shown to increase mortality risk and increase progression
7 to end-stage renal disease in CKD patients.⁵⁹ Unlike patients receiving dialysis, treatment
8 requirements for predialysis CKD patient are based upon the principle of maintaining a “healthy
9 weight” and the prevention or attenuation of obesity.¹⁰ In this overview, the effectiveness of
10 exercise for body mass index was supported by 4 analyses with small effect sizes and a moderate
11 quality of evidence. Based on the results, exercise may contribute to lower body mass index in
12 CKD patients. However, additional studies are needed to confirm the benefits of exercise
13 programs for reducing sarcopenia and weight.
14
15
16
17

18 CKD population experience multiple symptoms that affect patient’s prognosis and HRQOL.⁶⁰
19 Patients who received dialysis treatment commonly reported restless legs syndrome, fatigue, and
20 dialysis inadequate due to both the deterioration of kidney function and dialysis-related side
21 effects.^{61 62} These symptoms affect sleep, daily activities, and impose a considerable amount of
22 psychological distress and economic burden.⁶³ An increasing number of researchers have
23 investigated the role of exercise as an important non-pharmacological strategy for preventing
24 and/or treating symptoms.^{64 65} The results of a small number of meta-analyses suggested that the
25 beneficial effect of exercise on dialysis adequacy (SMD: 0.19 to 2.21), and improving restless legs
26 syndrome (SMD: -1.79) and fatigue symptoms (SMD: -0.97 to -0.85). Nevertheless, the efficacy
27 of exercise in CKD patients for preventing dialysis-related symptoms awaits new clinical
28 evidence.
29
30
31
32
33
34
35

36 With similar results obtained in another overview that included chronic disease,⁶⁶ results from this
37 overview demonstrated small beneficial effects of exercise on HRQOL, irrespective of the
38 evidence level in CKD patients. Improved HRQOL is important because most of the population
39 reported ongoing poor health and well-being due to diet restriction, weakness, and dialysis
40 treatment.⁶⁷ The consistent health benefits of exercise in this overview demonstrated that exercise
41 could be a strategy to improve the poor long-term prognosis in CKD patients.
42
43
44
45

46 Several meta-analyses reported exercise-related adverse events. Based on the number of adverse
47 events reported, we calculate that only 3 adverse events occurred per 1000 CKD patients. The low
48 incidence of adverse events indicated that the benefits of exercise in CKD patients outweigh its
49 potential risks. However, most meta-analyses only included intradialytic exercise for hemodialysis
50 patients in their assessments. Exercises during hemodialysis are usually performed under the
51 supervision of a healthcare worker to ensure safety.⁶⁸ Due to the potential lack of supervision in an
52 in-home exercise regime, a stepwise exercise is recommended for CKD patients.
53
54
55
56

57 Taken together, there is good reason to recommend exercise for improving prognosis in CKD
58 patients. Evidence from most randomized controlled trials increased confidence in the findings of
59 this umbrella review. Because most of the meta-analyses assessed in this study did not detail the
60

1
2
3 exercises instituted, it is difficult to make recommendations about the type of exercise that would
4 be the most beneficial for CKD patients. Although the effect sizes of exercise on improving the
5 health prognosis of CKD patients were generally moderate, these effects may bring some clinical
6 benefit to patients experiencing impaired function or symptom distress. Despite numerous
7 meta-analyses provided only low or very low-quality evidence, similar beneficial effects of
8 exercise were reported by meta-analyses of randomized controlled trials with different grades of
9 evidence. Remarkably, a recently published trial found that a 6-month program of intradialytic
10 exercise is effective in reducing healthcare costs.⁶⁹ Overall, exercise should be integrated into the
11 care of CKD.

12
13
14
15
16
17
18 There are several limitations to this overview: 1) the majority of meta-analyses included in this
19 review involves hemodialysis patients. This limits the extrapolation of the results to other stages
20 of CKD; 2) improvement of flexibility in CKD patients was not investigated. Flexibility is an
21 important component of physical fitness that is believed to have an impact on muscular injury.⁷⁰
22 The evidence for the efficacy of exercise on flexibility improvement is insufficient for a
23 systematic review or meta-analysis; 3) language bias may exist in this review because the search
24 strategy was limited to English. It is unknown if meta-analyses published in other languages
25 would influence the outcomes of our findings; 4) the results may be had been influenced by
26 overlap in the original studies; 5) the accuracy of the MD data cannot be guaranteed; and 6)
27 sub-group analyses of different types of exercise were not performed as described in the published
28 protocol because of most the included meta-analyses did not detail the exercises.

34 35 **CONCLUSION**

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Exercise appears to be effective in improving muscle strength and endurance, body composition,
and HRQOL in CKD patients. At the same time, exercise appears to decrease blood pressure and
dialysis-related symptoms in CKD patients. Accordingly, exercise should be integrated into renal
care for a patient with any stage of CKD.

44 45 **Contributors**

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
FZ, LYH, HCZ conceptualized and designed the review. YB and XZ searched databases, extracted the
data, and statistical analysis. WQZ and WQW revised the manuscript. HCZ provided technical
support. All authors had read and approved the final manuscript and agreed on its submission.

51
52
53
54
55
56
57
58
59
60
Funding This study was supported by Longhua Hospital Shanghai University of Traditional
Chinese Medicine (Grant number: Y21026).

55
56
57
58
59
60
Competing interests None declared.

58
59
60
Data availability statement Data are available in a public, open access repository. All data in the
overview were published through journals.

1
2
3 **Patient consent for publication** Not required.
4

5 **Provenance and peer review** Not commissioned; externally peer reviewed.
6
7
8
9

10 REFERENCES

- 11 1. Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. *Nat Rev Nephrol* 2017;13(6):344-58. doi: 10.1038/nrneph.2017.52 [published Online First: 2017/04/25]
- 12 2. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis
13 for the Global Burden of Disease Study 2017. *Lancet* 2020;395(10225):709-33. doi:
14 10.1016/s0140-6736(20)30045-3 [published Online First: 2020/02/18]
- 15 3. Yang C, Gao B, Zhao X, et al. Executive summary for China Kidney Disease Network (CK-NET)
16 2016 Annual Data Report. *Kidney Int* 2020;98(6):1419-23. doi: 10.1016/j.kint.2020.09.003
17 [published Online First: 2020/12/06]
- 18 4. Cheng HT, Xu X, Lim PS, et al. Worldwide Epidemiology of Diabetes-Related End-Stage Renal
19 Disease, 2000-2015. *Diabetes Care* 2020 doi: 10.2337/dc20-1913 [published Online First:
20 2020/11/19]
- 21 5. Roshanravan B, Robinson-Cohen C, Patel KV, et al. Association between physical performance and
22 all-cause mortality in CKD. *J Am Soc Nephrol* 2013;24(5):822-30. doi:
23 10.1681/asn.2012070702 [published Online First: 2013/04/20]
- 24 6. Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. *Nat Rev Nephrol*
25 2014;10(9):504-16. doi: 10.1038/nrneph.2014.112 [published Online First: 2014/07/02]
- 26 7. Hoshino J. Renal Rehabilitation: Exercise Intervention and Nutritional Support in Dialysis Patients.
27 *Nutrients* 2021;13(5):1444.
- 28 8. Wilund KR, Viana JL, Perez LM. A Critical Review of Exercise Training in Hemodialysis Patients:
29 Personalized Activity Prescriptions Are Needed. *Exerc Sport Sci Rev* 2020;48(1):28-39. doi:
30 10.1249/jes.000000000000209 [published Online First: 2019/08/28]
- 31 9. March DS, Graham-Brown MP, Young HM, et al. 'There is nothing more deceptive than an obvious
32 fact': more evidence for the prescription of exercise during haemodialysis (intradialytic
33 exercise) is still required. *Br J Sports Med* 2017;51(18):1379. doi:
34 10.1136/bjsports-2017-097542 [published Online First: 2017/04/01]
- 35 10. The Renal Association. Clinical Practice Guideline: Exercise and Lifestyle in Chronic Kidney
36 Disease 2021 [Available from:
37 [https://renal.org/sites/renal.org/files/Exercise%20and%20Lifestyle%20in%20CKD%20clinical](https://renal.org/sites/renal.org/files/Exercise%20and%20Lifestyle%20in%20CKD%20clinical%20practice%20guideline33_v4_FINAL_0.pdf)
38 [l%20practice%20guideline33_v4_FINAL_0.pdf](https://renal.org/sites/renal.org/files/Exercise%20and%20Lifestyle%20in%20CKD%20clinical%20practice%20guideline33_v4_FINAL_0.pdf).
39
- 40 11. Yamagata K, Hoshino J, Sugiyama H, et al. Clinical practice guideline for renal rehabilitation:
41 Systematic reviews and recommendations of exercise therapies in patients with kidney
42 diseases. *Renal Replacement Therapy* 2019;5 doi: 10.1186/s41100-019-0209-8
43
- 44 12. Deschamps T. Let's programme exercise during haemodialysis (intradialytic exercise) into the care
45 plan for patients, regardless of age. *Br J Sports Med* 2016;50(22):1357-58. doi:
46 10.1136/bjsports-2016-096356 [published Online First: 2016/11/03]
- 47 13. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and
48 meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*
49
50
51
52
53
54
55
56
57
58
59
60

- 2015;350:g7647. doi: 10.1136/bmj.g7647 [published Online First: 2015/01/04]
14. Zhang F, Wang H, Huang L, et al. Therapeutic effects of exercise interventions for patients with chronic kidney disease: protocol for an overview of systematic reviews and meta-analyses of clinical trials. *BMJ Open* 2021;11(2):e043011. doi: 10.1136/bmjopen-2020-043011 [published Online First: 2021/02/13]
15. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *Bmj* 2017;358:j4008. doi: 10.1136/bmj.j4008 [published Online First: 2017/09/25]
16. Grgic J, Grgic I, Pickering C, et al. Wake up and smell the coffee: caffeine supplementation and exercise performance-an umbrella review of 21 published meta-analyses. *Br J Sports Med* 2020;54(11):681-88. doi: 10.1136/bjsports-2018-100278 [published Online First: 2019/03/31]
17. Cohen J. Quantitative methods in psychology: A power primer. *Psychological Bulletin* 1992;112:115-59.
18. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online First: 2003/09/06]
19. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *Bmj* 2004;328(7454):1490. doi: 10.1136/bmj.328.7454.1490 [published Online First: 2004/06/19]
20. Andrade FP, Rezende PS, Ferreira TS, et al. Effects of intradialytic exercise on cardiopulmonary capacity in chronic kidney disease: systematic review and meta-analysis of randomized clinical trials. *Sci Rep* 2019;9(1):18470. doi: 10.1038/s41598-019-54953-x [published Online First: 2019/12/06]
21. Bogataj S, Pajek M, Pajek J, et al. Exercise-Based Interventions in Hemodialysis Patients: A Systematic Review with a Meta-Analysis of Randomized Controlled Trials. *J Clin Med* 2019;9(1) doi: 10.3390/jcm9010043 [published Online First: 2019/12/28]
22. Cheema BS, Chan D, Fahey P, et al. Effect of progressive resistance training on measures of skeletal muscle hypertrophy, muscular strength and health-related quality of life in patients with chronic kidney disease: a systematic review and meta-analysis. *Sports Med* 2014;44(8):1125-38. doi: 10.1007/s40279-014-0176-8 [published Online First: 2014/04/04]
23. Chen G, Gao L, Li X. Effects of exercise training on cardiovascular risk factors in kidney transplant recipients: a systematic review and meta-analysis. *Ren Fail* 2019;41(1):408-18. doi: 10.1080/0886022X.2019.1611602 [published Online First: 2019/05/21]
24. Chung YC, Yeh ML, Liu YM. Effects of intradialytic exercise on the physical function, depression and quality of life for haemodialysis patients: a systematic review and meta-analysis of randomised controlled trials. *J Clin Nurs* 2017;26(13-14):1801-13. doi: 10.1111/jocn.13514 [published Online First: 2016/08/18]
25. Clarkson MJ, Bennett PN, Fraser SF, et al. Exercise interventions for improving objective physical function in patients with end-stage kidney disease on dialysis: a systematic review and meta-analysis. *Am J Physiol Renal Physiol* 2019;316(5):F856-f72. doi: 10.1152/ajprenal.00317.2018 [published Online First: 2019/02/14]
26. Ferrari F, Helal L, Dipp T, et al. Intradialytic training in patients with end-stage renal disease: a systematic review and meta-analysis of randomized clinical trials assessing the effects of five different training interventions. *J Nephrol* 2020;33(2):251-66. doi: 10.1007/s40620-019-00687-y [published Online First: 2019/12/23]

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
27. Ferreira GD, Bohlke M, Correa CM, et al. Does Intradialytic Exercise Improve Removal of Solutes by Hemodialysis? A Systematic Review and Meta-analysis. *Arch Phys Med Rehabil* 2019;100(12):2371-80. doi: 10.1016/j.apmr.2019.02.009 [published Online First: 2019/03/30]
28. Gomes Neto M, de Lacerda FFR, Lopes AA, et al. Intradialytic exercise training modalities on physical functioning and health-related quality of life in patients undergoing maintenance hemodialysis: systematic review and meta-analysis. *Clin Rehabil* 2018;32(9):1189-202. doi: 10.1177/0269215518760380 [published Online First: 2018/02/27]
29. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. *Cochrane Database Syst Rev* 2011(10):Cd003236. doi: 10.1002/14651858.CD003236.pub2 [published Online First: 2011/10/07]
30. Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. *Am J Kidney Dis* 2014;64(3):383-93. doi: 10.1053/j.ajkd.2014.03.020 [published Online First: 2014/06/11]
31. Huang M, Lv A, Wang J, et al. Exercise Training and Outcomes in Hemodialysis Patients: Systematic Review and Meta-Analysis. *Am J Nephrol* 2019;50(4):240-54. doi: 10.1159/000502447 [published Online First: 2019/08/28]
32. Ju H, Chen H, Mi C, et al. The Impact of Home-Based Exercise Program on Physical Function of Chronic Kidney Disease Patients: A Meta-Analysis of Randomized Controlled Trials. *Physikalische Medizin, Rehabilitationsmedizin, Kurortmedizin* 2020;30(02):108-14. doi: 10.1055/a-1079-3714
33. Lu Y, Wang Y, Lu Q. Effects of Exercise on Muscle Fitness in Dialysis Patients: A Systematic Review and Meta-Analysis. *Am J Nephrol* 2019;50(4):291-302. doi: 10.1159/000502635 [published Online First: 2019/09/04]
34. Matsuzawa R, Hoshi K, Yoneki K, et al. Exercise Training in Elderly People Undergoing Hemodialysis: A Systematic Review and Meta-analysis. *Kidney Int Rep* 2017;2(6):1096-110. doi: 10.1016/j.ekir.2017.06.008 [published Online First: 2017/12/23]
35. Nakamura K, Sasaki T, Yamamoto S, et al. Effects of exercise on kidney and physical function in patients with non-dialysis chronic kidney disease: a systematic review and meta-analysis. *Sci Rep* 2020;10(1):18195. doi: 10.1038/s41598-020-75405-x [published Online First: 2020/10/25]
36. Oguchi H, Tsujita M, Yazawa M, et al. The efficacy of exercise training in kidney transplant recipients: a meta-analysis and systematic review. *Clin Exp Nephrol* 2019;23(2):275-84. doi: 10.1007/s10157-018-1633-8 [published Online First: 2018/09/01]
37. Pei G, Tang Y, Tan L, et al. Aerobic exercise in adults with chronic kidney disease (CKD): a meta-analysis. *Int Urol Nephrol* 2019;51(10):1787-95. doi: 10.1007/s11255-019-02234-x [published Online First: 2019/07/25]
38. Pu J, Jiang Z, Wu W, et al. Efficacy and safety of intradialytic exercise in haemodialysis patients: a systematic review and meta-analysis. *BMJ Open* 2019;9(1):e020633. doi: 10.1136/bmjopen-2017-020633 [published Online First: 2019/01/24]
39. Salhab N, Karavetian M, Kooman J, et al. Effects of intradialytic aerobic exercise on hemodialysis patients: a systematic review and meta-analysis. *J Nephrol* 2019;32(4):549-66. doi: 10.1007/s40620-018-00565-z [published Online First: 2019/01/20]
40. Sheng K, Zhang P, Chen L, et al. Intradialytic exercise in hemodialysis patients: a systematic review and meta-analysis. *Am J Nephrol* 2014;40(5):478-90. doi: 10.1159/000368722

- [published Online First: 2014/12/17]
41. Smart N, Steele M. Exercise training in haemodialysis patients: a systematic review and meta-analysis. *Nephrology (Carlton)* 2011;16(7):626-32. doi: 10.1111/j.1440-1797.2011.01471.x [published Online First: 2011/05/12]
 42. Song YY, Hu RJ, Diao YS, et al. Effects of Exercise Training on Restless Legs Syndrome, Depression, Sleep Quality, and Fatigue Among Hemodialysis Patients: A Systematic Review and Meta-analysis. *J Pain Symptom Manage* 2018;55(4):1184-95. doi: 10.1016/j.jpainsymman.2017.12.472 [published Online First: 2017/12/17]
 43. Thompson S, Wiebe N, Padwal RS, et al. The effect of exercise on blood pressure in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. *PLoS One* 2019;14(2):e0211032. doi: 10.1371/journal.pone.0211032 [published Online First: 2019/02/07]
 44. Vanden Wyngaert K, Van Craenenbroeck AH, Van Biesen W, et al. The effects of aerobic exercise on eGFR, blood pressure and VO₂peak in patients with chronic kidney disease stages 3-4: A systematic review and meta-analysis. *PLoS One* 2018;13(9):e0203662. doi: 10.1371/journal.pone.0203662 [published Online First: 2018/09/12]
 45. Wu X, Yang L, Wang Y, et al. Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis. *Clin Rehabil* 2020;34(7):851-65. doi: 10.1177/0269215520924459 [published Online First: 2020/06/10]
 46. Yamamoto R, Ito T, Nagasawa Y, et al. Efficacy of aerobic exercise on the cardiometabolic and renal outcomes in patients with chronic kidney disease: a systematic review of randomized controlled trials. *J Nephrol* 2021;34(1):155-64. doi: 10.1007/s40620-020-00865-3 [published Online First: 2021/01/03]
 47. Yang H, Wu X, Wang M. Exercise Affects Cardiopulmonary Function in Patients with Chronic Kidney Disease: A Meta-Analysis. *Biomed Res Int* 2017;2017:6405797. doi: 10.1155/2017/6405797 [published Online First: 2017/09/22]
 48. Zhang F, Zhou W, Sun Q, et al. Effects of intradialytic resistance exercises on physical performance, nutrient intake and quality of life among haemodialysis people: A systematic review and meta-analysis. *Nurs Open* 2021;8(2):529-38. doi: 10.1002/nop2.274 [published Online First: 2021/02/12]
 49. Zhang L, Wang Y, Xiong L, et al. Exercise therapy improves eGFR, and reduces blood pressure and BMI in non-dialysis CKD patients: evidence from a meta-analysis. *BMC Nephrol* 2019;20(1):398. doi: 10.1186/s12882-019-1586-5 [published Online First: 2019/10/31]
 50. Zhao QG, Zhang HR, Wen X, et al. Exercise interventions on patients with end-stage renal disease: a systematic review. *Clin Rehabil* 2019;33(2):147-56. doi: 10.1177/0269215518817083 [published Online First: 2019/02/23]
 51. Clyne N, Anding-Rost K. Exercise training in chronic kidney disease-effects, expectations and adherence. *Clin Kidney J* 2021;14(Suppl 2):ii3-ii14. doi: 10.1093/ckj/sfab012 [published Online First: 2021/05/14]
 52. Webster AC, Nagler EV, Morton RL, et al. Chronic Kidney Disease. *Lancet* 2017;389(10075):1238-52. doi: 10.1016/s0140-6736(16)32064-5 [published Online First: 2016/11/27]
 53. Cheung AK, Chang TI, Cushman WC, et al. Blood pressure in chronic kidney disease: conclusions

- 1
2
3 from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
4 *Kidney Int* 2019;95(5):1027-36. doi: 10.1016/j.kint.2018.12.025 [published Online First:
5 2019/04/24]
6
7 54. Kuo CP, Tsai MT, Lee KH, et al. Dose-response effects of physical activity on all-cause mortality
8 and major cardiorenal outcomes in chronic kidney disease. *Eur J Prev Cardiol* 2021 doi:
9 10.1093/eurjpc/zwaa162 [published Online First: 2021/03/12]
10
11 55. Graham-Brown MPM, March DS, Young R, et al. A randomized controlled trial to investigate the
12 effects of intra-dialytic cycling on left ventricular mass. *Kidney International* 2021 doi:
13 <https://doi.org/10.1016/j.kint.2021.02.027>
14
15 56. Zelle DM, Klaassen G, van Adrichem E, et al. Physical inactivity: a risk factor and target for
16 intervention in renal care. *Nat Rev Nephrol* 2017;13(3):152-68. doi: 10.1038/nrneph.2016.187
17 [published Online First: 2017/02/01]
18
19 57. Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in
20 cardiac rehabilitation: a joint position statement of the European Association for
21 Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular
22 and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. *Eur J*
23 *Prev Cardiol* 2013;20(3):442-67. doi: 10.1177/2047487312460484 [published Online First:
24 2012/10/30]
25
26 58. Chan D, Cheema BS. Progressive Resistance Training in End-Stage Renal Disease: Systematic
27 Review. *Am J Nephrol* 2016;44(1):32-45. doi: 10.1159/000446847 [published Online First:
28 2016/06/30]
29
30 59. Androga L, Sharma D, Amodu A, et al. Sarcopenia, obesity, and mortality in US adults with and
31 without chronic kidney disease. *Kidney Int Rep* 2017;2(2):201-11. doi:
32 10.1016/j.ekir.2016.10.008 [published Online First: 2017/04/26]
33
34 60. Weisbord SD, Fried LF, Arnold RM, et al. Prevalence, severity, and importance of physical and
35 emotional symptoms in chronic hemodialysis patients. *J Am Soc Nephrol* 2005;16(8):2487-94.
36 doi: 10.1681/asn.2005020157 [published Online First: 2005/06/25]
37
38 61. Flythe JE, Hilliard T, Castillo G, et al. Symptom Prioritization among Adults Receiving In-Center
39 Hemodialysis: A Mixed Methods Study. *Clin J Am Soc Nephrol* 2018;13(5):735-45. doi:
40 10.2215/cjn.10850917 [published Online First: 2018/03/22]
41
42 62. Gregg LP, Bossola M, Ostrosky-Frid M, et al. Fatigue in CKD: Epidemiology, Pathophysiology,
43 and Treatment. *Clin J Am Soc Nephrol* 2021 doi: 10.2215/cjn.19891220 [published Online
44 First: 2021/04/17]
45
46 63. Flythe JE, Dorough A, Narendra JH, et al. Perspectives on symptom experiences and symptom
47 reporting among individuals on hemodialysis. *Nephrol Dial Transplant* 2018;33(10):1842-52.
48 doi: 10.1093/ndt/gfy069 [published Online First: 2018/04/20]
49
50 64. Metzger M, Abdel-Rahman EM, Boykin H, et al. A Narrative Review of Management Strategies
51 for Common Symptoms in Advanced CKD. *Kidney Int Rep* 2021;6(4):894-904. doi:
52 10.1016/j.ekir.2021.01.038 [published Online First: 2021/04/30]
53
54 65. Johansen KL. The Promise and Challenge of Aerobic Exercise in People Undergoing Long-Term
55 Hemodialysis. *Clin J Am Soc Nephrol* 2021;16(4):505-07. doi: 10.2215/cjn.01960221
56 [published Online First: 2021/03/27]
57
58 66. Fuller JT, Hartland MC, Maloney LT, et al. Therapeutic effects of aerobic and resistance exercises
59 for cancer survivors: a systematic review of meta-analyses of clinical trials. *Br J Sports Med*
60

- 1
2
3 2018;52(20):1311. doi: 10.1136/bjsports-2017-098285 [published Online First: 2018/03/20]
4
5 67. Amir N, Tong A, McCarthy H, et al. Trajectories of quality of life in chronic kidney disease: a
6 novel perspective of disease progression. *Nephrol Dial Transplant* 2021 doi:
7 10.1093/ndt/gfab006 [published Online First: 2021/01/29]
8
9 68. Parker K. Intradialytic Exercise is Medicine for Hemodialysis Patients. *Curr Sports Med Rep*
10 2016;15(4):269-75. doi: 10.1249/jsr.0000000000000280 [published Online First: 2016/07/12]
11
12 69. March DS, Hurt AW, Grantham CE, et al. A Cost-Effective Analysis of the CYCLE-HD
13 Randomized Controlled Trial. *Kidney International Reports* doi: 10.1016/j.ekir.2021.02.036
14
15 70. Fuhrmann I, Krause R. Principles of exercising in patients with chronic kidney disease, on dialysis
16 and for kidney transplant recipients. *Clin Nephrol* 2004;61 Suppl 1:S14-25. [published Online
17 First: 2004/07/06
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Summary of the effect of exercise on cardiovascular risk factor in CKD patients

Author (year)	Design	Stage of CKD	k (n)	Exercise type	Mode	SMD or MD (95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
SBP										
Pei (2019)	RCT/quasi-RCT	Mixed	12(514)	AE	-	MD:-2.91 (-6.68, 0.87)	-	0.13	40.0%	⊕⊕○○
Wu (2020)	RCT/quasi-RCT	Predialysis	3 (204)	AE+RT	-	SMD:-0.19(-0.46,0.08)	Small	0.16	50.0%	⊕○○○
Chen (2019)	RCT	KTRs	5(198)	Mixed	-	SMD:0.18(-0.10,0.46)	Small	0.21	0.0%	⊕○○○
Pu (2019)	RCT	HD	7(287)	Mixed	Intradialytic	SMD:-0.28(-0.52,-0.05)	Small	0.02	0.0%	⊕○○○
Yamamoto (2021)	RCT	Predialysis	10(392)	AE	-	SMD:-0.75(-1.24,-0.26)	Moderate	0.003	80.3%	⊕○○○
Thompson (2019)	RCT	Predialysis	10(335)	Mixed	-	MD:-4.30(-9.00,0.40)	-	N.P.	50.4%	⊕○○○
Zhang (2019)	RCT	Predialysis	14(463)	Mixed	-	SMD:-0.41(-0.70,-0.11)	Small	0.007	55.0%	⊕⊕⊕○
Huang (2019)	RCT	HD	7(260)	Mixed	Mixed	SMD:-0.17(-0.41,0.08)	Small	0.18	8.0%	⊕⊕○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	9(347)	Mixed	-	SMD:0.25(0.04,0.47)	Small	0.02	0.0%	⊕○○○
Heiwe (2014)	RCT	HD	10(312)	Mixed	-	SMD:0.04(-0.34,0.41)	Small	0.8	58.0%	⊕○○○
Sheng (2014)	RCT	HD	7(296)	Mixed	Intradialytic	SMD:-0.27(-0.50,-0.04)	Small	0.02	0.0%	⊕○○○
Ferrari (2019)	RCT	HD	10(332)	AE	Intradialytic	MD:-10.07(16.35,-3.78)	-	0.002	44.0%	⊕○○○
Wyngaert (2018)	RCT	Predialysis	8(269)	AE	-	SMD:0.08(-0.58,0.74)	Small	0.81	84%	⊕○○○
DBP										
Pei (2019)	RCT/quasi-RCT	Mixed	12(514)	AE	-	MD:-1.11 (-3.41, 1.20)	-	0.35	0.0%	⊕⊕○○
Wu (2020)	RCT/quasi-RCT	Predialysis	4 (194)	AE+RT	-	SMD:-0.47(-1.10,0.15)	Small	0.14	70.0%	⊕○○○
Chen (2019)	RCT	KTRs	5(198)	Mixed	-	SMD:0.04(-0.45,0.52)	Small	0.89	59.0%	⊕○○○
Pu (2019)	RCT	HD	7(287)	Mixed	Intradialytic	SMD:-0.32(-0.55,-0.08)	Small	0.008	42.0%	⊕○○○

Thompson (2019)	RCT	Predialysis	8(303)	Mixed	-	MD:-1.18(-4.76,2.40)	-	N.P.	60.5%	⊕○○○
Zhang (2019)	RCT	Predialysis	12(399)	Mixed	-	SMD:-0.31(-0.71,0.08)	Small	0.12	70.0%	⊕⊕○○
Huang (2019)	RCT	HD	7(260)	Mixed	Mixed	SMD:-0.23(-0.69,0.24)	Small	0.34	68.0%	⊕○○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	11(419)	Mixed	-	SMD:0.16(-0.04,0.36)	Small	0.11	40.0%	⊕○○○
Heiwe (2014)	RCT	HD	10(212)	Mixed	Mixed	SMD:0.17(-0.16,0.49)	Small	0.3	45.0%	⊕⊕○○
Sheng (2014)	RCT	HD	7(296)	Mixed	Intradialytic	SMD:-0.24(-0.47,-0.01)	Small	0.04	52.1%	⊕○○○
Ferrari (2019)	RCT	HD	10(334)	AE	Intradialytic	MD:-2.96(-7.71,1.78)	-	0.22	0.0%	⊕○○○
Wyngaert (2018)	RCT	Predialysis	7(237)	AE	-	SMD-0.09(-0.78,0.59)	Small	0.79	83%	⊕○○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; DBP = diastolic blood pressure; SBP = systolic blood pressure; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; GRADE = Grading of Recommendations Assessment, Development, and Evaluation; N.P. = no report.

Table 2 Summary of the effect of exercise on cardiopulmonary fitness in CKD patients

Author (year)	Design	Stage of CKD	k (n)	Exercise type	Mode	SMD or MD (95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
VO_{2peak}										
Pei (2019)	RCT/quasi-RCT	Mixed	17(464)	AE	-	MD:2.08(1.10,3.05)	-	<0.001	25.0%	⊕⊕○○
Nakamura (2020)	RCT/cross-over	Predialysis	10(401)	Mixed	-	SMD:0.88(0.53,1.23)	Large	<0.001	56.0%	⊕⊕○○
Chen (2019)	RCT	KTRs	6(202)	Mixed	-	SMD:0.33(-0.02,0.69)	Small	0.06	27.0%	⊕○○○
Andrade (2019)	RCT	HD	5(201)	AE+RT	Intradialytic	SMD:1.01(0.71,1.30)	Large	<0.001	0.0%	⊕⊕○○
Chung (2016)	RCT	HD	6(238)	Mixed	Intradialytic	SMD:0.55(0.18,0.92)	Moderate	0.003	52.9%	⊕○○○
Pu (2019)	RCT	HD	10(400)	Mixed	Intradialytic	SMD:0.57(0.23,0.90)	Moderate	<0.001	59.0%	⊕⊕○○
Yamamoto (2021)	RCT	Predialysis	10(365)	AE	-	SMD:0.54(0.29,0.78)	Moderate	<0.001	24.6%	⊕○○○
Yang (2017)	RCT	Mixed	5(179)	Mixed	-	SMD:0.33(0.03,0.63)	Small	0.003	47.0%	⊕⊕○○
Huang (2019)	RCT	HD	10(371)	Mixed	Mixed	SMD:0.73(0.52,0.95)	Moderate	<0.001	71.0%	⊕⊕○○
Matsuzawa (2017)	RCT	HD	18(582)	Mixed	Mixed	SMD:0.62(0.38,0.87)	Moderate	<0.001	49.0%	⊕⊕⊕⊕
Smart (2011)	RCT	HD	8(365)	Mixed	Mixed	SMD:0.75(0.39,1.11)	Moderate	<0.001	60.0%	⊕⊕○○
Bogataj (2020)	RCT	HD	20(504)	Mixed	Mixed	SMD:0.58(0.32,0.85)	Moderate	<0.001	57.4%	⊕○○○
Sheng (2014)	RCT	HD	7(310)	Mixed	Intradialytic	SMD:0.53(0.30,0.76)	Moderate	<0.001	36.0%	⊕○○○
Neto (2018)	RCT	HD	10(394)	Mixed	Intradialytic	SMD:0.60(0.15,1.04)	Moderate	0.008	76.0%	⊕○○○
Ferrari (2019)	RCT	HD	5(201)	AE+RT	Intradialytic	MD:5.41(4.03,6.79)	-	<0.001	0.0%	⊕○○○
Ferrari (2019)	RCT	HD	7(248)	AE	Intradialytic	MD:2.07(0.42,3.72)	-	<0.001	0.0%	⊕○○○
Wyngaert (2018)	RCT	Predialysis	11(325)	AE	-	SMD:0.99(0.49,1.48)	Large	<0.001	74.0%	⊕○○○
Oguchi (2018)	RCT	KTRs	4(182)	Mixed	-	SMD:0.38(-0.06,0.82)	Small	0.09	45.0%	⊕⊕○○

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

6MWT										
Pei (2019)	RCT/quasi-RCT	Mixed	8 (496)	AE	-	MD:0.04 (-0.52, 0.59)	-	0.90	86.0%	⊕○○○
Nakamura (2020)	RCT/cross-over	Predialysis	5(392)	Mixed	-	SMD:1.04(0.17,1.90)	Large	0.02	92.0%	⊕○○○
Lu (2019)	RCT	Dialysis	11(300)	Mixed	Mixed	SMD:0.52(0.31,0.72)	Moderate	<0.001	39.0%	⊕⊕⊕○
Chung (2016)	RCT	HD	4(127)	Mixed	Intradialytic	SMD:0.44(0.09,0.80)	Small	0.015	0.0%	⊕⊕○○
Zhang (2021)	RCT	HD	8(299)	RT	Intradialytic	SMD:0.52(0.28,0.75)	Moderate	<0.001	18.7%	⊕⊕○○
Pu (2019)	RCT	HD	7(219)	Mixed	Intradialytic	SMD:0.57(0.30,0.84)	Moderate	<0.001	0.0%	⊕⊕○○
Clarkson (2019)	RCT	Dialysis	18(744)	Mixed	-	MD:33.64(23.74,43.54)	-	<0.001	0.0%	⊕⊕⊕○
Huang (2019)	RCT	HD	7(205)	Mixed	Mixed	SMD:1.01(0.26,1.76)	Large	0.008	83.0%	⊕○○○
Matsuzawa (2017)	RCT	HD	10(326)	Mixed	Mixed	SMD:0.58(0.24,0.93)	Moderate	<0.001	53.0%	⊕⊕○○
Bogataj (2020)	RCT	HD	19	Mixed	Mixed	SMD:0.44(0.21,0.67)	Small	<0.001	49.6%	⊕○○○
Sheng (2014)	RCT	HD	4(146)	Mixed	Intradialytic	SMD:0.58(0.23,0.93)	Moderate	<0.001	89.7%	⊕○○○
Neto (2018)	RCT	HD	6(158)	Mixed	Intradialytic	SMD:0.96(0.11,1.80)	Large	0.03	82.0%	⊕○○○
Ferrari (2019)	RCT	HD	6(211)	RT	Intradialytic	MD:68.5(29.05,107.96)	-	<0.001	36.0%	⊕○○○
Ferrari (2019)	RCT	HD	6(188)	AE	Intradialytic	MD:64.98(43.86,86.11)	-	<0.001	0.0%	⊕○○○
Aerobic capacity										
Heiwe (2011)	RCT/quasi-RCT	Mixed	24(847)	Mixed	-	SMD:-0.56(-0.70,-0.42)	Moderate	<0.001	12.0%	⊕○○○
Heiwe (2014)	RCT	HD	21(374)	Mixed	Mixed	SMD:-0.80(-1.02,-0.58)	Large	<0.001	0.0%	⊕⊕○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; VO_{2peak} = peak oxygen uptake; 6MWT = 6 minutes walk test; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

Table 3 Summary of the effect of exercise on muscle strength in CKD patients

Author(year)	Design	Stage of CKD	k (n)	Exercise type	Mode	SMD or MD (95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
Cheema (2014)	RCT	Predialysis	7(249)	RT	-	SMD:1.15(0.80,1.49)	Large	0.161	35.0%	⊕⊕○○
Nakamura (2020)	RCT/cross-over	Predialysis	4(119)	Mixed	-	SMD:0.35(-0.03,0.73)	Small	0.07	7.0%	⊕○○○
Lu (2019)	RCT	Dialysis	5(234)	Mixed	Mixed	SMD:0.59(0.20,0.98)	Moderate	0.003	52.0%	⊕⊕○○
Lu (2019)	RCT	Dialysis	7(224)	Mixed	Mixed	SMD:0.47(0.20,0.74)	Small	<0.001	0.0%	⊕⊕○○
Zhang (2021)	RCT	HD	6(300)	RT	Intradialytic	SMD:0.35(0.12,0.58)	Small	0.003	41.6%	⊕⊕○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	9(358)	Mixed	-	SMD:-0.52(-0.73,-0.31)	Moderate	<0.001	0.0%	⊕○○○
Heiwe (2014)	RCT	HD	12(385)	Mixed	Mixed	SMD:-0.56(-0.77,-0.35)	Moderate	<0.001	0.0%	⊕○○○
Matsuzawa (2017)	RCT	HD	9(281)	Mixed	Mixed	SMD:0.94(0.67,1.21)	Large	<0.001	10.0%	⊕○○○
Neto (2018)	RCT	HD	9(250)	Mixed	Intradialytic	SMD:0.61(0.39,0.83)	Moderate	<0.001	58.9%	⊕○○○
Ju (2020)	RCT	Mixed	3(115)	Mixed	-	SMD:0.52(0.14,0.89)	Moderate	0.007	0.0%	⊕○○○

Abbreviation: RCT = randomized controlled trial; RT = resistance training; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Table 4 Summary of the effect of exercise on muscle endurance in CKD patients

Author (year)	Design	Stage of CKD	k (n)	Exercise type	Mode	Outcome	SMD or MD (95% CI)	Effect size	P	I ²	GRADE
Lu (2019)	RCT	Dialysis	3(193)	Mixed	Mixed	STS 10	MD:-4.69(-9.01,-0.38)	-	0.028	72.2%	⊕○○○
Bogataj (2020)	RCT	HD	5(461)	Mixed	-	STS 10	SMD:-0.55(-1.00,-0.09)	Moderate	0.019	71.6%	⊕○○○
Lu (2019)	RCT	Dialysis	6(240)	Mixed	Mixed	STS 30	SMD:0.43(0.17,0.69)	Small	0.001	2.0%	⊕⊕○○
Zhang (2021)	RCT	HD	5(164)	RT	Intradialytic	STS 30	SMD:0.42(0.11,0.74)	Small	0.008	0.0%	⊕○○○
Sheng (2014)	RCT	HD	3(106)	Mixed	Intradialytic	STS 60	SMD:0.71(0.31,1.12)	Moderate	<0.001	0.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	5(445)	AE	-	STS 60	MD:2.08(1.1,3.05)	-	0.98	82.0%	⊕○○○
Nakamura (2020)	RCT/cross-over	Predialysis	3(170)	Mixed	-	TUGT	SMD:-0.42(-0.73,-0.11)	Small	0.007	0.0%	⊕○○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	7(191)	Mixed	-	Walking capacity	SMD:-0.48(-0.79,-0.17)	Small	0.003	2.0%	⊕○○○
Heiwe (2014)	RCT	HD	7(174)	Mixed	Mixed	Walking capacity	SMD:-0.33(-0.67,0.01)	Small	0.06	16.0%	⊕⊕⊕○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; STS 10 = sit to stand 10 test; STS 30 = sit to stand 30 test; STS 60 = sit to stand 60 test; TUGT = timed up and go test; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

Table 5 Summary of the effect of exercise on body composition in CKD patients

Author (year)	Design	Stage of CKD	k (n)	Exercise type	Mode	SMD (95% CI)	Effect size	P	I ²	GRADE
Chen (2019)	RCT	KTRs	4(166)	Mixed	-	SMD:0.02(-0.28,0.33)	Small	0.89	0.0%	⊕○○○
Yamamoto (2021)	RCT	Predialysis	10(414)	AE	-	SMD:-0.19(-0.38,-0.00)	Small	0.026	0.0%	⊕⊕○○
Zhang (2019)	RCT	Predialysis	13(466)	Mixed	-	SMD:-0.21(-0.39,-0.03)	Small	0.02	0.0%	⊕⊕⊕○
Wyngaert (2018)	RCT	Predialysis	9(294)	AE	-	SMD:-0.36(-0.60,-0.13)	Small	0.002	48.0%	⊕⊕○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; SMD = standardized mean difference; KTRs = kidney transplant recipients;;GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 6 Summary of the effect of exercise on dialysis-related symptoms in CKD patients

Author (year)	Design	Stage of CKD	k (n)	Exercise type	Mode	Outcomes	SMD or MD (95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
Ferreira (2019)	RCT/quasi-RCT	HD	10(346)	AE	Intradialytic	Kt/V	SMD:2.21(1.17,3.25)	Large	<0.001	92.0%	⊕○○○
Pu (2019)	RCT	HD	10(301)	Mixed	Intradialytic	Kt/V	SMD:0.29(0.06,0.52)	Small	0.01	0.0%	⊕○○○
Huang (2019)	RCT	HD	8(257)	Mixed	Mixed	Kt/V	SMD:0.19(-0.06,0.43)	Small	0.14	0.0%	⊕○○○
Sheng (2014)	RCT	HD	7(233)	Mixed	Intradialytic	Kt/V	SMD:0.27(0.01,0.53)	Small	0.04	0.0%	⊕○○○
Ferrari (2019)	RCT	HD	12(370)	AE	Intradialytic	Kt/V	MD:0.08(0.0,0.15)	-	0.04	56.0%	⊕○○○
Ferrari (2019)	RCT	HD	6(220)	RT	Intradialytic	Kt/V	MD:0.10(0.0,0.2)	-	0.06	6.0%	⊕○○○
Song (2018)	RCT	HD	4(141)	Mixed	Mixed	RLS	SMD:-1.79(-2.21,-1.37)	Large	<0.001	87.0%	⊕○○○
Song (2018)	RCT	HD	3(139)	Mixed	Mixed	Fatigue	SMD:-0.85(-1.20,-0.50)	Large	<0.001	0.0%	⊕○○○
Zhao (2019)	RCT	Dialysis	3(141)	Mixed	-	Fatigue	SMD:-0.97(-1.32,-0.62)	Large	<0.001	47.0%	⊕⊕○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; RLS = Restless Legs Syndrome; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

Table 7 Summary of the effect of exercise on health-related quality of lifes in CKD patients

Author (year)	Design	Stage of CKD	k (n)	Exercise type	Mode	Outcomes	SMD or MD (95% CI)	Effect size	P	I ²	GRADE
Salhab (2019)	RCT	HD	5(282)	AE	Intradialytic	PCS	SMD:1.82(-0.92,4.55)	Large	0.19	98.0%	⊕○○○
Chung (2016)	RCT	HD	6(229)	Mixed	Intradialytic	PCS	SMD:0.46(0.20,0.73)	Small	<0.001	1.90%	⊕⊕○○
Zhang (2021)	RCT	HD	7(297)	RT	Intradialytic	PCS	SMD:0.23(-0.00,0.46)	Small	0.055	0.0%	⊕⊕○○
Pu (2019)	RCT	HD	10(320)	Mixed	Intradialytic	PCS	SMD:0.57(0.14,1.01)	Moderate	0.01	70.0%	⊕○○○
Zhao (2019)	RCT	Dialysis	5(186)	Mixed	-	PCS	SMD:0.31(0.02,0.61)	Small	0.04	46.0%	⊕⊕○○
Huang (2019)	RCT	HD	7(263)	Mixed	Mixed	PCS	SMD:0.34(0.09,0.59)	Small	0.007	27.0%	⊕⊕○○
Matsuzawa (2017)	RCT	HD	9(264)	Mixed	Mixed	PCS	SMD:0.53(0.52,0.82)	Moderate	<0.001	19.0%	⊕○○○
Sheng (2014)	RCT	HD	7(256)	Mixed	Intradialytic	PCS	SMD:0.30(0.05,0.55)	Small	0.02	39.5%	⊕○○○
Neto (2018)	RCT	HD	7(187)	Mixed	Intradialytic	PCS	SMD:0.50(-0.19,1.18)	Moderate	0.16	62.0%	⊕○○○
Salhab (2019)	RCT	HD	5(282)	AE	Intradialytic	MCS	SMD:1.02(0.31,1.73)	Large	0.005	75.0%	⊕○○○
Chung (2016)	RCT	HD	5(193)	Mixed	Intradialytic	MCS	SMD:0.23(-0.05,0.52)	Small	0.109	0.0%	⊕⊕○○
Zhang (2021)	RCT	HD	7(297)	RT	Intradialytic	MCS	SMD:0.13(-0.10,0.36)	Small	0.082	46.5%	⊕⊕○○
Pu (2019)	RCT	HD	8(219)	Mixed	Intradialytic	MCS	SMD:0.19(-0.09,0.46)	Small	0.18	30.0%	⊕⊕○○
Zhao (2019)	RCT	Dialysis	5(186)	Mixed	-	MCS	SMD:0.30(-0.20,0.80)	Small	0.24	64.0%	⊕○○○
Huang (2019)	RCT	HD	7(263)	Mixed	Mixed	MCS	SMD:0.27(0.02,0.51)	Small	0.03	0.0%	⊕⊕○○
Matsuzawa (2017)	RCT	HD	8(228)	Mixed	Mixed	MCS	SMD:0.14(-0.15,0.42)	Small	0.34	10.0%	⊕○○○
Sheng (2014)	RCT	HD	5(167)	Mixed	Intradialytic	MCS	SMD:0.14(-0.16,0.43)	Small	0.37	14.8%	⊕○○○

Neto (2018)	RCT	HD	7(185)	Mixed	Intradialytic	MCS	SMD:0.39(-0.19,0.98)	Small	0.19	50.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	6(522)	AE	-	Physical function (SF-36)	MD:8.36(-1.24,17.95)	-	0.09	76.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	7(562)	AE	-	Physical role (SF-36)	MD:14.65(1.47,27.84)	-	0.03	78.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	6(447)	AE	-	Social function (SF-36)	MD:8.24(-1.09,17.58)	-	0.08	85.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	6(513)	AE	-	Pain (SF-36)	MD:5.94(1.65,10.23)	-	0.007	49.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	7(562)	AE	-	General health (SF-36)	MD:8.90(2.48,15.32)	-	0.007	71.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	6(542)	AE	-	Mental health (SF-36)	MD:7.30(-0.94,15.54)	-	0.08	84.0%	⊕○○○
Cheema (2014)	RCT	Predialysis	6 (223)	RT	-	HRQOL	SMD:0.83(0.51,1.16)	Large	0.226	27.8%	⊕⊕○○
Oguchi (2018)	RCT	KTRs	4(179)	Mixed	-	HRQOL	SMD:0.54(0.02,1.07)	Moderate	0.04	58.0%	⊕○○○
Ju (2020)	RCT	Mixed	3 (387)	Mixed	-	Symptom/problem (KDQOL)	SMD:1.92(-1.06,4.90)	Large	0.21	99.0%	⊕○○○
Ju (2020)	RCT	Mixed	3 (387)	Mixed	-	Effects of kidney disease (KDQOL)	SMD:-3.69(-8.56,1.19)	Large	0.14	99.0%	⊕○○○
Ju (2020)	RCT	Mixed	3 (387)	Mixed	-	Burden of kidney disease (KDQOL)	SMD:1.04 (-0.75,2.82)	Large	0.26	98.0%	⊕○○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; COM = combine; HRQOL = health-related quality of life; PCS = physical component summary; MCS = mental component summary; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; SF-36 = Short-Form Health Survey-36; KDQOL = kidney disease quality of life; GRADE = Grading of Recommendations Assessment,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Development, and Evaluation.

For peer review only

Supplementary Table S1 The detailed search strategy

Databases	#	Search strategy
Pubmed	1	"renal insufficiency, chronic"[MeSH Terms]
	2	"chronic renal insufficiency"[Title/Abstract] or "chronic kidney insufficiency"[Title/Abstract] or "chronic kidney disease"[Title/Abstract] or "chronic renal disease"[Title/Abstract]
	3	"CKD"[Title/Abstract] or "CKF"[Title/Abstract] or "CRD"[Title/Abstract] or "CRF"[Title/Abstract]
	4	"end-stage kidney"[Title/Abstract] or "end-stage renal"[Title/Abstract] or "endstage kidney"[Title/Abstract] or "endstage renal"[Title/Abstract]
	5	"ESRD"[Title/Abstract] or "ESRF"[Title/Abstract] or "ESKD"[Title/Abstract] or "ESKF"[Title/Abstract]
	6	"Renal Replacement Therapy"[MeSH Terms]
	7	"dialysis"[Title/Abstract]
	8	"hemodialysis"[Title/Abstract] or "haemodialysis"[Title/Abstract] or "hemodiafiltration"[Title/Abstract] or "haemodiafiltration"[Title/Abstract] or "HD"[Title/Abstract]
	9	"PD"[Title/Abstract]
	10	"renal transplantation"[Title/Abstract] or "kidney grafting"[Title/Abstract] or "kidney transplantation"[Title/Abstract]
	11	"KTRs"[Title/Abstract]
	12	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
	13	"Exercise"[MeSH Terms]
	14	"Exercise Movement Techniques"[MeSH Terms]
	15	"Exercise Therapy"[MeSH Terms]
	16	"Sports"[MeSH Terms]
	17	"train"[Title/Abstract] or "physical activity"[Title/Abstract] or "exercise"[Title/Abstract]
	18	#13 or #14 or #15 or #16 or #17
	19	"Systematic Review"[Publication Type] or "Systematic Reviews as Topic"[MeSH Terms]
	20	"meta analysis"[Publication Type] or "Meta-Analysis as Topic"[MeSH Terms]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	21	"Systematic Review"[Title/Abstract] or "system review"[Title/Abstract] or "data pooling"[Title/Abstract] or "meta"[Title/Abstract]
	22	#19 or #20 or #21
	23	#12 and #18 and #22
CDSR	1	MeSH descriptor: [Kidney Diseases] explode all trees
	2	("chronic kidney disease") or ("chronic renal disease") or ("chronic kidney failure") or ("chronic renal failure"):ti,ab,kw
	3	(CKF or CKD or CRF or CRD):ti,ab,kw
	4	("end-stage kidney") or ("end-stage renal") or ("endstage kidney") or ("endstage renal"):ti,ab,kw
	5	ESRD or ESRF or ESKD or ESKF:ti,ab,kw
	6	MeSH descriptor: [Renal Replacement Therapy] explode all trees
	7	dialysis:ti,ab,kw
	8	(hemodialysis or haemodialysis or hemodiafiltration or haemodiafiltration or HD):ti,ab,kw
	9	PD:ti,ab,kw
	10	("renal transplantation") or ("kidney grafting") or ("kidney transplantation"):ti,ab,kw
	11	KTRs:ti,ab,kw
	12	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
	13	MeSH descriptor: [Exercise] explode all trees
	14	MeSH descriptor: [Exercise Movement Techniques] explode all trees
	15	MeSH descriptor: [Exercise Therapy] explode all trees
	16	MeSH descriptor: [Sports] explode all trees
	17	(train or ("physical activity") or exercise):ti,ab,kw
	18	#13 or #14 or #15 or #16 or #17
	19	MeSH descriptor: [Meta-Analysis as Topic] explode all trees
	20	MeSH descriptor: [Systematic Reviews as Topic] explode all trees
	21	("systematic review") or ("system review") or ("data pooling") or (meta):ti,ab,kw
	22	#19 or #20 or #21

	23	#12 and #18 and #22
Embase	1	'kidney disease'/exp
	2	('chronic kidney disease' or 'chronic renal disease' or 'chronic kidney failure' or 'chronic renal failure'):ti,ab,kw
	3	(CKF or CKD or CRF or CRD):ti,ab,kw
	4	('end-stage kidney' or 'end-stage renal' or 'endstage kidney' or 'endstage renal'):ti,ab,kw
	5	(ESRD or ESRF or ESKD or ESKF):ti,ab,kw
	6	'renal replacement therapy'/exp
	7	'dialysis':ti,ab,kw
	8	(hemodialysis or haemodialysis or hemofiltration or haemofiltration or hemodiafiltration or haemodiafiltration or HD):ti,ab,kw
	9	PD:ti,ab,kw
	10	('renal transplantation' or 'kidney grafting' or 'kidney transplantation'):ti,ab,kw
	11	KTRs:ti,ab,kw
	12	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
	13	'exercise'/exp
	14	'physical activity'/exp
	15	'sport'/exp
	16	(train or 'physical activity' or exercise):ti,ab,kw
	17	#13 or #14 or #15 or #16
	18	'systematic review (topic)'/exp or 'systematic review'/exp
	19	'meta analysis (topic)'/exp or 'meta analysis'/exp
	20	('systematic review' or 'system review' or 'data pooling' or meta):ti,ab,kw
	21	#18 or #19 or #20
	22	#12 and #17 and #21
Web of Science	1	TS: ("chronic kidney disease" or "chronic renal disease" or "chronic kidney failure" or "chronic renal failure" or CKD or CRD or CKF or CRF)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	2	TS: ("end-stage kidney" or "end-stage renal" or "endstage kidney" or "endstage renal" or ESKD or ESKF or ESRD or ESRF)
	3	TS: ("renal replacement therapy" or dialysis or hemodialysis or haemodialysis or hemofiltration or haemofiltration or hemodiafiltration or haemodiafiltration or HD or PD)
	4	TS: ("renal transplantation" or "kidney grafting" or "kidney transplantation" or KTRs)
	5	#1 or #2 or #3 or #4
	6	TS: (train or exercise or "physical activity")
	7	TS: ("systematic review" or "system review" or "data pooling" or meta)
	8	#1 and #2 and #3 and #4 and #5

Supplementary Table S2 The characteristic of excluded studies

Studies	Reasons for exclusion
Nantakool et al (2020)	Non predefine outcome
Sawant et al (2014)	Non predefine outcome
Smart et al (2014)	Duplicate literature
Barcellos et al (2015)	Meta-analysis was not conducted
Yang et al (2020)	Non predefine outcome
Young et al (2018)	Included cases<100
Phan et al (2015)	Duplicate literature
Molsted et al (2019)	Included cases<100
Segura et al (2010)	Non-English
Ferreira et al (2020)	Non predefine outcome
Koufaki et al (2013)	Meta-analysis was not conducted
Smart et al (2012)	Abstracts
Howden et al (2012)	Meta-analysis was not conducted
Calella et al (2019)	Meta-analysis was not conducted
Singh et al (2005)	Meta-analysis was not conducted
Cardoso et al (2020)	Non predefine outcome
Villanego et al (2020)	Non-English
Medeiros et al (2017)	Intervention did not fit
Macdonald et al (2009)	Meta-analysis was not conducted
Wen et al (2019)	Non predefine outcome
Yang et al (2015)	Non predefine outcome
Thangarasa et al (2018)	Included cases<100
Chan et al (2016)	Meta-analysis was not conducted

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Johansen et al (2010)	Intervention did not fit
Thompson et al (2020)	Correction for published paper
Bakaloudi et al (2020)	Meta-analysis was not conducted
Kirkman et al (2019)	Meta-analysis was not conducted
Afsar et al (2018)	Meta-analysis was not conducted

For peer review only

Supplementary Table S3 The basic characteristics of the included meta-analyses

Author (year)	Design	Stage of CKD	k (n)	Exercise type	Mode	Outcomes	SMD or MD(95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
Pei (2019)	RCT/quasi-RCT	Mixed	17(464)	AE	-	VO _{2peak}	MD:2.08 (1.1,3.05)	-	<0.001	25.0%	Low
			5 (445)			STS 60	MD:2.08 (1.1,3.05)	-	0.98	82.0%	Very low
			8 (496)			6MWT	MD:0.04 (-0.52, 0.59)	-	0.9	86.0%	Very low
			12(514)			SBP	MD:-2.91 (-6.68, 0.87)	-	0.13	40.0%	Low
			12(514)			DBP	MD:-1.11 (-3.41, 1.20)	-	0.35	0.0%	Low
			6(522)			Physical function (SF-36)	MD:8.36(-1.24,17.95)	-	0.09	76.0%	Very low
			7(562)			Physical role (SF-36)	MD:14.65(1.47,27.84)	-	0.03	78.0%	Very low
			6(447)			Social function (SF-36)	MD:8.24(-1.09,17.58)	-	0.08	85.0%	Very low
			6(513)			Pain (SF-36)	MD:5.94(1.65,10.23)	-	0.007	49.0%	Very low
			7(562)			General health (SF-36)	MD:8.90(2.48,15.32)	-	0.007	71.0%	Very low
6(542)	Mental health (SF-36)	MD:7.30(-0.94,15.54)	-	0.08	84.0%	Very low					
Ferreira (2019)	RCT/quasi-RCT	HD	10(346)	AE	Intradialytic	Kt/V	SMD:2.21(1.17,3.25)	Large	<0.001	92.0%	Very low
Cheema (2014)	RCT	Predialysis	7(249)	RT	-	Muscle Strength	SMD:1.15 (0.80-1.49)	Large	0.161	35.0%	Low
			6(223)			HRQoL	SMD:0.83(0.51-1.16)	Large	0.226	27.8%	Low
Wu (2020)	RCT/quasi-RCT	Predialysis	3(204)	AE+RT	-	SBP	SMD:-0.19(-0.46,0.08)	Small	0.16	50.0%	Very low
			4(194)			DBP	SMD:-0.47(-1.10,0.15)	Small	0.14	70.0%	Very low

Nakamura (2020)	RCT/cross-over	Predialysis	10(401)	Mixed	-	VO _{2peak}	SMD:0.88(0.53,1.23)	Large	<0.001	56.0%	Low
			4(119)			Muscle Strength	SMD:0.35(-0.03,0.73)	Small	0.07	7.0%	Very low
			5(392)			6MWT	SMD:1.04(0.17,1.90)	Large	0.02	92.0%	Very low
			3(170)			TUGT	SMD:-0.42(-0.73,-0.11)	Small	0.007	0.0%	Very low
Lu (2019)	RCT	Dialysis	11(300)	Mixed	Mixed	6MWT	MD:67.6(49.93,85.26)	-	<0.001	30.6%	Moderate
			3(193)			STS 10	MD:-4.69(-9.01,-0.38)	-	0.028	72.2%	Very low
			5(234)			HGS	MD:5.35(3.34,7.37)	-	<0.001	0.3%	Low
			7(224)			Muscle strength	MD:3.67(1.37,5.97)	-	0.020	38.6%	Low
			6(240)			STS 30	MD:2.43(0.91,3.96)	-	0.002	21.2%	Low
Chen (2019)	RCT	KTRs	5(198)	Mixed	-	SBP	SMD:0.18(-0.10,0.46)	Small	0.21	0.0%	Very low
			5(198)			DBP	SMD:0.04(-0.45,0.52)	Small	0.89	59.0%	Very low
			4(166)			BMI	SMD:0.02(-0.28,0.33)	Small	0.89	0.0%	Very low
			6(202)			VO _{2peak}	SMD:0.33(-0.02,0.69)	Small	0.06	27.0%	Very low
Song (2018)	RCT	HD	4(141)	Mixed	Mixed	RLS	SMD:-1.79(-2.21,-1.37)	Large	<0.001	87.0%	Very low
			3(139)			Fatigue	SMD:-0.85(-1.20,-0.50)	Large	<0.001	0.0%	Very low
Salhab (2019)	RCT	HD	5(282)	AE	Intradialytic	PCS	SMD:1.82(-0.92,4.55)	Large	0.19	98.0%	Very low
			5(282)			MCS	SMD:1.02(0.31,1.73)	Large	0.005	75.0%	Very low
Andrade (2019)	RCT	HD	5(201)	AE+RT	Intradialytic	VO _{2peak}	SMD:1.01(0.71,1.30)	Large	<0.001	0.0%	Low
Chung (2016)	RCT	HD	4(127)	Mixed	Intradialytic	6MWT	SMD:0.44(0.09,0.80)	Small	0.015	0.0%	Low
			6(238)			VO _{2peak}	SMD:0.55(0.18,0.92)	Moderate	0.003	52.9%	Very low
			6(229)			PCS	SMD:0.46(0.20,0.73)	Small	<0.001	1.90%	Low
			5(193)			MCS	SMD:0.23(-0.05,0.52)	Small	0.109	0.0%	Low
Zhang (2021)	RCT	HD	8(299)	RT	Intradialytic	6MWT	SMD:0.52(0.28,0.75)	Moderate	<0.001	18.7%	Very low
			5(164)			STS 30	SMD:0.42(0.11,0.74)	Small	0.008	0.0%	Very low

			6(300)			HGS	SMD:0.35(0.12,0.58)	Small	0.003	41.6%	Very low
			7(297)			PCS	SMD:0.23(-0.00,0.46)	Small	0.055	0.0%	Very low
			7(297)			MCS	SMD:0.13(-0.10,0.36)	Small	0.082	46.5%	Very low
Pu (2019)	RCT	HD	10(301)	Mixed	Intradialytic	Kt/V	SMD:0.29(0.06,0.52)	Small	0.01	0.0%	Very low
			10(400)			VO _{2peak}	SMD:0.57(0.23,0.90)	Moderate	<0.001	59.0%	Low
			7(219)			6MWT	SMD:0.57(0.30,0.84)	Moderate	<0.001	0.0%	Low
			10(320)			PCS	SMD:0.57(0.14,1.01)	Moderate	0.01	70.0%	Very low
			8(219)			MCS	SMD:0.19(-0.09,0.46)	Small	0.18	30.0%	Low
			7(287)			SBP	SMD:-0.28(-0.52,-0.05)	Small	0.02	0.0%	Very low
			7(287)			DBP	SMD:-0.32(-0.55,-0.08)	Small	0.008	42.0%	Very low
Yamamoto (2021)	RCT	Predialysis	10(392)	AE	-	SBP	SMD:-0.75(-1.24,-0.26)	Moderate	0.003	80.3%	Very low
			10(365)			VO _{2peak}	SMD:0.54(0.29,0.78)	Moderate	<0.001	24.6%	Very low
			10(414)			BMI	SMD:-0.19(-0.38,-0.00)	Small	0.026	0.0%	Low
Thompson (2019)	RCT	Predialysis	10(335)	Mixed	-	SBP	MD:-4.3(-9.0,0.4)	-	N.P.	50.4%	Very low
			8(303)			DBP	MD:-1.18(-4.76,2.40)	-	N.P.	60.5%	Very low
Yang (2017)	RCT	Mixed	4(150)	Mixed	-	VO _{2peak}	SMD:0.33(0.03,0.63)	Small	0.003	47.0%	Low
Clarkson (2019)	RCT	Dialysis	18(744)	Mixed	-	6MWT	MD:33.64(23.74,43.54)	-	<0.001	0.0%	Moderate
Zhao (2019)	RCT	Dialysis	3(141)	Mixed	-	Fatigue	SMD:-0.97(-1.32,-0.62)	Large	<0.001	47.0%	Low
			5(186)			PCS	SMD:0.31(0.02,0.61)	Small	0.04	46.0%	Low
			5(186)			MCS	SMD:0.30(-0.20,0.80)	Small	0.24	64.0%	Very low
Zhang (2019)	RCT	Predialysis	14(463)	Mixed	-	SBP	SMD:-0.41(-0.70,-0.11)	Small	0.007	55.0%	Moderate
			12(399)			DBP	SMD:-0.31(-0.71,0.08)	Small	0.12	70.0%	Low
			13(466)			BMI	SMD:-0.21(-0.39,-0.03)	Small	0.02	0.0%	Moderate

Huang (2019)	RCT	HD	8(257)	Mixed	-	Kt/V	SMD:0.19(-0.06,0.43)	Small	0.14	0.0%	Very low
			7(260)			SBP	SMD:-0.17(-0.41,0.08)	Small	0.18	8.0%	Low
			7(260)			DBP	SMD:-0.23(-0.69,0.24)	Small	0.34	68.0%	Very low
			7(205)			6MWT	SMD:1.01(0.26,1.76)	Large	0.008	83.0%	Very low
			7(263)			PCS	SMD:0.34(0.09,0.59)	Small	0.007	27.0%	Low
			7(263)			MCS	SMD:0.27(0.02,0.51)	Small	0.03	0.0%	Low
			10(371)			VO _{2peak}	SMD:0.73(0.52,0.95)	Moderate	<0.001	71.0%	Low
Heiwe (2011)	RCT/quasi-RCT	Mixed	24(847)	Mixed	-	Aerobic capacity	SMD:-0.56(-0.70,-0.42)	Moderate	<0.001	12.0%	Moderate
			9(358)			Muscle strength	SMD:-0.52(-0.73,-0.31)	Moderate	<0.001	0.0%	Low
			7(191)			Walking capacity	SMD:-0.48(-0.79,-0.17)	Small	0.003	2.0%	Low
			9(347)			SBP	SMD:0.25(0.04,0.47)	Small	0.02	0.0%	Low
			11(419)			DBP	SMD:0.16(-0.04,0.36)	Small	0.11	40.0%	High
Heiwe (2014)	RCT	HD	21(374)	Mixed	-	Aerobic capacity	SMD:-0.80(-1.02,-0.58)	Large	<0.001	0.0%	Low
			10(212)			DBP	SMD:0.17(-0.16,0.49)	Small	0.3	45.0%	Low
			10(312)			SBP	SMD:0.04(-0.4,0.41)	Small	0.8	58.0%	Very low
			10(385)			Muscle strength	SMD:-0.56(-0.77,-0.35)	Moderate	<0.001	0.0%	Very low
			7(174)			Walking capacity	SMD:-0.33(-0.67,0.01)	Small	0.06	16.0%	Low
Matsuzawa (2017)	RCT	HD	18(582)	Mixed	-	VO _{2peak}	SMD:0.62(0.38,0.87)	Moderate	<0.001	49.0%	High
			10(326)			6MWT	SMD:0.58(0.24,0.93)	Moderate	<0.001	53.0%	Low
			9(281)			Muscle strength	SMD:0.94(0.67,1.21)	Large	<0.001	10.0%	Very low
			9(264)			PCS	SMD:0.53(0.52,0.82)	Moderate	<0.001	19.0%	Very low
			8(228)			MCS	SMD:0.14(-0.15,0.42)	Small	0.34	10.0%	Very low
Smart (2011)	RCT	HD	8(365)	Mixed	-	VO _{2peak}	SMD:0.75(0.39,1.11)	Moderate	<0.001	60.0%	Low
Bogataj	RCT	HD	19(571)	Mixed	-	6MWT	SMD:0.44(0.21,0.67)	Small	<0.001	49.6%	Very low

(2020)			20(504)			VO _{2peak}	SMD:0.58(0.32,0.85)	Moderate	<0.001	57.4%	Very low
			5(461)			STS 10	SMD:-0.55(-1.00,-0.09)	Moderate	0.019	71.6%	Very low
Sheng (2014)	RCT	HD	7(233)	Mixed	Intradialytic	Kt/V	SMD:0.27(0.01,0.53)	Small	0.040	0.0%	Very low
			7(310)			VO _{2peak}	SMD:0.53(0.30,0.76)	Moderate	<0.001	36.0%	Very low
			7(256)			PCS	SMD:0.30(0.05,0.55)	Small	0.02	39.5%	Very low
			5(167)			MCS	SMD:0.14(-0.16,0.43)	Small	0.37	14.8%	Very low
			4(146)			6MWT	SMD:0.58(0.23,0.93)	Moderate	<0.001	89.7%	Very low
			7(296)			DBP	SMD:-0.24(-0.47,-0.01)	Small	0.04	52.1%	Very low
			7(296)			SBP	SMD:-0.27(-0.50,-0.04)	Small	0.02	0.0%	Very low
			3(106)			STS 60	SMD:0.71(0.31,1.12)	Moderate	<0.001	0.0%	Very low
Neto (2018)	RCT	HD	10(394)	Mixed	Intradialytic	VO _{2peak}	SMD:0.60(0.15,1.04)	Moderate	0.008	76.0%	Very low
			7(187)			PCS	SMD:0.50(-0.19,1.18)	Moderate	0.16	62.0%	Very low
			7(185)			MCS	SMD:0.39(-0.19,0.98)	Small	0.19	50.0%	Very low
			6(158)			6MWT	SMD:0.96(0.11,1.80)	Large	0.03	82.0%	Very low
			9(250)			Muscle strength	SMD:0.61(0.39,0.83)	Moderate	<0.001	58.9%	Very low
Ferrari (2019)	RCT	HD	12(370)	AE	Intradialytic	Kt/V	MD:0.08(0,0.15)	-	0.04	56.0%	Low
			6(220)	RT		Kt/V	MD:0.1(0,0.2)	-	0.06	6.0%	Very low
			5(201)	COM		VO _{2peak}	MD:5.41(4.03,6.79)	-	<0.001	0.0%	Low
			7(248)	AE		VO _{2peak}	MD:2.07(0.42,3.72)	-	<0.001	0.0%	Very low
			6(211)	RT		6MWT	MD:68.5(29.05,107.96)	-	<0.001	36.0%	Low
			6(188)	AE		6MWT	MD:64.98(43.86,86.11)	-	<0.001	0.0%	Low
			10(332)	AE		SBP	MD:-10.07(16.35,-3.78)	-	0.002	44.0%	Low
			10(334)	AE		DBP	MD:-2.96(-7.71,1.78)	-	0.22	0.0%	Low
Wyngaert (2018)	RCT	Predialysis	8(269)	AE	-	SBP	SMD:0.08(-0.58,0.74)	Small	0.81	84%	Very low
			7(237)	AE		DBP	SMD:-0.09(-0.78,0.59)	Small	0.79	83%	Very low

			11(325)			VO _{2peak}	SMD:0.99(0.49,1.48)	Large	<0.001	74.0%	Very low
			9(294)			BMI	SMD:-0.36(-0.60,-0.13)	Small	0.002	48.0%	Low
Oguch (2018)	RCT	KTRs	4(182)	Mixed	-	VO _{2peak}	SMD:0.38(-0.06,0.82)	Small	0.09	45.0%	Low
			4(179)			HRQoL	SMD:0.54(0.02,1.07)	Moderate	0.04	58.0%	Very low
Ju (2020)	RCT		3 (115)	Mixed	-	HGS	SMD:0.52(0.14,0.89)	Moderate	0.007	0.0%	Very low
			3 (387)			Symptom/problem (KDQoL)	SMD:1.92(-1.06,4.90)	Large	0.21	99.0%	Very low
			3 (387)			Effects of kidney disease (KDQoL)	SMD:-3.69(-8.56,1.19)	Large	0.14	99.0%	Very low
			3 (387)			Burden of kidney disease (KDQoL)	SMD:1.04 (-0.75,2.82)	Large	0.26	98.0%	Very low

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; COM = combine; VO_{2peak} = peak oxygen uptake; HRQoL = health-related quality of life; DBP = diastolic blood pressure; SBP = systolic blood pressure; PCS = physical component summary; MCS = mental component summary; 6MWT = 6 minutes walk test; STS 10 = sit to stand 10 test; STS 30 = sit to stand 30 test; STS 60 = sit to stand 60 test; TUGT = timed up and go test; RLS = Restless Legs Syndrome; BMI = body mass index; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; SF-36 = short form-36; KDQoL = kidney disease quality of life; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

Supplementary Table S4 Results of the assessment of the methodological quality of the included meta-analyses using AMSTAR-2

Author	AMSTAR-2 Items																Score
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
Pei(2019)	√	×	√	○	√	√	×	√	√	×	√	×	×	×	√	×	53.1%
Ferreira(2019)	√	√	√	○	√	√	×	○	√	×	√	×	×	×	×	×	50.0%
Cheema(2014)	√	×	√	√	√	√	√	√	√	×	√	√	√	√	√	√	87.5%
Wu(2020)	√	√	√	○	√	√	×	√	√	×	√	√	√	√	√	√	84.4%
Nakamura(2020)	√	√	√	○	√	√	×	√	√	×	√	√	√	√	√	√	84.4%
Lu(2019)	√	×	√	○	√	×	×	○	○	×	√	×	×	×	√	√	46.9%
Chen(2019)	√	×	√	○	×	√	×	√	○	×	√	×	×	×	×	√	43.8%
Song(2018)	√	×	√	○	√	√	×	√	√	×	√	×	√	√	√	√	71.9%
Salhab(2021)	√	√	√	○	√	√	×	√	×	×	√	×	×	√	×	×	53.1%
Andrade(2019)	√	√	√	○	√	√	×	√	√	×	√	×	×	√	×	√	65.6%
Chung(2016)	√	×	√	○	√	√	√	√	√	×	√	√	√	√	√	×	78.1%
Zhang(2019)	√	×	√	○	√	√	×	√	√	×	√	×	√	√	√	×	65.6%
Pu(2019)	√	×	√	○	√	√	×	√	√	×	√	√	√	√	×	√	71.9%
Yamamoto(2021)	√	×	√	×	√	√	×	○	√	×	√	√	√	√	√	√	71.9%
Thompson(2019)	√	×	√	○	√	√	×	√	√	√	√	√	√	√	√	√	84.4%
Yang(2017)	√	×	√	○	√	√	×	○	√	×	√	√	√	√	√	√	75.0%
Clarkson(2019)	√	×	√	○	√	√	×	√	√	×	√	√	√	√	√	√	78.1%
Zhao(2019)	√	×	√	○	√	√	×	√	√	×	√	×	√	×	×	√	59.4%
Zhang(2019)	√	×	√	○	√	√	×	○	√	×	√	√	×	×	√	√	62.5%
Huang(2019)	√	√	√	○	√	√	×	√	√	×	√	√	×	×	√	√	71.9%
Heiwe(2011)	√	√	√	√	√	√	√	√	√	√	√	√	√	√	√	√	100.0%
Heiwe(2014)	√	√	√	○	√	√	√	√	√	×	√	×	√	√	×	√	78.1%

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Matsuzawa(2017)	√	√	√	○	√	√	×	√	√	×	√	×	×	√	√	√	71.9%
Smart(2011)	√	×	√	○	√	×	×	○	○	×	√	×	×	√	×	×	40.6%
Bogataj(2020)	√	×	√	○	√	×	×	√	√	×	√	√	×	√	×	√	59.4%
Sheng(2014)	√	×	√	○	√	√	√	√	√	×	√	×	×	√	√	×	65.6%
Neto(2018)	√	×	√	○	√	√	×	√	√	×	√	×	×	×	×	√	53.1%
Ferrari(2019)	√	√	√	○	√	√	√	√	√	×	√	√	√	√	√	√	90.6%
Wyngaert(2018)	√	√	√	○	√	√	×	√	√	×	√	√	√	√	√	√	84.4%
Oguchi(2018)	√	√	√	○	√	√	×	√	√	×	√	√	√	×	√	×	71.9%
Ju(2020)	√	×	√	○	×	×	×	√	√	×	√	×	×	×	×	×	34.4%

√ mean yes; ○ mean partial yes; ×mean no.

1. Did the research questions and inclusion criteria for the review include the components of PICO? 2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? 3. Did the review authors explain their selection of the study designs for inclusion in the review? 4. Did the review authors use a comprehensive literature search strategy? 5. Did the review authors perform study selection in duplicate? 6. Did the review authors perform data extraction in duplicate? 7. Did the review authors provide a list of excluded studies and justify the exclusions? 8. Did the review authors describe the included studies in adequate detail? 9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? 10. Did the review authors report on the sources of funding for the studies included in the review? 11. If meta-analysis was performed did the review authors use appropriate methods for statistical combination of results? 12. If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? 13. Did the review authors account for RoB in individual studies when interpreting/ discussing the results of the review? 14. Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? 15. If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? 16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?

Supplementary Table S5: Results of the assessment of the quality of evidence for each outcome of the included meta-analyses using GRADE

Author	Outcome	GRADE items					Quality of the evidence
		Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	
Pei (2019)	VO _{2peak}	Very serious (-2)	Neutral	Neutral	Neutral	Neutral	Moderate
	STS 60	Serious (-1)	Very serious (-2)	Neutral	Neutral	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Neutral	Serious (-1)	Very low
	SBP	Serious (-1)	Neutral	Neutral	Neutral	Not reported (-1)	Moderate
	DBP	Serious (-1)	Neutral	Neutral	Neutral	Not reported (-1)	Moderate
	Physical function (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	Physical role (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	Social function (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	Pain (SF-36)	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	General health (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
Mental health (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low	
Ferreira (2019)	Kt/V	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
Cheema (2014)	Muscle Strength	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	HRQoL	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Wu (2020)	SBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Nakamura (2020)	VO _{2peak}	Neutral	Serious (-1)	Neutral	Neutral	Serious (-1)	Moderate
	Muscle Strength	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Neutral	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	TUGT	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Lu (2019)	6MWT	Neutral	Neutral	Neutral	Serious (-1)	Neutral	Moderate
	STS 10	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	HGS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	Muscle strength	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	STS 30	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Chen (2019)	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	BMI	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Song (2018)	RLS	Serious (-1)	Serious (-1)	Neutral	Very serious (-2)	Serious (-1)	Very low
	Fatigue	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Salhab (2019)	PCS	Not reported (-1)	Serious (-1)	Neutral	Very serious (-2)	Serious (-1)	Very low
	MCS	Not reported (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Andrade (2019)	VO _{2peak}	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Chung (2019)	6MWT	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	VO _{2peak}	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	MCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Zhang (2021)	6MWT	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	STS 30	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low

	HGS	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Pu (2019)	Kt/V	Serious (-1)	Neutral	Neutral	Serious (-1)	Not reported (-1)	Very low
	VO _{2peak}	Neutral	Serious (-1)	Neutral	Neutral	Not reported (-1)	Moderate
	6MWT	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	PCS	Neutral	Serious (-1)	Neutral	Serious (-1)	Not reported (-1)	Very low
	MCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Yamamoto (2021)	SBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Very serious (-2)	Neutral	Neutral	Serious (-1)	Neutral	Very low
	BMI	Very serious (-2)	Neutral	Neutral	Neutral	Neutral	Low
Thompson (2019)	SBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Yang (2017)	VO _{2peak}	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
Clarkson (2019)	6MWT	Neutral	Neutral	Neutral	Neutral	Serious (-1)	Moderate
Zhao (2019)	Fatigue	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	PCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	MCS	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Zhang (2019)	SBP	Neutral	Serious (-1)	Neutral	Neutral	Neutral	Moderate
	DBP	Neutral	Serious (-1)	Neutral	Serious (-1)	Neutral	Low
	BMI	Serious (-1)	Neutral	Neutral	Neutral	Neutral	Moderate

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Huang (2019)	Kt/V	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	SBP	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	DBP	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	MCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	VO _{2peak}	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
Heiwe (2011)	Aerobic capacity	Neutral	Neutral	Neutral	Neutral	Serious (-1)	Moderate
	Muscle strength	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	Walking capacity	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	SBP	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	DBP	Neutral	Neutral	Neutral	Neutral	Neutral	High
Heiwe (2014)	Aerobic capacity	Neutral	Neutral	Neutral	Serious (-1)	Not reported (-1)	Low
	DBP	Neutral	Neutral	Neutral	Serious (-1)	Not reported (-1)	Low
	SBP	Neutral	Serious (-1)	Neutral	Serious (-1)	Not reported (-1)	Very low
	Muscle strength	Serious (-1)	Neutral	Neutral	Serious (-1)	Not reported (-1)	Very low
	Walking capacity	Neutral	Neutral	Neutral	Serious (-1)	Not reported (-1)	Low
Matsuzawa (2017)	VO _{2peak}	Neutral	Neutral	Neutral	Neutral	Neutral	High
	6MWT	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Neutral	Very low
	Muscle strength	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Smart (2011)	VO _{2peak}	Neutral	Serious (-1)	Neutral	Neutral	Serious (-1)	Low
Bogataj	6MWT	Serious (-1)	Serious (-1)	Neutral	Not reported (-1)	Not reported (-1)	Very low

(2020)	VO _{2peak}	Very serious (-2)	Serious (-1)	Neutral	Not reported (-1)	Not reported (-1)	Very low
	STS 10	Neutral	Serious (-1)	Neutral	Not reported (-1)	Serious (-1)	Very low
Sheng (2014)	Kt/V	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	STS60	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Neto (2018)	VO _{2peak}	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
	PCS	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	Muscle strength	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Ferrari (2019)	Kt/V (AE)	Neutral	Serious (-1)	Neutral	Serious (-1)	Neutral	Low
	Kt/V (RT)	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak} (COM)	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	VO _{2peak} (AE)	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT (RT)	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	6MWT(AE)	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
	DBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
Wyngaert (2018)	SBP	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	VO _{2peak}	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Neutral	Very low
	BMI	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
Oguchi (2018)	VO _{2peak}	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	HRQoL	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Ju (2020)	HGS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Neutral	Very low
	Symptom/problem (KDQoL)	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
	effects of kidney disease (KDQoL)	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
	burden of kidney disease (KDQoL)	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low

Abbreviation: AE = aerobic exercise; RT = resistance training; COM = combine; VO_{2peak} = peak oxygen uptake; HRQoL = health-related quality of life; DBP = diastolic blood pressure; SBP = systolic blood pressure; PCS = physical component summary; MCS = mental component summary; 6MWT = 6 minutes walk test; STS 10 = sit to stand 10 test; STS 30 = sit to stand 30 test; STS 60 = sit to stand 60 test; TUGT = timed up and go test; BMI = body mass index; SMD = standardized mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; SF-36 = short form-36; KDQoL = kidney disease quality of life;

Very serious mean the included studies existed two or more high risk of bias in terms of randomization, blinding, allocation concealment, completeness of result data, or selective reporting, or $75\% \leq I^2 \leq 100\%$.


Serious mean the included studies existed two or more high risk of bias in terms of randomization, blinding, allocation concealment, completeness of result data, or selective reporting, or $50\% \leq I^2 < 75\%$, or the included study sample size < 400, asymmetric funnel plot or less than 9 studies included.



Supplemental Figures S1

peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Supplemental Figures S2

CDSR = Cochrane Database of Systemic Review



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page 4-5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Page 4
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page 5
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 5
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page 4-5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 5
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page 5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page 5-6
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Page 4-5
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page 5
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	None
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Not applicable
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	None
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	None
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	None
Certainty	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page 6



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
assessment			
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 6
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Page 6
Study characteristics	17	Cite each included study and present its characteristics.	Page 6
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Page 6
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Page 18-32
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Not applicable
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Not applicable
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Not applicable
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	None
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Page 6
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Page 6
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 10
	23b	Discuss any limitations of the evidence included in the review.	Page 12
	23c	Discuss any limitations of the review processes used.	Page 12
	23d	Discuss implications of the results for practice, policy, and future research.	None
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 2
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 2
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	None
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 1
Competing interests	26	Declare any competing interests of review authors.	Page 1
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	Page 1



PRISMA 2020 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

For peer review only

BMJ Open

Therapeutic effects of exercise interventions for patients with chronic kidney disease: an umbrella review of systematic reviews and meta-analyses

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054887.R1
Article Type:	Original research
Date Submitted by the Author:	08-Mar-2022
Complete List of Authors:	Zhang, Fan; Long Hua Hospital, Department of Nephrology Bai, Yan; Shanghai University of Traditional Chinese Medicine, Longhua Clinical Medical College Zhao, Xing; Shanghai University of Traditional Chinese Medicine, Longhua Clinical Medical College Huang, Liuyan; Shanghai University of Traditional Chinese Medicine Wang, Weiqiong; Long Hua Hospital, Blood Purification Centre Zhou, Wenqin; Long Hua Hospital, Department of Nursing Zhang, Huachun; Long Hua Hospital, Department of Nephrology
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Rehabilitation medicine, Evidence based practice
Keywords:	Nephrology < INTERNAL MEDICINE, Rehabilitation medicine < INTERNAL MEDICINE, Chronic renal failure < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Therapeutic effects of exercise interventions for patients with chronic kidney disease: an**
4 **umbrella review of systematic reviews and meta-analyses**
5
6

7 Title page
8

9 Fan Zhang¹, Yan Bai², Xing Zhao², Liuyan Huang¹, Weiqiong Wang³, Wenqin Zhou⁴, Huachun
10 Zhang⁴
11
12

13 1 Department of Nephrology, Longhua Hospital Shanghai University of Traditional Chinese
14 Medicine, ShangHai, 200032, China.
15

16
17 2 Longhua Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shang
18 Hai, 200032, China.
19

20
21 3 Blood Purification Centre, Longhua Hospital Shanghai University of Traditional Chinese
22 Medicine, ShangHai, 200032, China.
23

24 4 Department of Nursing, Longhua Hospital Shanghai University of Traditional Chinese Medicine,
25 ShangHai, 200032, China.
26

27
28 **Key words:** Exercise, chronic kidney disease, systematic review, meta-analyses
29

30 **Running Head:** Exercise for chronic kidney disease
31

32 **First author**
33

34 Fan Zhang, Department of Nephrology, No. 725, Wan Ping Nan Road, Xuhui District, Shanghai,
35 200032, P.R. China E-mail: fan_zhang1993@163.com
36
37

38 **Corresponding author**
39

40 Huachun Zhang, Department of Nursing, No. 725, Wan Ping Nan Road, Xuhui District, Shanghai,
41 200032, P.R. China, E-mail: lhlky@163.com
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective To conduct an overview of meta-analyses evaluating the impact of exercise interventions for improving health outcomes in patients with chronic kidney disease (CKD).

Design An umbrella review of systematic review and meta-analyses of intervention trials was performed.

Data sources PubMed, Web of Science, Embase, and the Cochrane Database of Systematic Reviews were searched from inception to March 9th, 2021 for relevant articles.

Eligibility criteria for selecting studies Eligible meta-analyses compared the effects of usual care with and without exercise in CKD patients. Health outcomes included those related to cardiovascular risk factors, physical fitness, dialysis-related symptoms, dialysis adequacy, and health-related quality of life. Systematic reviews and meta-analyses that included fewer than three RCTs or fewer than 100 participants were excluded from the analysis.

Results A total of 31 eligible systematic reviews and meta-analyses were included that assessed 120 outcomes. For physical fitness, there was a moderate effect size for cardiorespiratory fitness, muscle strength, and body composition and a small effect size for muscle endurance. The effect sizes for cardiovascular risk factors, dialysis-related symptoms, and health-related quality of life outcomes were small. According to the Grading of Recommendations Assessment, Development, and Evaluation framework, most outcomes were scored as low or very low quality.

Conclusion Exercise appears to be a safe way to affect concomitant cardiovascular risk factors, such as blood pressure, improve physical fitness and health-related quality of life, and reduce dialysis-related symptoms in CKD patients.

Keywords: Exercise, Chronic Kidney Disease, Systematic Review, Meta-Analyses

PROSPERO registration number CRD42020223591.

Strengths and limitations of this study

- 1) This overview provides a comprehensive summary of the therapeutic effects of exercise interventions for patients with chronic kidney disease.
- 2) Methodological quality of the included reviews was assessed using standardized measures.
- 3) The limitation of this overview is that language bias may exist in this review because the search strategy was limited to English.
- 4) Most studies are based on hemodialysis-dependent chronic kidney disease.

INTRODUCTION

Chronic kidney disease (CKD) is a long-term condition characterized by the gradual loss of renal function over time.[1] In the past 30 years, the mortality attributed to CKD increased by 41.5%, a percentage rate that exceeds several cancers and cardiovascular diseases.[2] With the increasing incidence of hypertension, diabetes, and obesity, this number will continue to rise.[3, 4] CKD patients experience a high symptom burden with progressively impaired physical performance, leading to decreased kidney function, lower health-related quality of life (HRQOL), increased risk of cardiovascular events, and increased all-cause mortality.[5, 6]

With an increasing number of patients with CKD living longer, the effectiveness and accessibility of their health services have never been more critical. Renal rehabilitation is a multifaceted intervention program. Rehabilitation consists of exercise interventions, diet control, fluid management, and psychological support to alleviate physical/mental deficiencies caused by kidney disease and renal replacement therapy to improve disease prognosis and prolong life expectancy.[7] Since exercise is the core of renal rehabilitation, there is an increasing number of systematic reviews and meta-analyses investigating the influence of exercise on health outcomes in CKD patients.[8]

Data from large cohort studies show that mortality risk was lower for regular (equal to or more than once/week) versus non-regular (less than once/week) exercisers [adjusted hazard ratio (HR)=0.73, 95% confidence interval (CI): 0.69–0.78], and mortality risk tended to decrease as exercise frequency increased (HR for participants who exercised once/week = 0.82, 95% CI: 0.73–0.91; HR for those who exercised 6–7 times/week = 0.69, 95% CI: 0.63–0.76) and patients who exercised daily had lower mortality risk (HR = 0.84, 95% CI: 0.74–0.96) than patients exercising once/week.[9] Based on data from 41 randomized controlled trials (RCT), Heiwe et al. reported effective improvements in aerobic capacity, muscular function, and walking capacity in CKD patients after exercise, [10] indicators that are the core of frailty. [11] In other words, exercise is an essential non-pharmacological strategy to improve frailty symptoms in CKD patients, the latter being a significant cause of sedentary behavior in such population. [12] Because of this, some researchers and guidelines recommend that healthcare providers prescribe exercise for CKD patients.[13-16] However, the results of meta-analyses of exercise in CKD patients are inconsistent.

This umbrella review aims to assess the therapeutic effects of exercise regarding cardiovascular risk factors, physical fitness, dialysis-related symptoms, dialysis adequacy, and HRQOL in CKD patients summarized in systematic reviews and meta-analyses.

METHODS AND ANALYSIS

This umbrella review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[17] The review was prospectively registered (PROSPERO: CRD42020223591), and the protocol for this review was published.[18]

Patient and public involvement

Patients and the public were not involved in the design, conduct, reporting, or dissemination plans of this research.

Literature Search

A comprehensive search strategy was performed to identify systematic reviews and meta-analyses of CKD patients that compared usual care procedures with and without exercise interventions. PubMed, Embase, the Cochrane Database of Systematic Reviews (CDSR), and the Web of Science were searched for systematic reviews and meta-analyses from inception to March 9th, 2021. The detailed search strategy is summarized in **Supplementary Table S1**. The references of existing systematic reviews were also screened. Any reviews considered potentially relevant by authors were retrieved for further consideration.

Eligibility Criteria

Eligible systematic reviews and meta-analyses included those 1) where patients were diagnosed with CKD at various stages of treatment; 2) that compared exercise interventions with sham/no exercise or usual/standard care; 3) that reported outcomes on at least one of the following: cardiovascular risk factors (blood pressure), physical fitness, dialysis-related symptoms, dialysis adequacy, and HRQOL. The methods to assess each outcome were shown in **Supplement Figure S1**; 4) systematic reviews with meta-analysis of intervention trials (RCTs and quasi-experimental studies). A meta-analysis that included less than three studies or less than 100 participants was excluded. For duplicate literature, the article with the most comprehensive data was selected. The language was restricted to English. Letters to the editor, trial protocols, and conference abstracts were excluded.

Study selection

Two independent authors screened all titles and abstracts compiled from the search results. Each paper was examined for appropriate eligibility criteria, and a third author resolved disagreements.

Data extraction

Requisite data were extracted independently by two independent authors into a standardized format that included: 1) author, 2) publication year, 3) stage of CKD, 4) the number of included studies and participants, 5) exercise type, 6) exercise mode (intradialytic or interdialytic), 7) standardized mean difference (SMD) or mean difference (MD) with corresponding 95% CI for each outcome, 8) *P*-values, 9) *I*² values, and 10) exercise-related adverse events.

Risk of bias assessment

1
2
3 A Measurement Tool to Assess Systematic Reviews-2 (AMSTAR-2) was used to assess the risk of
4 bias among the included systematic reviews.[19] This checklist contains 16 items, and each item
5 was answered with a “yes” (1 point), “partial yes” (0.5 points), or “no” (0 points). A percentage
6 score was calculated for each study based on the total score as the numerator and the maximum 16
7 points as the denominator. A meta-analysis scoring $\geq 80\%$ was classified as high quality, those
8 scoring 40-79% as medium quality, and those scoring $< 40\%$ as low quality.[20] Two authors
9 performed the risk of bias assessment independently, and discussions resolved the disagreement.

14 Data analysis

15
16
17 The summary effect size from each meta-analysis was analyzed qualitatively based on the SMD and
18 its 95% CI for each outcome. If they were not presented as SMD in the original meta-analysis,
19 Review Manager V.5.3 was used to convert SMD outcomes. If data could not be converted into
20 SMD, we contacted the authors of the meta-analysis for the data. Effects were considered small
21 (SMD < 0.50), moderate (SMD from 0.50 to 0.79), and large (SMD ≥ 0.80).[21] I^2 values were
22 interpreted as follows: $\leq 25\%$ indicate low heterogeneity, $25\% < I^2 \leq 50\%$ indicate mild heterogeneity,
23 $50\% < I^2 \leq 75\%$ indicate moderate heterogeneity and $> 75\%$ indicate high heterogeneity.[22]

24
25
26
27
28 The level of evidence for each meta-analysis was evaluated using the Grading of Recommendations
29 Assessment, Development, and Evaluation (GRADE) system.[23] The quality of evidence was
30 assessed using five domains: risk of bias, inconsistency, indirectness, imprecision, and publication
31 bias. Beginning with an initial score of 4 points, the score for each of these five domains was reduced
32 accordingly: “not reported (-1)”, “serious (-1)”, “very serious (-2)”, or “neutral (0)”. Studies were
33 rated as high (4 points), moderate (3 points), low (2 points), or very low (≤ 1 point) using the
34 GRADE system. The GRADE assessment was conducted independently by two authors. Any
35 differences were resolved by discussion or adjudication by a third author. The incidence of adverse
36 events was based on the number of reported divided by the patients in the exercise group.

41 RESULTS

42 Characteristics of the meta-analyses

43
44
45
46 The search identified 2305 potential articles, of which 648 were duplicates. After reading the title
47 and abstract, 1598 papers were excluded, and 28 were excluded after full-text review resulting in
48 31 final studies. [10, 24-53] The PRISMA flowchart of study inclusion is illustrated in **Figure 1**.
49 The reasons for excluded articles are listed in **Supplementary Table S2**.

50
51
52
53 The 31 included systematic reviews and meta-analyses were published from September 2011
54 through March 2021. The number of included studies assessed in the articles ranged from 3 to 24,
55 with a mean of 8 studies. The study sample sizes ranged from 106 to 874 participants, with a mean
56 of 304. The characteristics of the included meta-analyses are shown in **Supplement Table S3**. SMD
57 data from four papers could not be obtained from the authors, and the data of their effect size was
58 presented as MD.[29, 30, 40, 46]

1
2
3 The methodological quality assessment of the included meta-analyses was determined, and the
4 AMSTAR-2 scores ranged from 34.4% to 100.0%, with a mean score of 68.0%. Seven (22.6%)
5 systematic reviews were rated of high quality, while 23 (74.2%) were rated of medium quality, and
6 just one (0.3%) was rated as low quality (**Supplement Table S4**).
7
8
9

10 Of the GRADE evidence quality of the 120 outcomes, 1.7% (2/120) reported evidence of high
11 quality, 17.5% (21/120) reported evidence of moderate quality, 20.0% (24/120) reported evidence
12 of low quality, and 60.8% (73/120) reported evidence of very low quality (**Supplement Table S5**).
13
14

15 **Blood pressure**

16
17 There were 25 meta-analyses (reported in 13 articles) investigating the effect of exercise on
18 cardiovascular risk factors (systolic and diastolic blood pressure) in CKD patients. [10, 27, 30, 33,
19 34, 40, 41, 43, 46-49, 52] Of which, the number of studies ranged from 3 to 12 with a mean of 314
20 participants (range from 198 to 514) were included in each meta-analysis (**Table 1**).
21
22
23

24 The effect of exercise on systolic blood pressure was investigated in 13 meta-analyses with a mild
25 heterogeneity (average $I^2 = 36.1\%$), [10, 27, 30, 33, 34, 40, 41, 43, 46-49, 52] and six reported a
26 positive statistically significant outcome. [30, 33, 41, 43, 49, 52] Of the 13 meta-analyses, nine
27 reported a small effect size, [10, 27, 33, 34, 41, 43, 47, 48, 52] and one reported moderate. [49]
28 GRADE assessment of quality indicated the overall evidence as being very low (10 meta-
29 analyses [10, 27, 30, 33, 41, 43, 46-49]), low (two meta-analyses [34, 40]), and moderate (one meta-
30 analysis [52]).
31
32
33
34

35 The effect of exercise on diastolic blood pressure was investigated in 12 meta-analyses with a mild
36 heterogeneity (average $I^2 = 49.1\%$), [10, 27, 30, 33, 34, 40, 41, 43, 46-48, 52] and 2 reported a positive
37 statistically significant outcome. [41, 43] Of the 12 meta-analyses, nine reported small effect sizes
38 [10, 27, 33, 34, 41, 43, 47, 48, 52], and all were graded as low or very low quality of evidence.
39
40
41
42

43 **Cardiorespiratory fitness**

44
45 There were 34 meta-analyses (reported in 21 articles) that investigated the effects of exercise on
46 cardiorespiratory fitness in CKD patients using a peak oxygen uptake (18 of 34), 6-minute walk test
47 (14 of 34), or aerobic capacity (2 of 34). The meta-analyses included a mean of nine studies (ranging
48 from 5 to 20) and a mean of 330 participants (ranging from 179 to 504) (**Table 2**).
49
50
51

52 The effect of exercise on peak oxygen consumption was investigated in 18 meta-analyses (reported
53 in 17 articles) with a mild heterogeneity (average $I^2 = 42.2\%$), [24, 25, 27, 28, 30, 32, 34, 37, 38, 40,
54 41, 43, 44, 49, 50, 54] and 16 reported positive statistically significant outcomes. [24, 25, 28, 30,
55 32, 34, 37, 38, 40, 41, 43, 44, 47, 49, 50] Of the 18 meta-analyses, three reported a low effect size, [27,
56 39, 50] nine reported a moderate effect size [25, 28, 32, 34, 37, 41, 43, 44, 49] and three reported a
57 large effect size. [24, 38, 47] GRADE assessment of quality indicated the overall evidence as being
58
59
60

1
2
3
4 very low (9 meta-analyses[25, 27, 28, 30, 32, 37, 43, 47, 49]), low (8 meta-analyses[24, 34, 38-41,
5 44, 50]), and high (one meta-analysis[37]). A meta-analysis that included kidney transplant
6 recipients found no statistically significant difference in the SMD of the exercise group (0.38; 95%
7 CI, -0.06 to 0.82; $P=0.09$).[39]
8
9

10 The effect of exercise on 6-minute walk test was investigated in 14 meta-analyses (reported in 13
11 articles) with a mild heterogeneity (average $I^2=44.9\%$),[25, 28-30, 32, 34, 36-38, 40, 41, 43, 51] and
12 13 reported positive statistically significant outcomes.[25, 28-30, 32, 34, 36-38, 41, 43, 51] Of the
13 14 meta-analyses, two reported a small effect size,[25, 28] five reported a moderate effect size,[36,
14 37, 41, 43, 51] and three reported a large effect size.[32, 34, 38] GRADE assessment of quality
15 indicated the overall evidence as being very low (eight meta-analyses[25, 30, 32, 34, 38, 40, 43]),
16 low (four meta-analyses[28, 37, 41, 51]), and moderate (two meta-analyses[29, 36]). In addition,
17 the meta-analysis by Heiwe et al. (2014) showed that regular exercise had significant beneficial
18 effects on aerobic capacity. [10, 33]
19
20
21
22

23 **Muscle strength**

24
25
26 Ten meta-analyses (reported in nine articles) investigated the effects of exercise on muscle strength
27 in CKD patients with a low heterogeneity (average $I^2=19.1\%$).[10, 26, 32, 33, 35-38, 51] The meta-
28 analyses included a mean of seven studies (ranging from 3 to 12) and a mean of 252 participants
29 (ranging from 115 to 385) (**Table 3**).
30
31

32
33 Muscle strength was measured using handgrip strength and lower limb muscle strength. For patients
34 in 8 of 10 meta-analyses, exercise resulted in statistically significant improvements in muscle
35 strength. [10, 32, 33, 35-37, 51] Of the 10 meta-analyses, three reported a small effect size,[36, 38,
36 51] five reported a moderate effect size,[10, 32, 33, 35, 36] and two reported a large effect size,[26,
37 37] GRADE assessment of quality indicated the overall evidence as being very low (six meta-
38 analyses[10, 32, 33, 35, 37, 38]) and low (four meta-analyses[26, 36, 51]).
39
40
41

42 **Muscle endurance**

43
44 Nine meta-analyses (reported in 8 articles) investigated the effects of exercise on muscle endurance
45 with a mild heterogeneity (average $I^2=29.4\%$).[10, 25, 33, 36, 38, 40, 43, 51] A mean of five studies
46 (ranging from 3 to 7) and a mean of 238 participants (ranging from 106 to 461) were included in
47 meta-analyses (**Table 4**).
48
49

50
51 Muscle endurance was measured using a sit-to-stand test, timed up and go test, and walking capacity
52 exercise. Pooled effect estimates from all nine meta-analyses suggested a beneficial effect of
53 exercise on muscle endurance in CKD patients. Seven of the nine meta-analyses reported power to
54 detect a statistically significant effect. [25, 33, 36, 38, 43, 51] Two meta-analyses reported moderate
55 effect size, and 5 reported small effect size. GRADE assessment of quality indicated the overall
56 evidence as being very low (seven meta-analyses[25, 33, 36, 38, 40, 43, 51]), low (one meta-
57 analyses[36]) and moderate (one meta-analyses[10]).
58
59
60

Body composition

Four meta-analyses consisting of a mean of 9 studies (ranging from 4 to 13) and a mean of 335 participants (ranging from 166 to 466) included body mass index as an outcome.[27, 47, 49, 52] There was a low heterogeneity (average $I^2=12.0\%$) among the study outcomes (**Table 5**).

Of the four meta-analyses, three showed a positive statistically significant impact on body mass index using exercise interventions in CKD patients.[47, 49, 52] Small effect size was reported in all meta-analyses. GRADE assessment of quality indicated the overall evidence as being very low (one meta-analysis), low (two meta-analyses[47, 49]), and moderate (one meta-analysis [52]).

Dialysis-related symptoms

Nine meta-analyses (reported in seven articles) investigated the effect of exercise on dialysis-related symptoms in CKD patients.[30, 31, 34, 41, 43, 45, 53] Each meta-analysis included a mean of seven studies (ranging from 3 to 12 studies) and a mean of 239 participants (ranging from 139 to 370). (**Table 6**).

Fatigue was measured using the Rhoten Fatigue Scale, Visual Analogue Scale, and Hemodialysis Patients Fatigue Scale. The effect of exercise on fatigue was investigated in 2 meta-analyses with a low heterogeneity (average $I^2=23.5\%$).[45, 53] The two meta-analyses revealed a statistically significant effect of exercise on fatigue. Although the meta-analyses reported a large effect size, the quality of evidence was low[45] or very low[53] according to GRADE criteria.

Just one meta-analysis investigated the effects of exercise on restless legs syndrome in CKD patients.[45] The results showed that pooled effect estimated for restless legs syndrome with statistically significant but considerable average heterogeneity ($I^2=87.0\%$). According to GRADE criteria, the overall evidence for this outcome was rated as very low.

Dialysis adequacy

Dialysis adequacy was measured using the value of Kt/V. Six meta-analyses (reported in 5 articles) investigated the effects of exercise on Kt/V in CKD patients with a mild heterogeneity (average $I^2=25.7\%$).[30, 31, 34, 41, 43] Comprehensive effect estimates from all the six meta-analyses with Kt/V outcomes showed that exercise had a beneficial effect. Of the six meta-analyses, 3 reported a small effect size[34, 41, 43], and one reported large effect size.[31] According to GRADE criteria, all meta-analyses were rated as very low quality of evidence (**Table 6**).

Health-related quality of life

Twenty-nine meta-analyses (reported in 13 articles) investigated the effect of exercise on HRQOL in CKD patients.[26, 28, 32, 34, 35, 37, 39-43, 51, 53] Among them, nine the meta-analyses each assessed physical and mental subscale of the Short-Form Health Survey-36.[28, 32, 34, 37, 41-43, 51, 53] A mean of six studies (ranging from 3 to 10) and a mean of 311 participants (ranging from

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

167 to 562) were included in each meta-analysis. The included meta-analyses had moderate heterogeneity (average $I^2=51.0\%$) (Table 7).

Of the 29 meta-analyses, a comprehensive effect estimate of the 28 meta-analyses shows that exercise is beneficial to the HRQOL of CKD patients, but only 12 of 29 meta-analyses reported a statistically significant outcome.[28, 34, 37, 39, 41-43, 53] There were 13 of 29 meta-analyses reporting a small effect size, [28, 32, 34, 37, 41, 43, 51, 53] 4 were moderate,[32, 37, 39, 41] and 6 were large.[26, 35, 42] According to GRADE criteria, the overall of evidence for HRQOL was rated as very low (20 meta-analyses[32, 35, 37, 39-43, 53]) or low (nine meta-analyses[26, 28, 34, 41, 51, 53]).

Adverse events

Six meta-analyses reported exercise-related adverse events.[26, 28, 38, 41, 43, 44] Of the adverse effects, the most commonly reported were hypotension and cramping. Overall, the incidence of adverse events was approximately 0.3%.

DISCUSSION

Summary of main results

Several meta-analyses have been published in exercise interventions in CKD patients.[55] The findings of these meta-analyses should be assessed to determine if the evidence is consistent among the studies. This umbrella review included 31 eligible articles involving 120 separate meta-analyses investigating the effect of exercise on the health outcomes in CKD patients. There was low- or very low-quality evidence for moderate beneficial effects of exercise on cardiorespiratory fitness, muscle strength, and body composition. In addition, there was very low-quality evidence for minor beneficial effects of exercise on muscle endurance, cardiovascular risk factors, dialysis-related symptoms, and HRQOL. There were few adverse events related to exercise, indicating that exercise is safe for CKD patients.

Interpretation of study effects

Cardiovascular disease is a frequent complication of CKD and is the leading cause of death in CKD patients.[56] Hypertension is an important modifiable risk factor for cardiovascular diseases and progressive renal dysfunction in CKD patients.[57] The present overview showed that exercise has a small to moderate effect on blood pressure (SMD: -0.75 to 0.04 for systolic blood pressure, and SMD: -0.47 to 0.04 for diastolic blood pressure), it is an appealing strategy for blood pressure control in CKD patients. However, the dose effects of exercise in the context of the cardiovascular health of CKD patients should be considered. A recent cohort study found that 7.5-15 metabolic equivalent hours per week (MET-h/week) was associated with the lowest risk of cardiovascular events.[58] Regrettably, the benefit of exercise on cardiovascular risk factors cannot be determined

1
2
3 because there are an insufficient number of conclusive studies that assess exercise effects on overall
4 cardiovascular health. In a systematic review by Heiwe et al., a meta-analysis including two trials
5 found that exercise improved cardiovascular function in patients with CKD, as reflected in the
6 standard deviation of all normal RR intervals and left ventricular mass index.[10] Furthermore, a
7 recent randomized controlled trial published by Graham-Brown indicated that intradialytic exercise
8 could reduce left ventricular mass and is safe, deliverable, and well-tolerated.[59] Although
9 the GRADE evidence generated was low, exercise should be recommended for CKD patients,
10 particularly those comorbid with cardiovascular disease. Future randomized controlled exercise
11 trials need to focus more on the role of exercise in cardiovascular events in patients with CKD.
12
13

14
15
16
17
18 Physical fitness is necessary for participation in activities of daily living. The exercise provided the
19 best results in improving cardiorespiratory fitness and muscle strength in CKD patients, with more
20 than a half of the meta-analyses reporting moderate or large effect sizes, regardless of the quality of
21 evidence. Cardiorespiratory fitness is considered an important independent predictor of mortality,
22 and muscle strength is an important indicator of physical performance in CKD patients.[60] It is
23 well known that aerobic exercise is the “gold standard” for cardiorespiratory rehabilitation[61] and
24 resistance training for muscle strength improvement.[62] However, a combination of aerobic and
25 resistance exercises may have a more profound effect in CKD patients based on the current review.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Both sarcopenia and obesity have been shown to increase mortality risk and increase progression to end-stage renal disease in CKD patients.[63] Unlike patients receiving dialysis, treatment requirements for predialysis CKD patients are based upon the principle of maintaining a “healthy weight” and preventing or attenuating obesity.[14] In this overview, the effectiveness of exercise for body mass index was supported by four analyses with small effect sizes and moderate quality of evidence. Based on the results, exercise may contribute to lower body mass index in CKD patients. However, additional studies are needed to confirm the benefits of exercise programs for reducing sarcopenia and weight.

CKD population experience multiple symptoms that affect patient’s prognosis and HRQOL.[64] Patients who received dialysis treatment commonly reported restless legs syndrome, fatigue, and inadequate dialysis due to kidney function deterioration and dialysis-related side effects.[65, 66] These symptoms affect sleep, daily activities and impose a considerable amount of psychological distress and economic burden.[67] An increasing number of researchers have investigated the role of exercise as an important non-pharmacological strategy for preventing and/or treating symptoms. [68, 69] The results of a small number of meta-analyses suggested the beneficial effect of exercise on dialysis adequacy (SMD: 0.19 to 2.21) and improving restless legs syndrome (SMD: -1.79) and fatigue symptoms (SMD: -0.97 to -0.85). Nevertheless, the efficacy of exercise in CKD patients for preventing dialysis-related symptoms awaits new clinical evidence.

1
2
3 With similar results obtained in another overview that included chronic disease,[70] results from
4 this overview demonstrated minor beneficial effects of exercise on HRQOL, irrespective of the
5 evidence level in CKD patients. Improved HRQOL is important because most of the population
6 reported ongoing poor health and well-being due to diet restriction, weakness, and dialysis
7 treatment.[71] The consistent health benefits of exercise in this overview demonstrated that exercise
8 could be a strategy to improve the poor long-term prognosis in CKD patients.
9
10

11
12
13 Several meta-analyses reported exercise-related adverse events. Based on the number of adverse
14 events reported, we calculate that only three adverse events occurred per 1000 CKD patients. The
15 low incidence of adverse events indicated that the benefits of exercise in CKD patients outweigh its
16 potential risks and most reflected typical response to exercise (e.g., muscle soreness). However,
17 most meta-analyses only included intradialytic exercise for hemodialysis patients in their
18 assessments. Exercises during hemodialysis are usually performed under the supervision of a
19 healthcare worker to ensure safety.[72] It has been reported that all patients with CKD are at risk
20 for cardiovascular events (e.g., arrhythmias, myocardial ischemia) during exercise. Therefore,
21 medical screening should be performed before exercise to determine which patients may be at
22 increased risk for cardiovascular accidents. [73] In addition, special attention should be paid to dry
23 weight and blood pressure in patients with hemodialysis-dependent CKD to avoid excessive volume
24 loading or dehydration, which may increase the risk associated with exercise. [60]
25
26
27
28
29
30

31 **Implications for clinical**

32
33
34 Taken together, there is good reason to recommend exercise for improving prognosis in CKD
35 patients. Evidence from most randomized controlled trials increased confidence in the findings of
36 this umbrella review. Because most of the meta-analyses assessed in this study did not detail the
37 exercises instituted, it is difficult to make recommendations about the type of exercise that would
38 be the most beneficial for CKD patients. Although the effect sizes of exercise on improving the
39 health prognosis of CKD patients were generally moderate, these effects may bring some clinical
40 benefit to patients experiencing impaired function or symptom distress. Despite numerous meta-
41 analyses providing only low or very low-quality evidence, similar beneficial effects of exercise were
42 reported by meta-analyses of randomized controlled trials with different grades of evidence.
43 Remarkably, a recently published trial found that a 6-month program of intradialytic exercise
44 effectively reduces healthcare costs.[74] Overall, exercise should be integrated into the care of CKD,
45 but the overall benefit of the exercise to CKD is still debatable.
46
47
48
49
50
51

52 **Limitations**

53
54
55 There are several limitations to this overview: 1) Most meta-analyses included in this review
56 involve hemodialysis patients, limiting the extrapolation of the results to other stages of CKD; 2)
57 improvement of flexibility in CKD patients was not investigated. Flexibility is an important
58 component of physical fitness that impacts muscular injury.[75] The evidence for the efficacy of
59
60

1
2
3 exercise on flexibility improvement is insufficient for a systematic review or meta-analysis; 3)
4 language bias may exist in this review because the search strategy was limited to English. It is
5 unknown if meta-analyses published in other languages would influence the outcomes of our
6 findings; 4) the results may be had been influenced by an overlap in the original studies; 5) the
7 accuracy of the MD data cannot be guaranteed; 6) sub-group analyses of different types of exercise
8 were not performed as described in the published protocol because of most the included meta-
9 analyses did not detail the exercises, and 7) both body composition and cardiovascular risk factors
10 are common terms. However, the inclusion of studies was limited, so this review focused only on
11 body mass index and blood pressure, and more evidence is still needed for the effects of other
12 assessment metrics.
13
14
15
16
17

18 19 **CONCLUSION**

20
21 In CKD patients, exercise appears to improve muscle strength and endurance, body composition,
22 and HRQOL. At the same time, exercise decreases blood pressure and dialysis-related symptoms in
23 CKD patients. However, the quality of the evidence was considered low or very low for all outcomes
24 indicating that we have low certainty evidence to support the findings above, more rigorous study
25 is still needed in the future. Nevertheless, given the health benefits of physical activity, exercise
26 should be integrated into renal care for a patient with any stage of CKD.
27
28
29

30 31 **Contributors**

32
33 FZ and LYH conceived and designed the review. YB and XZ searched databases, extracted the data,
34 and statistical analysis. WQZ revised the manuscript. WQW and HCZ provided technical support.
35 All authors had read and approved the final manuscript and agreed on its submission.
36
37

38 39 **Ethics approval statement**

40
41 Ethics approval is not required as no private information from individuals is collected.
42

43 44 **Dissemination**

45
46 The results will be published in a peer-reviewed journal or disseminated in relevant conferences.
47

48
49 **Funding** This study was supported by Longhua Hospital Shanghai University of Traditional
50 Chinese Medicine (Grant number: Y21026).
51

52
53 **Competing interest statement** None declared.

54
55 **Data availability statement** Data are available in a public, open access repository. All data in the
56 overview were published through journals.
57

58
59 **Patient consent for publication** Not required.
60

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Fouque D, Heine GH, Jager KJ *et al*: **The systemic nature of CKD**. *Nat Rev Nephrol* 2017, **13**(6):344-358.
2. **Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017**. *Lancet* 2020, **395**(10225):709-733.
3. Yang C, Gao B, Zhao X, Su Z, Sun X, Wang HY, Zhang P, Wang R, Liu J, Tang W *et al*: **Executive summary for China Kidney Disease Network (CK-NET) 2016 Annual Data Report**. *Kidney Int* 2020, **98**(6):1419-1423.
4. Cheng HT, Xu X, Lim PS, Hung KY: **Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015**. *Diabetes Care* 2020.
5. Roshanravan B, Robinson-Cohen C, Patel KV, Ayers E, Littman AJ, de Boer IH, Ikizler TA, Himmelfarb J, Katznel LI, Kestenbaum B *et al*: **Association between physical performance and all-cause mortality in CKD**. *J Am Soc Nephrol* 2013, **24**(5):822-830.
6. Wang XH, Mitch WE: **Mechanisms of muscle wasting in chronic kidney disease**. *Nat Rev Nephrol* 2014, **10**(9):504-516.
7. Hoshino J: **Renal Rehabilitation: Exercise Intervention and Nutritional Support in Dialysis Patients**. *Nutrients* 2021, **13**(5):1444.
8. Wilund KR, Viana JL, Perez LM: **A Critical Review of Exercise Training in Hemodialysis Patients: Personalized Activity Prescriptions Are Needed**. *Exerc Sport Sci Rev* 2020, **48**(1):28-39.
9. Tentori F, Elder SJ, Thumma J, Pisoni RL, Bommer J, Fissell RB, Fukuhara S, Jadoul M, Keen ML, Saran R *et al*: **Physical exercise among participants in the Dialysis Outcomes and Practice Patterns Study (DOPPS): correlates and associated outcomes**. *Nephrol Dial Transplant* 2010, **25**(9):3050-3062.
10. Heiwe S, Jacobson SH: **Exercise training in adults with CKD: a systematic review and meta-analysis**. *Am J Kidney Dis* 2014, **64**(3):383-393.
11. Wong L, Duque G, McMahon LP: **Sarcopenia and Frailty: Challenges in Mainstream Nephrology Practice**. *Kidney Int Rep* 2021, **6**(10):2554-2564.
12. Rampersad C, Darcel J, Harasemiw O, Brar RS, Komenda P, Rigatto C, Prasad B, Bohm C, Tangri N: **Change in Physical Activity and Function in Patients with Baseline Advanced Nondialysis CKD**. *Clin J Am Soc Nephrol* 2021, **16**(12):1805-1812.
13. March DS, Graham-Brown MP, Young HM, Greenwood SA, Burton JO: **'There is nothing more deceptive than an obvious fact': more evidence for the prescription of exercise during haemodialysis (intradialytic exercise) is still required**. *Br J Sports Med* 2017, **51**(18):1379.
14. **Clinical Practice Guideline: Exercise and Lifestyle in Chronic Kidney Disease** [https://renal.org/sites/renal.org/files/Exercise%20and%20Lifestyle%20in%20CKD%20clinical%20practice%20guideline33_v4_FINAL_0.pdf]
15. Yamagata K, Hoshino J, Sugiyama H, Hanafusa N, Shibagaki Y, Komatsu Y, Konta T, Fujii N, Kanda E, Sofue T *et al*: **Clinical practice guideline for renal rehabilitation: Systematic reviews and recommendations of exercise therapies in patients with kidney diseases**. *Renal*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Replacement Therapy* 2019, **5**.
16. Deschamps T: **Let's programme exercise during haemodialysis (intradialytic exercise) into the care plan for patients, regardless of age.** *Br J Sports Med* 2016, **50**(22):1357-1358.
17. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA: **Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.** *Bmj* 2015, **350**:g7647.
18. Zhang F, Wang H, Huang L, Zhang H: **Therapeutic effects of exercise interventions for patients with chronic kidney disease: protocol for an overview of systematic reviews and meta-analyses of clinical trials.** *BMJ Open* 2021, **11**(2):e043011.
19. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E *et al*: **AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.** *Bmj* 2017, **358**:j4008.
20. Grgic J, Grgic I, Pickering C, Schoenfeld BJ, Bishop DJ, Pedisic Z: **Wake up and smell the coffee: caffeine supplementation and exercise performance-an umbrella review of 21 published meta-analyses.** *Br J Sports Med* 2020, **54**(11):681-688.
21. Cohen J: **Quantitative methods in psychology: A power primer.** *Psychological Bulletin* 1992, **112**:115-159.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG: **Measuring inconsistency in meta-analyses.** *Bmj* 2003, **327**(7414):557-560.
23. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D *et al*: **Grading quality of evidence and strength of recommendations.** *Bmj* 2004, **328**(7454):1490.
24. Andrade FP, Rezende PS, Ferreira TS, Borba GC, Muller AM, Rovedder PME: **Effects of intradialytic exercise on cardiopulmonary capacity in chronic kidney disease: systematic review and meta-analysis of randomized clinical trials.** *Sci Rep* 2019, **9**(1):18470.
25. Bogataj S, Pajek M, Pajek J, Buturovic Ponikvar J, Paravlic A: **Exercise-Based Interventions in Hemodialysis Patients: A Systematic Review with a Meta-Analysis of Randomized Controlled Trials.** *J Clin Med* 2019, **9**(1).
26. Cheema BS, Chan D, Fahey P, Atlantis E: **Effect of progressive resistance training on measures of skeletal muscle hypertrophy, muscular strength and health-related quality of life in patients with chronic kidney disease: a systematic review and meta-analysis.** *Sports Med* 2014, **44**(8):1125-1138.
27. Chen G, Gao L, Li X: **Effects of exercise training on cardiovascular risk factors in kidney transplant recipients: a systematic review and meta-analysis.** *Ren Fail* 2019, **41**(1):408-418.
28. Chung YC, Yeh ML, Liu YM: **Effects of intradialytic exercise on the physical function, depression and quality of life for haemodialysis patients: a systematic review and meta-analysis of randomised controlled trials.** *J Clin Nurs* 2017, **26**(13-14):1801-1813.
29. Clarkson MJ, Bennett PN, Fraser SF, Warmington SA: **Exercise interventions for improving objective physical function in patients with end-stage kidney disease on dialysis: a systematic review and meta-analysis.** *Am J Physiol Renal Physiol* 2019, **316**(5):F856-f872.
30. Ferrari F, Helal L, Dipp T, Soares D, Soldatelli A, Mills AL, Paz C, Tenorio MCC, Motta MT, Barcellos FC *et al*: **Intradialytic training in patients with end-stage renal disease: a systematic review and meta-analysis of randomized clinical trials assessing the effects of**

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- five different training interventions. *J Nephrol* 2020, **33**(2):251-266.
31. Ferreira GD, Bohlke M, Correa CM, Dias EC, Orcy RB: **Does Intradialytic Exercise Improve Removal of Solutes by Hemodialysis? A Systematic Review and Meta-analysis.** *Arch Phys Med Rehabil* 2019, **100**(12):2371-2380.
32. Gomes Neto M, de Lacerda FFR, Lopes AA, Martinez BP, Saquetto MB: **Intradialytic exercise training modalities on physical functioning and health-related quality of life in patients undergoing maintenance hemodialysis: systematic review and meta-analysis.** *Clin Rehabil* 2018, **32**(9):1189-1202.
33. Heiwe S, Jacobson SH: **Exercise training for adults with chronic kidney disease.** *Cochrane Database Syst Rev* 2011(10):Cd003236.
34. Huang M, Lv A, Wang J, Xu N, Ma G, Zhai Z, Zhang B, Gao J, Ni C: **Exercise Training and Outcomes in Hemodialysis Patients: Systematic Review and Meta-Analysis.** *Am J Nephrol* 2019, **50**(4):240-254.
35. Ju H, Chen H, Mi C, Chen Y, Zuang C: **The Impact of Home-Based Exercise Program on Physical Function of Chronic Kidney Disease Patients: A Meta-Analysis of Randomized Controlled Trials.** *Physikalische Medizin, Rehabilitationsmedizin, Kurortmedizin* 2020, **30**(02):108-114.
36. Lu Y, Wang Y, Lu Q: **Effects of Exercise on Muscle Fitness in Dialysis Patients: A Systematic Review and Meta-Analysis.** *Am J Nephrol* 2019, **50**(4):291-302.
37. Matsuzawa R, Hoshi K, Yoneki K, Harada M, Watanabe T, Shimoda T, Yamamoto S, Matsunaga A: **Exercise Training in Elderly People Undergoing Hemodialysis: A Systematic Review and Meta-analysis.** *Kidney Int Rep* 2017, **2**(6):1096-1110.
38. Nakamura K, Sasaki T, Yamamoto S, Hayashi H, Ako S, Tanaka Y: **Effects of exercise on kidney and physical function in patients with non-dialysis chronic kidney disease: a systematic review and meta-analysis.** *Sci Rep* 2020, **10**(1):18195.
39. Oguchi H, Tsujita M, Yazawa M, Kawaguchi T, Hoshino J, Kohzuki M, Ito O, Yamagata K, Shibagaki Y, Sofue T: **The efficacy of exercise training in kidney transplant recipients: a meta-analysis and systematic review.** *Clin Exp Nephrol* 2019, **23**(2):275-284.
40. Pei G, Tang Y, Tan L, Tan J, Ge L, Qin W: **Aerobic exercise in adults with chronic kidney disease (CKD): a meta-analysis.** *Int Urol Nephrol* 2019, **51**(10):1787-1795.
41. Pu J, Jiang Z, Wu W, Li L, Zhang L, Li Y, Liu Q, Ou S: **Efficacy and safety of intradialytic exercise in haemodialysis patients: a systematic review and meta-analysis.** *BMJ Open* 2019, **9**(1):e020633.
42. Salhab N, Karavetian M, Kooman J, Fiaccadori E, El Khoury CF: **Effects of intradialytic aerobic exercise on hemodialysis patients: a systematic review and meta-analysis.** *J Nephrol* 2019, **32**(4):549-566.
43. Sheng K, Zhang P, Chen L, Cheng J, Wu C, Chen J: **Intradialytic exercise in hemodialysis patients: a systematic review and meta-analysis.** *Am J Nephrol* 2014, **40**(5):478-490.
44. Smart N, Steele M: **Exercise training in haemodialysis patients: a systematic review and meta-analysis.** *Nephrology (Carlton)* 2011, **16**(7):626-632.
45. Song YY, Hu RJ, Diao YS, Chen L, Jiang XL: **Effects of Exercise Training on Restless Legs Syndrome, Depression, Sleep Quality, and Fatigue Among Hemodialysis Patients: A Systematic Review and Meta-analysis.** *J Pain Symptom Manage* 2018, **55**(4):1184-1195.
46. Thompson S, Wiebe N, Padwal RS, Gyenes G, Headley SAE, Radhakrishnan J, Graham M:

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- The effect of exercise on blood pressure in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials.** *PLoS One* 2019, **14**(2):e0211032.
47. Vanden Wyngaert K, Van Craenenbroeck AH, Van Biesen W, Dhondt A, Tanghe A, Van Ginckel A, Celie B, Calders P: **The effects of aerobic exercise on eGFR, blood pressure and VO₂peak in patients with chronic kidney disease stages 3-4: A systematic review and meta-analysis.** *PLoS One* 2018, **13**(9):e0203662.
48. Wu X, Yang L, Wang Y, Wang C, Hu R, Wu Y: **Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis.** *Clin Rehabil* 2020, **34**(7):851-865.
49. Yamamoto R, Ito T, Nagasawa Y, Matsui K, Egawa M, Nanami M, Isaka Y, Okada H: **Efficacy of aerobic exercise on the cardiometabolic and renal outcomes in patients with chronic kidney disease: a systematic review of randomized controlled trials.** *J Nephrol* 2021, **34**(1):155-164.
50. Yang H, Wu X, Wang M: **Exercise Affects Cardiopulmonary Function in Patients with Chronic Kidney Disease: A Meta-Analysis.** *Biomed Res Int* 2017, **2017**:6405797.
51. Zhang F, Zhou W, Sun Q, Zhai Y, Zhang Y, Su H, Wang Z: **Effects of intradialytic resistance exercises on physical performance, nutrient intake and quality of life among haemodialysis people: A systematic review and meta-analysis.** *Nurs Open* 2021, **8**(2):529-538.
52. Zhang L, Wang Y, Xiong L, Luo Y, Huang Z, Yi B: **Exercise therapy improves eGFR, and reduces blood pressure and BMI in non-dialysis CKD patients: evidence from a meta-analysis.** *BMC Nephrol* 2019, **20**(1):398.
53. Zhao QG, Zhang HR, Wen X, Wang Y, Chen XM, Chen N, Sun Y, Liu H, Lu PJ: **Exercise interventions on patients with end-stage renal disease: a systematic review.** *Clin Rehabil* 2019, **33**(2):147-156.
54. !!! INVALID CITATION !!! .
55. Clyne N, Anding-Rost K: **Exercise training in chronic kidney disease-effects, expectations and adherence.** *Clin Kidney J* 2021, **14**(Suppl 2):ii3-ii14.
56. Webster AC, Nagler EV, Morton RL, Masson P: **Chronic Kidney Disease.** *Lancet* 2017, **389**(10075):1238-1252.
57. Cheung AK, Chang TI, Cushman WC, Furth SL, Ix JH, Pecoits-Filho R, Perkovic V, Sarnak MJ, Tobe SW, Tomson CRV *et al*: **Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.** *Kidney Int* 2019, **95**(5):1027-1036.
58. Kuo CP, Tsai MT, Lee KH, Lin YP, Huang SS, Huang CC, Tseng WC, Tarng DC: **Dose-response effects of physical activity on all-cause mortality and major cardiorenal outcomes in chronic kidney disease.** *Eur J Prev Cardiol* 2021.
59. Graham-Brown MPM, March DS, Young R, Highton PJ, Young HML, Churchward DR, Dungey M, Stensel DJ, Bishop NC, Brunskill NJ *et al*: **A randomized controlled trial to investigate the effects of intra-dialytic cycling on left ventricular mass.** *Kidney International* 2021.
60. Zelle DM, Klaassen G, van Adrichem E, Bakker SJ, Corpeleijn E, Navis G: **Physical inactivity: a risk factor and target for intervention in renal care.** *Nat Rev Nephrol* 2017, **13**(3):152-168.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61. Mezzani A, Hamm LF, Jones AM, McBride PE, Moholdt T, Stone JA, Urhausen A, Williams MA: **Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation.** *Eur J Prev Cardiol* 2013, **20**(3):442-467.
62. Chan D, Cheema BS: **Progressive Resistance Training in End-Stage Renal Disease: Systematic Review.** *Am J Nephrol* 2016, **44**(1):32-45.
63. Androga L, Sharma D, Amodu A, Abramowitz MK: **Sarcopenia, obesity, and mortality in US adults with and without chronic kidney disease.** *Kidney Int Rep* 2017, **2**(2):201-211.
64. Weisbord SD, Fried LF, Arnold RM, Fine MJ, Levenson DJ, Peterson RA, Switzer GE: **Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients.** *J Am Soc Nephrol* 2005, **16**(8):2487-2494.
65. Flythe JE, Hilliard T, Castillo G, Ikeler K, Orazi J, Abdel-Rahman E, Pai AB, Rivara MB, St Peter WL, Weisbord SD *et al*: **Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed Methods Study.** *Clin J Am Soc Nephrol* 2018, **13**(5):735-745.
66. Gregg LP, Bossola M, Ostrosky-Frid M, Hedayati SS: **Fatigue in CKD: Epidemiology, Pathophysiology, and Treatment.** *Clin J Am Soc Nephrol* 2021.
67. Flythe JE, Dorough A, Narendra JH, Forfang D, Hartwell L, Abdel-Rahman E: **Perspectives on symptom experiences and symptom reporting among individuals on hemodialysis.** *Nephrol Dial Transplant* 2018, **33**(10):1842-1852.
68. Metzger M, Abdel-Rahman EM, Boykin H, Song MK: **A Narrative Review of Management Strategies for Common Symptoms in Advanced CKD.** *Kidney Int Rep* 2021, **6**(4):894-904.
69. Johansen KL: **The Promise and Challenge of Aerobic Exercise in People Undergoing Long-Term Hemodialysis.** *Clin J Am Soc Nephrol* 2021, **16**(4):505-507.
70. Fuller JT, Hartland MC, Maloney LT, Davison K: **Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials.** *Br J Sports Med* 2018, **52**(20):1311.
71. Amir N, Tong A, McCarthy H, Howell M: **Trajectories of quality of life in chronic kidney disease: a novel perspective of disease progression.** *Nephrol Dial Transplant* 2021.
72. Parker K: **Intradialytic Exercise is Medicine for Hemodialysis Patients.** *Curr Sports Med Rep* 2016, **15**(4):269-275.
73. Smart NA, Williams AD, Levinger I, Selig S, Howden E, Coombes JS, Fasset RG: **Exercise & Sports Science Australia (ESSA) position statement on exercise and chronic kidney disease.** *J Sci Med Sport* 2013, **16**(5):406-411.
74. March DS, Hurt AW, Grantham CE, Churchward DR, Young HML, Highton PJ, Dungey M, Bishop NC, Smith AC, Graham-Brown MPM *et al*: **A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial.** *Kidney International Reports*.
75. Fuhrmann I, Krause R: **Principles of exercising in patients with chronic kidney disease, on dialysis and for kidney transplant recipients.** *Clin Nephrol* 2004, **61** Suppl 1:S14-25.

Table 1 Summary of the effect of exercise on cardiovascular risk factor in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD or MD (95% CI)	Effect size	P	I ²	GRADE
SBP										
Pei (2019)	RCT/quasi-RCT	Mixed	12(514)	AE	-	MD:-2.91 (-6.68, 0.87)	-	0.13	40.0%	⊕⊕○○
Wu (2020)	RCT/quasi-RCT	Predialysis	3 (204)	AE+RT	-	SMD:-0.19(-0.46,0.08)	Small	0.16	50.0%	⊕○○○
Chen (2019)	RCT	KTRs	5(198)	Mixed	-	SMD:0.18(-0.10,0.46)	Small	0.21	0.0%	⊕○○○
Pu (2019)	RCT	HD	7(287)	Mixed	Intradialytic	SMD:-0.28(-0.52,-0.05)	Small	0.02	0.0%	⊕○○○
Yamamoto (2021)	RCT	Predialysis	10(392)	AE	-	SMD:-0.75(-1.24,-0.26)	Moderate	0.003	80.3%	⊕○○○
Thompson (2019)	RCT	Predialysis	10(335)	Mixed	-	MD:-4.30(-9.00,0.40)	-	N.P.	50.4%	⊕○○○
Zhang (2019)	RCT	Predialysis	14(463)	Mixed	-	SMD:-0.41(-0.70,-0.11)	Small	0.007	55.0%	⊕⊕⊕○
Huang (2019)	RCT	HD	7(260)	Mixed	Mixed	SMD:-0.17(-0.41,0.08)	Small	0.18	8.0%	⊕⊕○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	9(347)	Mixed	-	SMD:0.25(0.04,0.47)	Small	0.02	0.0%	⊕○○○
Heiwe (2014)	RCT	HD	10(312)	Mixed	-	SMD:0.04(-0.34,0.41)	Small	0.8	58.0%	⊕○○○
Sheng (2014)	RCT	HD	7(296)	Mixed	Intradialytic	SMD:-0.27(-0.50,-0.04)	Small	0.02	0.0%	⊕○○○
Ferrari (2019)	RCT	HD	10(332)	AE	Intradialytic	MD:-10.07(16.35,-3.78)	-	0.002	44.0%	⊕○○○
Wynngaert (2018)	RCT	Predialysis	8(269)	AE	-	SMD:0.08(-0.58,0.74)	Small	0.81	84%	⊕○○○
DBP										
Pei (2019)	RCT/quasi-RCT	Mixed	12(514)	AE	-	MD:-1.11 (-3.41, 1.20)	-	0.35	0.0%	⊕⊕○○
Wu (2020)	RCT/quasi-RCT	Predialysis	4 (194)	AE+RT	-	SMD:-0.47(-1.10,0.15)	Small	0.14	70.0%	⊕○○○
Chen (2019)	RCT	KTRs	5(198)	Mixed	-	SMD:0.04(-0.45,0.52)	Small	0.89	59.0%	⊕○○○
Pu (2019)	RCT	HD	7(287)	Mixed	Intradialytic	SMD:-0.32(-0.55,-0.08)	Small	0.008	42.0%	⊕○○○
Thompson (2019)	RCT	Predialysis	8(303)	Mixed	-	MD:-1.18(-4.76,2.40)	-	N.P.	60.5%	⊕○○○

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Zhang (2019)	RCT	Predialysis	12(399)	Mixed	-	SMD:-0.31(-0.71,0.08)	Small	0.12	70.0%	⊕⊕○○
Huang (2019)	RCT	HD	7(260)	Mixed	Mixed	SMD:-0.23(-0.69,0.24)	Small	0.34	68.0%	⊕○○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	11(419)	Mixed	-	SMD:0.16(-0.04,0.36)	Small	0.11	40.0%	⊕○○○
Heiwe (2014)	RCT	HD	10(212)	Mixed	Mixed	SMD:0.17(-0.16,0.49)	Small	0.3	45.0%	⊕⊕○○
Sheng (2014)	RCT	HD	7(296)	Mixed	Intradialytic	SMD:-0.24(-0.47,-0.01)	Small	0.04	52.1%	⊕○○○
Ferrari (2019)	RCT	HD	10(334)	AE	Intradialytic	MD:-2.96(-7.71,1.78)	-	0.22	0.0%	⊕○○○
Wyngaert (2018)	RCT	Predialysis	7(237)	AE	-	SMD-0.09(-0.78,0.59)	Small	0.79	83%	⊕○○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; DBP = diastolic blood pressure; SBP = systolic blood pressure; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; GRADE = Grading of Recommendations Assessment, Development, and Evaluation; N.P. = no report.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Table 2 Summary of the effect of exercise on cardiopulmonary fitness in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD or MD (95% CI)	Effect size	P	I ²	GRADE
VO _{2peak}										
Pei (2019)	RCT/quasi-RCT	Mixed	17(464)	AE	-	MD:2.08(1.10,3.05)	-	<0.001	25.0%	⊕⊕○○
Nakamura (2020)	RCT/cross-over	Predialysis	10(401)	Mixed	-	SMD:0.88(0.53,1.23)	Large	<0.001	56.0%	⊕⊕○○
Chen (2019)	RCT	KTRs	6(202)	Mixed	-	SMD:0.33(-0.02,0.69)	Small	0.06	27.0%	⊕○○○
Andrade (2019)	RCT	HD	5(201)	AE+RT	Intradialytic	SMD:1.01(0.71,1.30)	Large	<0.001	0.0%	⊕⊕○○
Chung (2016)	RCT	HD	6(238)	Mixed	Intradialytic	SMD:0.55(0.18,0.92)	Moderate	0.003	52.9%	⊕○○○
Pu (2019)	RCT	HD	10(400)	Mixed	Intradialytic	SMD:0.57(0.23,0.90)	Moderate	<0.001	59.0%	⊕⊕○○
Yamamoto (2021)	RCT	Predialysis	10(365)	AE	-	SMD:0.54(0.29,0.78)	Moderate	<0.001	24.6%	⊕○○○
Yang (2017)	RCT	Mixed	5(179)	Mixed	-	SMD:0.33(0.03,0.63)	Small	0.003	47.0%	⊕⊕○○
Huang (2019)	RCT	HD	10(371)	Mixed	Mixed	SMD:0.73(0.52,0.95)	Moderate	<0.001	71.0%	⊕⊕○○
Matsuzawa (2017)	RCT	HD	18(582)	Mixed	Mixed	SMD:0.62(0.38,0.87)	Moderate	<0.001	49.0%	⊕⊕⊕⊕

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Smart (2011)	RCT	HD	8(365)	Mixed	Mixed	SMD:0.75(0.39,1.11)	Moderate	<0.001	60.0 %	⊕⊕○○
Bogataj (2020)	RCT	HD	20(504)	Mixed	Mixed	SMD:0.58(0.32,0.85)	Moderate	<0.001	57.4 %	⊕○○○
Sheng (2014)	RCT	HD	7(310)	Mixed	Intradialyti c	SMD:0.53(0.30,0.76)	Moderate	<0.001	36.0 %	⊕○○○
Neto (2018)	RCT	HD	10(394)	Mixed	Intradialyti c	SMD:0.60(0.15,1.04)	Moderate	0.008	76.0 %	⊕○○○
Ferrari (2019)	RCT	HD	5(201)	AE+RT	Intradialyti c	MD:5.41(4.03,6.79)	-	<0.001	0.0%	⊕○○○
Ferrari (2019)	RCT	HD	7(248)	AE	Intradialyti c	MD:2.07(0.42,3.72)	-	<0.001	0.0%	⊕○○○
Wyngaert (2018)	RCT	Predialysi s	11(325)	AE	-	SMD:0.99(0.49,1.48)	Large	<0.001	74.0 %	⊕○○○
Oguchi (2018)	RCT	KTRs	4(182)	Mixed	-	SMD:0.38(-0.06,0.82)	Small	0.09	45.0 %	⊕⊕○○
6MWT										
Pei (2019)	RCT/quasi- RCT	Mixed	8 (496)	AE	-	MD:0.04 (-0.52, 0.59)	-	0.90	86.0 %	⊕○○○
Nakamura (2020)	RCT/cross-over	Predialysi s	5(392)	Mixed	-	SMD:1.04(0.17,1.90)	Large	0.02	92.0 %	⊕○○○
Lu (2019)	RCT	Dialysis	11(300)	Mixed	Mixed	SMD:0.52(0.31,0.72)	Moderate	<0.001	39.0 %	⊕⊕⊕○
Chung (2016)	RCT	HD	4(127)	Mixed	Intradialyti c	SMD:0.44(0.09,0.80)	Small	0.015	0.0%	⊕⊕○○

Zhang (2021)	RCT	HD	8(299)	RT	Intradialytic	SMD:0.52(0.28,0.75)	Moderate	<0.001	18.7%	⊕⊕○○
Pu (2019)	RCT	HD	7(219)	Mixed	Intradialytic	SMD:0.57(0.30,0.84)	Moderate	<0.001	0.0%	⊕⊕○○
Clarkson (2019)	RCT	Dialysis	18(744)	Mixed	-	MD:33.64(23.74,43.54)	-	<0.001	0.0%	⊕⊕⊕○
Huang (2019)	RCT	HD	7(205)	Mixed	Mixed	SMD:1.01(0.26,1.76)	Large	0.008	83.0%	⊕○○○
Matsuzawa (2017)	RCT	HD	10(326)	Mixed	Mixed	SMD:0.58(0.24,0.93)	Moderate	<0.001	53.0%	⊕⊕○○
Bogataj (2020)	RCT	HD	19	Mixed	Mixed	SMD:0.44(0.21,0.67)	Small	<0.001	49.6%	⊕○○○
Sheng (2014)	RCT	HD	4(146)	Mixed	Intradialytic	SMD:0.58(0.23,0.93)	Moderate	<0.001	89.7%	⊕○○○
Neto (2018)	RCT	HD	6(158)	Mixed	Intradialytic	SMD:0.96(0.11,1.80)	Large	0.03	82.0%	⊕○○○
Ferrari (2019)	RCT	HD	6(211)	RT	Intradialytic	MD:68.5(29.05,107.96)	-	<0.001	36.0%	⊕○○○
Ferrari (2019)	RCT	HD	6(188)	AE	Intradialytic	MD:64.98(43.86,86.11)	-	<0.001	0.0%	⊕○○○
Aerobic capacity										
Heiwe (2011)	RCT/quasi-RCT	Mixed	24(847)	Mixed	-	SMD:-0.56(-0.70,-0.42)	Moderate	<0.001	12.0%	⊕○○○
Heiwe (2014)	RCT	HD	21(374)	Mixed	Mixed	SMD:-0.80(-1.02,-0.58)	Large	<0.001	0.0%	⊕⊕○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; VO_{2peak} = peak oxygen uptake; 6MWT = 6 minutes walk test; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

*Number of included studies and corresponding sample size.
Mixed means aerobic exercise combined with resistance training.

For peer review only

Table 3 Summary of the effect of exercise on muscle strength in CKD patients

Author(year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD or MD(95% CI)	Effect size	P	I ²	GRADE
Cheema (2014)	RCT	Predialysis	7(249)	RT	-	SMD:1.15(0.80,1.49)	Large	0.161	35.0%	⊕⊕○○
Nakamura (2020)	RCT/cross-over	Predialysis	4(119)	Mixed	-	SMD:0.35(-0.03,0.73)	Small	0.07	7.0%	⊕○○○
Lu (2019)	RCT	Dialysis	5(234)	Mixed	Mixed	SMD:0.59(0.20,0.98)	Moderate	0.003	52.0%	⊕⊕○○
Lu (2019)	RCT	Dialysis	7(224)	Mixed	Mixed	SMD:0.47(0.20,0.74)	Small	<0.001	0.0%	⊕⊕○○
Zhang (2021)	RCT	HD	6(300)	RT	Intradialytic	SMD:0.35(0.12,0.58)	Small	0.003	41.6%	⊕⊕○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	9(358)	Mixed	-	SMD:-0.52(-0.73,-0.31)	Moderate	<0.001	0.0%	⊕○○○
Heiwe (2014)	RCT	HD	12(385)	Mixed	Mixed	SMD:-0.56(-0.77,-0.35)	Moderate	<0.001	0.0%	⊕○○○
Matsuzawa (2017)	RCT	HD	9(281)	Mixed	Mixed	SMD:0.94(0.67,1.21)	Large	<0.001	10.0%	⊕○○○
Neto (2018)	RCT	HD	9(250)	Mixed	Intradialytic	SMD:0.61(0.39,0.83)	Moderate	<0.001	58.9%	⊕○○○
Ju (2020)	RCT	Mixed	3(115)	Mixed	-	SMD:0.52(0.14,0.89)	Moderate	0.007	0.0%	⊕○○○

Abbreviation: RCT = randomized controlled trial; RT = resistance training; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Table 4 Summary of the effect of exercise on muscle endurance in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcome	SMD or MD (95% CI)	Effect size	P	I ²	GRADE
Lu (2019)	RCT	Dialysis	3(193)	Mixed	Mixed	STS 10	MD:-4.69(-9.01,-0.38)	-	0.028	72.2%	⊕○○○
Bogataj (2020)	RCT	HD	5(461)	Mixed	-	STS 10	SMD:-0.55(-1.00,-0.09)	Moderate	0.019	71.6%	⊕○○○
Lu (2019)	RCT	Dialysis	6(240)	Mixed	Mixed	STS 30	SMD:0.43(0.17,0.69)	Small	0.001	2.0%	⊕⊕○○
Zhang (2021)	RCT	HD	5(164)	RT	Intradialytic	STS 30	SMD:0.42(0.11,0.74)	Small	0.008	0.0%	⊕○○○
Sheng (2014)	RCT	HD	3(106)	Mixed	Intradialytic	STS 60	SMD:0.71(0.31,1.12)	Moderate	<0.001	0.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	5(445)	AE	-	STS 60	MD:2.08(1.1,3.05)	-	0.98	82.0%	⊕○○○
Nakamura (2020)	RCT/cross-over	Predialysis	3(170)	Mixed	-	TUGT	SMD:-0.42(-0.73,-0.11)	Small	0.007	0.0%	⊕○○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	7(191)	Mixed	-	Walking capacity	SMD:-0.48(-0.79,-0.17)	Small	0.003	2.0%	⊕○○○
Heiwe (2014)	RCT	HD	7(174)	Mixed	Mixed	Walking capacity	SMD:-0.33(-0.67,0.01)	Small	0.06	16.0%	⊕⊕⊕○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; STS 10 = sit to stand 10 test; STS 30 = sit to stand 30 test; STS 60 = sit to stand 60 test; TUGT = timed up and go test; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Table 5 Summary of the effect of exercise on body composition in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD (95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
Chen (2019)	RCT	KTRs	4(166)	Mixed	-	SMD:0.02(-0.28,0.33)	Small	0.89	0.0%	⊕○○○
Yamamoto (2021)	RCT	Predialysis	10(414)	AE	-	SMD:-0.19(-0.38,-0.00)	Small	0.026	0.0%	⊕⊕○○
Zhang (2019)	RCT	Predialysis	13(466)	Mixed	-	SMD:-0.21(-0.39,-0.03)	Small	0.02	0.0%	⊕⊕⊕○
Wyngaert (2018)	RCT	Predialysis	9(294)	AE	-	SMD:-0.36(-0.60,-0.13)	Small	0.002	48.0%	⊕⊕○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; SMD = standardized mean difference; KTRs = kidney transplant recipients; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Table 6 Summary of the effect of exercise on dialysis-related symptoms in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcomes	SMD or MD(95% CI)	Effect size	P	I ²	GRADE
Ferreira (2019)	RCT/quasi-RCT	HD	10(346)	AE	Intradialytic	Kt/V	SMD:2.21(1.17,3.25)	Large	<0.001	92.0%	⊕○○○
Pu (2019)	RCT	HD	10(301)	Mixed	Intradialytic	Kt/V	SMD:0.29(0.06,0.52)	Small	0.01	0.0%	⊕○○○
Huang (2019)	RCT	HD	8(257)	Mixed	Mixed	Kt/V	SMD:0.19(-0.06,0.43)	Small	0.14	0.0%	⊕○○○
Sheng (2014)	RCT	HD	7(233)	Mixed	Intradialytic	Kt/V	SMD:0.27(0.01,0.53)	Small	0.04	0.0%	⊕○○○
Ferrari (2019)	RCT	HD	12(370)	AE	Intradialytic	Kt/V	MD:0.08(0.0,0.15)	-	0.04	56.0%	⊕○○○
Ferrari (2019)	RCT	HD	6(220)	RT	Intradialytic	Kt/V	MD:0.10(0.0,0.2)	-	0.06	6.0%	⊕○○○
Song (2018)	RCT	HD	4(141)	Mixed	Mixed	RLS	SMD:-1.79(-2.21,-1.37)	Large	<0.001	87.0%	⊕○○○
Song (2018)	RCT	HD	3(139)	Mixed	Mixed	Fatigue	SMD:-0.85(-1.20,-0.50)	Large	<0.001	0.0%	⊕○○○
Zhao (2019)	RCT	Dialysis	3(141)	Mixed	-	Fatigue	SMD:-0.97(-1.32,-0.62)	Large	<0.001	47.0%	⊕⊕○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; RLS = Restless Legs Syndrome; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.
Mixed means aerobic exercise combined with resistance training.


Table 7 Summary of the effect of exercise on health-related quality of lives in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcomes	SMD or MD (95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
Salhab (2019)	RCT	HD	5(282)	AE	Intradialytic	PCS	SMD:1.82(-0.92,4.55)	Large	0.19	98.0%	⊕○○○
Chung (2016)	RCT	HD	6(229)	Mixed	Intradialytic	PCS	SMD:0.46(0.20,0.73)	Small	<0.001	1.90%	⊕⊕○○
Zhang (2021)	RCT	HD	7(297)	RT	Intradialytic	PCS	SMD:0.23(-0.00,0.46)	Small	0.055	0.0%	⊕⊕○○
Pu (2019)	RCT	HD	10(320)	Mixed	Intradialytic	PCS	SMD:0.57(0.14,1.01)	Moderate	0.01	70.0%	⊕○○○
Zhao (2019)	RCT	Dialysis	5(186)	Mixed	-	PCS	SMD:0.31(0.02,0.61)	Small	0.04	46.0%	⊕⊕○○
Huang (2019)	RCT	HD	7(263)	Mixed	Mixed	PCS	SMD:0.34(0.09,0.59)	Small	0.007	27.0%	⊕⊕○○
Matsuzawa (2017)	RCT	HD	9(264)	Mixed	Mixed	PCS	SMD:0.53(0.52,0.82)	Moderate	<0.001	19.0%	⊕○○○
Sheng (2014)	RCT	HD	7(256)	Mixed	Intradialytic	PCS	SMD:0.30(0.05,0.55)	Small	0.02	39.5%	⊕○○○
Neto (2018)	RCT	HD	7(187)	Mixed	Intradialytic	PCS	SMD:0.50(-0.19,1.18)	Moderate	0.16	62.0%	⊕○○○
Salhab (2019)	RCT	HD	5(282)	AE	Intradialytic	MCS	SMD:1.02(0.31,1.73)	Large	0.005	75.0%	⊕○○○
Chung (2016)	RCT	HD	5(193)	Mixed	Intradialytic	MCS	SMD:0.23(-0.05,0.52)	Small	0.109	0.0%	⊕⊕○○
Zhang (2021)	RCT	HD	7(297)	RT	Intradialytic	MCS	SMD:0.13(-0.10,0.36)	Small	0.082	46.5%	⊕⊕○○
Pu (2019)	RCT	HD	8(219)	Mixed	Intradialytic	MCS	SMD:0.19(-0.09,0.46)	Small	0.18	30.0%	⊕⊕○○
Zhao (2019)	RCT	Dialysis	5(186)	Mixed	-	MCS	SMD:0.30(-0.20,0.80)	Small	0.24	64.0%	⊕○○○
Huang (2019)	RCT	HD	7(263)	Mixed	Mixed	MCS	SMD:0.27(0.02,0.51)	Small	0.03	0.0%	⊕⊕○○
Matsuzawa (2017)	RCT	HD	8(228)	Mixed	Mixed	MCS	SMD:0.14(-0.15,0.42)	Small	0.34	10.0%	⊕○○○
Sheng (2014)	RCT	HD	5(167)	Mixed	Intradialytic	MCS	SMD:0.14(-0.16,0.43)	Small	0.37	14.8%	⊕○○○
Neto (2018)	RCT	HD	7(185)	Mixed	Intradialytic	MCS	SMD:0.39(-0.19,0.98)	Small	0.19	50.0%	⊕○○○

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46
Pei (2019)	RCT/quasi-RCT	Mixed	6(522)	AE	-	Physical function (SF-36)	MD:8.36(-1.24,17.95)	-	0.09	76.0%	⊕○○○																																		
Pei (2019)	RCT/quasi-RCT	Mixed	7(562)	AE	-	Physical role (SF-36)	MD:14.65(1.47,27.84)	-	0.03	78.0%	⊕○○○																																		
Pei (2019)	RCT/quasi-RCT	Mixed	6(447)	AE	-	Social function (SF-36)	MD:8.24(-1.09,17.58)	-	0.08	85.0%	⊕○○○																																		
Pei (2019)	RCT/quasi-RCT	Mixed	6(513)	AE	-	Pain (SF-36)	MD:5.94(1.65,10.23)	-	0.007	49.0%	⊕○○○																																		
Pei (2019)	RCT/quasi-RCT	Mixed	7(562)	AE	-	General health (SF-36)	MD:8.90(2.48,15.32)	-	0.007	71.0%	⊕○○○																																		
Pei (2019)	RCT/quasi-RCT	Mixed	6(542)	AE	-	Mental health (SF-36)	MD:7.30(-0.94,15.54)	-	0.08	84.0%	⊕○○○																																		
Cheema (2014)	RCT	Predialysis	6 (223)	RT	-	HRQOL	SMD:0.83(0.51,1.16)	Large	0.226	27.8%	⊕⊕○○																																		
Oguchi (2018)	RCT	KTRs	4(179)	Mixed	-	HRQOL	SMD:0.54(0.02,1.07)	Moderate	0.04	58.0%	⊕○○○																																		
Ju (2020)	RCT	Mixed	3 (387)	Mixed	-	Symptom/problem (KDQOL)	SMD:1.92(-1.06,4.90)	Large	0.21	99.0%	⊕○○○																																		
Ju (2020)	RCT	Mixed	3 (387)	Mixed	-	Effects of kidney disease (KDQOL)	SMD:-3.69(-8.56,1.19)	Large	0.14	99.0%	⊕○○○																																		
Ju (2020)	RCT	Mixed	3 (387)	Mixed	-	Burden of kidney disease (KDQOL)	SMD:1.04 (-0.75,2.82)	Large	0.26	98.0%	⊕○○○																																		

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; COM = combine; HRQOL = health-related quality of life; PCS = physical component summary; MCS = mental component summary; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; SF-36 = Short-Form Health Survey-36; KDQOL = kidney disease quality of life; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.
 Mixed means aerobic exercise combined with resistance training.



Figures 1 Flowchart of literature screening.

CDSR = Cochrane Database of Systemic Review

Supplementary Table S1 The detailed search strategy

Databases	#	Search strategy
Pubmed	1	"renal insufficiency, chronic"[MeSH Terms]
	2	"chronic renal insufficiency"[Title/Abstract] or "chronic kidney insufficiency"[Title/Abstract] or "chronic kidney disease"[Title/Abstract] or "chronic renal disease"[Title/Abstract]
	3	"CKD"[Title/Abstract] or "CKF"[Title/Abstract] or "CRD"[Title/Abstract] or "CRF"[Title/Abstract]
	4	"end-stage kidney"[Title/Abstract] or "end-stage renal"[Title/Abstract] or "endstage kidney"[Title/Abstract] or "endstage renal"[Title/Abstract]
	5	"ESRD"[Title/Abstract] or "ESRF"[Title/Abstract] or "ESKD"[Title/Abstract] or "ESKF"[Title/Abstract]
	6	"Renal Replacement Therapy"[MeSH Terms]
	7	"dialysis"[Title/Abstract]
	8	"hemodialysis"[Title/Abstract] or "haemodialysis"[Title/Abstract] or "hemodiafiltration"[Title/Abstract] or "haemodiafiltration"[Title/Abstract] or "HD"[Title/Abstract]
	9	"PD"[Title/Abstract]
	10	"renal transplantation"[Title/Abstract] or "kidney grafting"[Title/Abstract] or "kidney transplantation"[Title/Abstract]
	11	"KTRs"[Title/Abstract]
	12	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
	13	"Exercise"[MeSH Terms]
	14	"Exercise Movement Techniques"[MeSH Terms]
	15	"Exercise Therapy"[MeSH Terms]
	16	"Sports"[MeSH Terms]
	17	"train"[Title/Abstract] or "physical activity"[Title/Abstract] or "exercise"[Title/Abstract]
	18	#13 or #14 or #15 or #16 or #17
	19	"Systematic Review"[Publication Type] or "Systematic Reviews as Topic"[MeSH Terms]
	20	"meta analysis"[Publication Type] or "Meta-Analysis as Topic"[MeSH Terms]

	21	"Systematic Review"[Title/Abstract] or "system review"[Title/Abstract] or "data pooling"[Title/Abstract] or "meta"[Title/Abstract]
	22	#19 or #20 or #21
	23	#12 and #18 and #22
CDSR	1	MeSH descriptor: [Kidney Diseases] explode all trees
	2	("chronic kidney disease") or ("chronic renal disease") or ("chronic kidney failure") or ("chronic renal failure"):ti,ab,kw
	3	(CKF or CKD or CRF or CRD):ti,ab,kw
	4	("end-stage kidney") or ("end-stage renal") or ("endstage kidney") or ("endstage renal"):ti,ab,kw
	5	ESRD or ESRF or ESKD or ESKF:ti,ab,kw
	6	MeSH descriptor: [Renal Replacement Therapy] explode all trees
	7	dialysis:ti,ab,kw
	8	(hemodialysis or haemodialysis or hemodiafiltration or haemodiafiltration or HD):ti,ab,kw
	9	PD:ti,ab,kw
	10	("renal transplantation") or ("kidney grafting") or ("kidney transplantation"):ti,ab,kw
	11	KTRs:ti,ab,kw
	12	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
	13	MeSH descriptor: [Exercise] explode all trees
	14	MeSH descriptor: [Exercise Movement Techniques] explode all trees
	15	MeSH descriptor: [Exercise Therapy] explode all trees
	16	MeSH descriptor: [Sports] explode all trees
	17	(train or ("physical activity") or exercise):ti,ab,kw
	18	#13 or #14 or #15 or #16 or #17
	19	MeSH descriptor: [Meta-Analysis as Topic] explode all trees
	20	MeSH descriptor: [Systematic Reviews as Topic] explode all trees
	21	("systematic review") or ("system review") or ("data pooling") or (meta):ti,ab,kw
	22	#19 or #20 or #21

	23	#12 and #18 and #22
Embase	1	'kidney disease'/exp
	2	('chronic kidney disease' or 'chronic renal disease' or 'chronic kidney failure' or 'chronic renal failure'):ti,ab,kw
	3	(CKF or CKD or CRF or CRD):ti,ab,kw
	4	('end-stage kidney' or 'end-stage renal' or 'endstage kidney' or 'endstage renal'):ti,ab,kw
	5	(ESRD or ESRF or ESKD or ESKF):ti,ab,kw
	6	'renal replacement therapy'/exp
	7	'dialysis':ti,ab,kw
	8	(hemodialysis or haemodialysis or hemofiltration or haemofiltration or hemodiafiltration or haemodiafiltration or HD):ti,ab,kw
	9	PD:ti,ab,kw
	10	('renal transplantation' or 'kidney grafting' or 'kidney transplantation'):ti,ab,kw
	11	KTRs:ti,ab,kw
	12	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
	13	'exercise'/exp
	14	'physical activity'/exp
	15	'sport'/exp
	16	(train or 'physical activity' or exercise):ti,ab,kw
	17	#13 or #14 or #15 or #16
	18	'systematic review (topic)'/exp or 'systematic review'/exp
	19	'meta analysis (topic)'/exp or 'meta analysis'/exp
	20	('systematic review' or 'system review' or 'data pooling' or meta):ti,ab,kw
	21	#18 or #19 or #20
	22	#12 and #17 and #21
Web of Science	1	TS: ("chronic kidney disease" or "chronic renal disease" or "chronic kidney failure" or "chronic renal failure" or CKD or CRD or CKF or CRF)

2	TS: ("end-stage kidney" or "end-stage renal" or "endstage kidney" or "endstage renal" or ESKD or ESKF or ESRD or ESRF)
3	TS: ("renal replacement therapy" or dialysis or hemodialysis or haemodialysis or hemofiltration or haemofiltration or hemodiafiltration or haemodiafiltration or HD or PD)
4	TS: ("renal transplantation" or "kidney grafting" or "kidney transplantation" or KTRs)
5	#1 or #2 or #3 or #4
6	TS: (train or exercise or "physical activity")
7	TS: ("systematic review" or "system review" or "data pooling" or meta)
8	#1 and #2 and #3 and #4 and #5

Supplementary Table S2 The characteristic of excluded studies

Studies	Reasons for exclusion
Nantakool et al (2020)	Non predefine outcome
Sawant et al (2014)	Non predefine outcome
Smart et al (2014)	Duplicate literature
Barcellos et al (2015)	Meta-analysis was not conducted
Yang et al (2020)	Non predefine outcome
Young et al (2018)	Included cases<100
Phan et al (2015)	Duplicate literature
Molsted et al (2019)	Included cases<100
Segura et al (2010)	Non-English
Ferreira et al (2020)	Non predefine outcome
Koufaki et al (2013)	Meta-analysis was not conducted
Smart et al (2012)	Abstracts
Howden et al (2012)	Meta-analysis was not conducted
Calella et al (2019)	Meta-analysis was not conducted
Singh et al (2005)	Meta-analysis was not conducted
Cardoso et al (2020)	Non predefine outcome
Villanego et al (2020)	Non-English
Medeiros et al (2017)	Intervention did not fit
Macdonald et al (2009)	Meta-analysis was not conducted
Wen et al (2019)	Non predefine outcome
Yang et al (2015)	Non predefine outcome
Thangarasa et al (2018)	Included cases<100
Chan et al (2016)	Meta-analysis was not conducted

Johansen et al (2010)	Intervention did not fit
Thompson et al (2020)	Correction for published paper
Bakaloudi et al (2020)	Meta-analysis was not conducted
Kirkman et al (2019)	Meta-analysis was not conducted
Afsar et al (2018)	Meta-analysis was not conducted

For peer review only

Supplementary Table S3 The basic characteristics of the included meta-analyses

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcomes	SMD or MD(95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
Pei (2019)	RCT/quasi-RCT	Mixed	17(464)	AE	-	VO _{2peak}	MD:2.08 (1.1,3.05)	-	<0.001	25.0%	Low
			5 (445)			STS 60	MD:2.08 (1.1,3.05)	-	0.98	82.0%	Very low
			8 (496)			6MWT	MD:0.04 (-0.52, 0.59)	-	0.9	86.0%	Very low
			12(514)			SBP	MD:-2.91 (-6.68, 0.87)	-	0.13	40.0%	Low
			12(514)			DBP	MD:-1.11 (-3.41, 1.20)	-	0.35	0.0%	Low
			6(522)			Physical function (SF-36)	MD:8.36(-1.24,17.95)	-	0.09	76.0%	Very low
			7(562)			Physical role (SF-36)	MD:14.65(1.47,27.84)	-	0.03	78.0%	Very low
			6(447)			Social function (SF-36)	MD:8.24(-1.09,17.58)	-	0.08	85.0%	Very low
			6(513)			Pain (SF-36)	MD:5.94(1.65,10.23)	-	0.007	49.0%	Very low
			7(562)			General health (SF-36)	MD:8.90(2.48,15.32)	-	0.007	71.0%	Very low
6(542)	Mental health (SF-36)	MD:7.30(-0.94,15.54)	-	0.08	84.0%	Very low					
Ferreira (2019)	RCT/quasi-RCT	HD	10(346)	AE	Intradialytic	Kt/V	SMD:2.21(1.17,3.25)	Large	<0.001	92.0%	Very low
Cheema (2014)	RCT	Predialysis	7(249)	RT	-	Muscle Strength	SMD:1.15 (0.80-1.49)	Large	0.161	35.0%	Low
			6(223)			HRQoL	SMD:0.83(0.51-1.16)	Large	0.226	27.8%	Low
Wu (2020)	RCT/quasi-RCT	Predialysis	3(204)	AE+RT	-	SBP	SMD:-0.19(-0.46,0.08)	Small	0.16	50.0%	Very low
			4(194)			DBP	SMD:-0.47(-1.10,0.15)	Small	0.14	70.0%	Very low

Nakamura (2020)	RCT/cross-over	Predialysis	10(401)	Mixed	-	VO _{2peak}	SMD:0.88(0.53,1.23)	Large	<0.001	56.0%	Low
			4(119)			Muscle Strength	SMD:0.35(-0.03,0.73)	Small	0.07	7.0%	Very low
			5(392)			6MWT	SMD:1.04(0.17,1.90)	Large	0.02	92.0%	Very low
			3(170)			TUGT	SMD:-0.42(-0.73,-0.11)	Small	0.007	0.0%	Very low
Lu (2019)	RCT	Dialysis	11(300)	Mixed	Mixed	6MWT	MD:67.6(49.93,85.26)	-	<0.001	30.6%	Moderate
			3(193)			STS 10	MD:-4.69(-9.01,-0.38)	-	0.028	72.2%	Very low
			5(234)			HGS	MD:5.35(3.34,7.37)	-	<0.001	0.3%	Low
			7(224)			Muscle strength	MD:3.67(1.37,5.97)	-	0.020	38.6%	Low
			6(240)			STS 30	MD:2.43(0.91,3.96)	-	0.002	21.2%	Low
Chen (2019)	RCT	KTRs	5(198)	Mixed	-	SBP	SMD:0.18(-0.10,0.46)	Small	0.21	0.0%	Very low
			5(198)			DBP	SMD:0.04(-0.45,0.52)	Small	0.89	59.0%	Very low
			4(166)			BMI	SMD:0.02(-0.28,0.33)	Small	0.89	0.0%	Very low
			6(202)			VO _{2peak}	SMD:0.33(-0.02,0.69)	Small	0.06	27.0%	Very low
Song (2018)	RCT	HD	4(141)	Mixed	Mixed	RLS	SMD:-1.79(-2.21,-1.37)	Large	<0.001	87.0%	Very low
			3(139)			Fatigue	SMD:-0.85(-1.20,-0.50)	Large	<0.001	0.0%	Very low
Salhab (2019)	RCT	HD	5(282)	AE	Intradialytic	PCS	SMD:1.82(-0.92,4.55)	Large	0.19	98.0%	Very low
			5(282)			MCS	SMD:1.02(0.31,1.73)	Large	0.005	75.0%	Very low
Andrade (2019)	RCT	HD	5(201)	AE+RT	Intradialytic	VO _{2peak}	SMD:1.01(0.71,1.30)	Large	<0.001	0.0%	Low
Chung (2016)	RCT	HD	4(127)	Mixed	Intradialytic	6MWT	SMD:0.44(0.09,0.80)	Small	0.015	0.0%	Low
			6(238)			VO _{2peak}	SMD:0.55(0.18,0.92)	Moderate	0.003	52.9%	Very low
			6(229)			PCS	SMD:0.46(0.20,0.73)	Small	<0.001	1.90%	Low
			5(193)			MCS	SMD:0.23(-0.05,0.52)	Small	0.109	0.0%	Low
Zhang (2021)	RCT	HD	8(299)	RT	Intradialytic	6MWT	SMD:0.52(0.28,0.75)	Moderate	<0.001	18.7%	Very low
			5(164)			STS 30	SMD:0.42(0.11,0.74)	Small	0.008	0.0%	Very low

			6(300)			HGS	SMD:0.35(0.12,0.58)	Small	0.003	41.6%	Very low
			7(297)			PCS	SMD:0.23(-0.00,0.46)	Small	0.055	0.0%	Very low
			7(297)			MCS	SMD:0.13(-0.10,0.36)	Small	0.082	46.5%	Very low
Pu (2019)	RCT	HD	10(301)	Mixed	Intradialytic	Kt/V	SMD:0.29(0.06,0.52)	Small	0.01	0.0%	Very low
			10(400)			VO _{2peak}	SMD:0.57(0.23,0.90)	Moderate	<0.001	59.0%	Low
			7(219)			6MWT	SMD:0.57(0.30,0.84)	Moderate	<0.001	0.0%	Low
			10(320)			PCS	SMD:0.57(0.14,1.01)	Moderate	0.01	70.0%	Very low
			8(219)			MCS	SMD:0.19(-0.09,0.46)	Small	0.18	30.0%	Low
			7(287)			SBP	SMD:-0.28(-0.52,-0.05)	Small	0.02	0.0%	Very low
			7(287)			DBP	SMD:-0.32(-0.55,-0.08)	Small	0.008	42.0%	Very low
Yamamoto (2021)	RCT	Predialysis	10(392)	AE	-	SBP	SMD:-0.75(-1.24,-0.26)	Moderate	0.003	80.3%	Very low
			10(365)			VO _{2peak}	SMD:0.54(0.29,0.78)	Moderate	<0.001	24.6%	Very low
			10(414)			BMI	SMD:-0.19(-0.38,-0.00)	Small	0.026	0.0%	Low
Thompson (2019)	RCT	Predialysis	10(335)	Mixed	-	SBP	MD:-4.3(-9.0,0.4)	-	N.P.	50.4%	Very low
			8(303)			DBP	MD:-1.18(-4.76,2.40)	-	N.P.	60.5%	Very low
Yang (2017)	RCT	Mixed	4(150)	Mixed	-	VO _{2peak}	SMD:0.33(0.03,0.63)	Small	0.003	47.0%	Low
Clarkson (2019)	RCT	Dialysis	18(744)	Mixed	-	6MWT	MD:33.64(23.74,43.54)	-	<0.001	0.0%	Moderate
Zhao (2019)	RCT	Dialysis	3(141)	Mixed	-	Fatigue	SMD:-0.97(-1.32,-0.62)	Large	<0.001	47.0%	Low
			5(186)			PCS	SMD:0.31(0.02,0.61)	Small	0.04	46.0%	Low
			5(186)			MCS	SMD:0.30(-0.20,0.80)	Small	0.24	64.0%	Very low
Zhang (2019)	RCT	Predialysis	14(463)	Mixed	-	SBP	SMD:-0.41(-0.70,-0.11)	Small	0.007	55.0%	Moderate
			12(399)			DBP	SMD:-0.31(-0.71,0.08)	Small	0.12	70.0%	Low
			13(466)			BMI	SMD:-0.21(-0.39,-0.03)	Small	0.02	0.0%	Moderate

Huang (2019)	RCT	HD	8(257)	Mixed	-	Kt/V	SMD:0.19(-0.06,0.43)	Small	0.14	0.0%	Very low
			7(260)			SBP	SMD:-0.17(-0.41,0.08)	Small	0.18	8.0%	Low
			7(260)			DBP	SMD:-0.23(-0.69,0.24)	Small	0.34	68.0%	Very low
			7(205)			6MWT	SMD:1.01(0.26,1.76)	Large	0.008	83.0%	Very low
			7(263)			PCS	SMD:0.34(0.09,0.59)	Small	0.007	27.0%	Low
			7(263)			MCS	SMD:0.27(0.02,0.51)	Small	0.03	0.0%	Low
			10(371)			VO _{2peak}	SMD:0.73(0.52,0.95)	Moderate	<0.001	71.0%	Low
Heiwe (2011)	RCT/quasi-RCT	Mixed	24(847)	Mixed	-	Aerobic capacity	SMD:-0.56(-0.70,-0.42)	Moderate	<0.001	12.0%	Moderate
			9(358)			Muscle strength	SMD:-0.52(-0.73,-0.31)	Moderate	<0.001	0.0%	Low
			7(191)			Walking capacity	SMD:-0.48(-0.79,-0.17)	Small	0.003	2.0%	Low
			9(347)			SBP	SMD:0.25(0.04,0.47)	Small	0.02	0.0%	Low
			11(419)			DBP	SMD:0.16(-0.04,0.36)	Small	0.11	40.0%	High
Heiwe (2014)	RCT	HD	21(374)	Mixed	-	Aerobic capacity	SMD:-0.80(-1.02,-0.58)	Large	<0.001	0.0%	Low
			10(212)			DBP	SMD:0.17(-0.16,0.49)	Small	0.3	45.0%	Low
			10(312)			SBP	SMD:0.04(-0.4,0.41)	Small	0.8	58.0%	Very low
			10(385)			Muscle strength	SMD:-0.56(-0.77,-0.35)	Moderate	<0.001	0.0%	Very low
			7(174)			Walking capacity	SMD:-0.33(-0.67,0.01)	Small	0.06	16.0%	Low
Matsuzawa (2017)	RCT	HD	18(582)	Mixed	-	VO _{2peak}	SMD:0.62(0.38,0.87)	Moderate	<0.001	49.0%	High
			10(326)			6MWT	SMD:0.58(0.24,0.93)	Moderate	<0.001	53.0%	Low
			9(281)			Muscle strength	SMD:0.94(0.67,1.21)	Large	<0.001	10.0%	Very low
			9(264)			PCS	SMD:0.53(0.52,0.82)	Moderate	<0.001	19.0%	Very low
			8(228)			MCS	SMD:0.14(-0.15,0.42)	Small	0.34	10.0%	Very low
Smart (2011)	RCT	HD	8(365)	Mixed	-	VO _{2peak}	SMD:0.75(0.39,1.11)	Moderate	<0.001	60.0%	Low
Bogataj	RCT	HD	19(571)	Mixed	-	6MWT	SMD:0.44(0.21,0.67)	Small	<0.001	49.6%	Very low

(2020)			20(504)			VO _{2peak}	SMD:0.58(0.32,0.85)	Moderate	<0.001	57.4%	Very low
			5(461)			STS 10	SMD:-0.55(-1.00,-0.09)	Moderate	0.019	71.6%	Very low
Sheng (2014)	RCT	HD	7(233)	Mixed	Intradialytic	Kt/V	SMD:0.27(0.01,0.53)	Small	0.040	0.0%	Very low
			7(310)			VO _{2peak}	SMD:0.53(0.30,0.76)	Moderate	<0.001	36.0%	Very low
			7(256)			PCS	SMD:0.30(0.05,0.55)	Small	0.02	39.5%	Very low
			5(167)			MCS	SMD:0.14(-0.16,0.43)	Small	0.37	14.8%	Very low
			4(146)			6MWT	SMD:0.58(0.23,0.93)	Moderate	<0.001	89.7%	Very low
			7(296)			DBP	SMD:-0.24(-0.47,-0.01)	Small	0.04	52.1%	Very low
			7(296)			SBP	SMD:-0.27(-0.50,-0.04)	Small	0.02	0.0%	Very low
			3(106)			STS 60	SMD:0.71(0.31,1.12)	Moderate	<0.001	0.0%	Very low
Neto (2018)	RCT	HD	10(394)	Mixed	Intradialytic	VO _{2peak}	SMD:0.60(0.15,1.04)	Moderate	0.008	76.0%	Very low
			7(187)			PCS	SMD:0.50(-0.19,1.18)	Moderate	0.16	62.0%	Very low
			7(185)			MCS	SMD:0.39(-0.19,0.98)	Small	0.19	50.0%	Very low
			6(158)			6MWT	SMD:0.96(0.11,1.80)	Large	0.03	82.0%	Very low
			9(250)			Muscle strength	SMD:0.61(0.39,0.83)	Moderate	<0.001	58.9%	Very low
Ferrari (2019)	RCT	HD	12(370)	AE	Intradialytic	Kt/V	MD:0.08(0,0.15)	-	0.04	56.0%	Low
			6(220)	RT		Kt/V	MD:0.1(0,0.2)	-	0.06	6.0%	Very low
			5(201)	COM		VO _{2peak}	MD:5.41(4.03,6.79)	-	<0.001	0.0%	Low
			7(248)	AE		VO _{2peak}	MD:2.07(0.42,3.72)	-	<0.001	0.0%	Very low
			6(211)	RT		6MWT	MD:68.5(29.05,107.96)	-	<0.001	36.0%	Low
			6(188)	AE		6MWT	MD:64.98(43.86,86.11)	-	<0.001	0.0%	Low
			10(332)	AE		SBP	MD:-10.07(16.35,-3.78)	-	0.002	44.0%	Low
			10(334)	AE		DBP	MD:-2.96(-7.71,1.78)	-	0.22	0.0%	Low
Wyngaert (2018)	RCT	Predialysis	8(269)	AE	-	SBP	SMD:0.08(-0.58,0.74)	Small	0.81	84%	Very low
			7(237)	AE		DBP	SMD:-0.09(-0.78,0.59)	Small	0.79	83%	Very low

			11(325)			VO _{2peak}	SMD:0.99(0.49,1.48)	Large	<0.001	74.0%	Very low
			9(294)			BMI	SMD:-0.36(-0.60,-0.13)	Small	0.002	48.0%	Low
Oguch (2018)	RCT	KTRs	4(182)	Mixed	-	VO _{2peak}	SMD:0.38(-0.06,0.82)	Small	0.09	45.0%	Low
			4(179)			HRQoL	SMD:0.54(0.02,1.07)	Moderate	0.04	58.0%	Very low
Ju (2020)	RCT		3 (115)	Mixed	-	HGS	SMD:0.52(0.14,0.89)	Moderate	0.007	0.0%	Very low
			3 (387)			Symptom/problem (KDQoL)	SMD:1.92(-1.06,4.90)	Large	0.21	99.0%	Very low
			3 (387)			Effects of kidney disease (KDQoL)	SMD:-3.69(-8.56,1.19)	Large	0.14	99.0%	Very low
			3 (387)			Burden of kidney disease (KDQoL)	SMD:1.04 (-0.75,2.82)	Large	0.26	98.0%	Very low

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; COM = combine; VO_{2peak} = peak oxygen uptake; HRQoL = health-related quality of life; DBP = diastolic blood pressure; SBP = systolic blood pressure; PCS = physical component summary; MCS = mental component summary; 6MWT = 6 minutes walk test; STS 10 = sit to stand 10 test; STS 30 = sit to stand 30 test; STS 60 = sit to stand 60 test; TUGT = timed up and go test; RLS = Restless Legs Syndrome; BMI = body mass index; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; SF-36 = short form-36; KDQoL = kidney disease quality of life; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Supplementary Table S4 Results of the assessment of the methodological quality of the included meta-analyses using AMSTAR-2

Author	AMSTAR-2 Items																Score
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
Pei(2019)	√	×	√	○	√	√	×	√	√	×	√	×	×	×	√	×	53.1%
Ferreira(2019)	√	√	√	○	√	√	×	○	√	×	√	×	×	×	×	×	50.0%
Cheema(2014)	√	×	√	√	√	√	√	√	√	×	√	√	√	√	√	√	87.5%
Wu(2020)	√	√	√	○	√	√	×	√	√	×	√	√	√	√	√	√	84.4%
Nakamura(2020)	√	√	√	○	√	√	×	√	√	×	√	√	√	√	√	√	84.4%
Lu(2019)	√	×	√	○	√	×	×	○	○	×	√	×	×	×	√	√	46.9%
Chen(2019)	√	×	√	○	×	√	×	√	○	×	√	×	×	×	×	√	43.8%
Song(2018)	√	×	√	○	√	√	×	√	√	×	√	×	√	√	√	√	71.9%
Salhab(2021)	√	√	√	○	√	√	×	√	×	×	√	×	×	√	×	×	53.1%
Andrade(2019)	√	√	√	○	√	√	×	√	√	×	√	×	×	√	×	√	65.6%
Chung(2016)	√	×	√	○	√	√	√	√	√	×	√	√	√	√	√	×	78.1%
Zhang(2019)	√	×	√	○	√	√	×	√	√	×	√	×	√	√	√	×	65.6%
Pu(2019)	√	×	√	○	√	√	×	√	√	×	√	√	√	√	×	√	71.9%
Yamamoto(2021)	√	×	√	×	√	√	×	○	√	×	√	√	√	√	√	√	71.9%
Thompson(2019)	√	×	√	○	√	√	×	√	√	√	√	√	√	√	√	√	84.4%
Yang(2017)	√	×	√	○	√	√	×	○	√	×	√	√	√	√	√	√	75.0%
Clarkson(2019)	√	×	√	○	√	√	×	√	√	×	√	√	√	√	√	√	78.1%
Zhao(2019)	√	×	√	○	√	√	×	√	√	×	√	×	√	×	×	√	59.4%
Zhang(2019)	√	×	√	○	√	√	×	○	√	×	√	√	×	×	√	√	62.5%
Huang(2019)	√	√	√	○	√	√	×	√	√	×	√	√	×	×	√	√	71.9%
Heiwe(2011)	√	√	√	√	√	√	√	√	√	√	√	√	√	√	√	√	100.0%
Heiwe(2014)	√	√	√	○	√	√	√	√	√	×	√	×	√	√	×	√	78.1%

Matsuzawa(2017)	√	√	√	○	√	√	×	√	√	×	√	×	×	√	√	√	71.9%
Smart(2011)	√	×	√	○	√	×	×	○	○	×	√	×	×	√	×	×	40.6%
Bogataj(2020)	√	×	√	○	√	×	×	√	√	×	√	√	×	√	×	√	59.4%
Sheng(2014)	√	×	√	○	√	√	√	√	√	×	√	×	×	√	√	×	65.6%
Neto(2018)	√	×	√	○	√	√	×	√	√	×	√	×	×	×	×	√	53.1%
Ferrari(2019)	√	√	√	○	√	√	√	√	√	×	√	√	√	√	√	√	90.6%
Wyngaert(2018)	√	√	√	○	√	√	×	√	√	×	√	√	√	√	√	√	84.4%
Oguchi(2018)	√	√	√	○	√	√	×	√	√	×	√	√	√	×	√	×	71.9%
Ju(2020)	√	×	√	○	×	×	×	√	√	×	√	×	×	×	×	×	34.4%

√ mean yes; ○ mean partial yes; ×mean no.

1. Did the research questions and inclusion criteria for the review include the components of PICO? 2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? 3. Did the review authors explain their selection of the study designs for inclusion in the review? 4. Did the review authors use a comprehensive literature search strategy? 5. Did the review authors perform study selection in duplicate? 6. Did the review authors perform data extraction in duplicate? 7. Did the review authors provide a list of excluded studies and justify the exclusions? 8. Did the review authors describe the included studies in adequate detail? 9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? 10. Did the review authors report on the sources of funding for the studies included in the review? 11. If meta-analysis was performed did the review authors use appropriate methods for statistical combination of results? 12. If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? 13. Did the review authors account for RoB in individual studies when interpreting/ discussing the results of the review? 14. Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? 15. If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? 16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?

Supplementary Table S5: Results of the assessment of the quality of evidence for each outcome of the included meta-analyses using GRADE

Author	Outcome	GRADE items					Quality of the evidence
		Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	
Pei (2019)	VO _{2peak}	Very serious (-2)	Neutral	Neutral	Neutral	Neutral	Moderate
	STS 60	Serious (-1)	Very serious (-2)	Neutral	Neutral	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Neutral	Serious (-1)	Very low
	SBP	Serious (-1)	Neutral	Neutral	Neutral	Not reported (-1)	Moderate
	DBP	Serious (-1)	Neutral	Neutral	Neutral	Not reported (-1)	Moderate
	Physical function (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	Physical role (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	Social function (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	Pain (SF-36)	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	General health (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
Mental health (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low	
Ferreira (2019)	Kt/V	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
Cheema (2014)	Muscle Strength	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	HRQoL	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Wu (2020)	SBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low

Nakamura (2020)	VO _{2peak}	Neutral	Serious (-1)	Neutral	Neutral	Serious (-1)	Moderate
	Muscle Strength	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Neutral	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	TUGT	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Lu (2019)	6MWT	Neutral	Neutral	Neutral	Serious (-1)	Neutral	Moderate
	STS 10	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	HGS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	Muscle strength	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	STS 30	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Chen (2019)	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	BMI	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Song (2018)	RLS	Serious (-1)	Serious (-1)	Neutral	Very serious (-2)	Serious (-1)	Very low
	Fatigue	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Salhab (2019)	PCS	Not reported (-1)	Serious (-1)	Neutral	Very serious (-2)	Serious (-1)	Very low
	MCS	Not reported (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Andrade (2019)	VO _{2peak}	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Chung (2019)	6MWT	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	VO _{2peak}	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	MCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Zhang (2021)	6MWT	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	STS 30	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	HGS	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Pu (2019)	Kt/V	Serious (-1)	Neutral	Neutral	Serious (-1)	Not reported (-1)	Very low
	VO _{2peak}	Neutral	Serious (-1)	Neutral	Neutral	Not reported (-1)	Moderate
	6MWT	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	PCS	Neutral	Serious (-1)	Neutral	Serious (-1)	Not reported (-1)	Very low
	MCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Yamamoto (2021)	SBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Very serious (-2)	Neutral	Neutral	Serious (-1)	Neutral	Very low
	BMI	Very serious (-2)	Neutral	Neutral	Neutral	Neutral	Low
Thompson (2019)	SBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Yang (2017)	VO _{2peak}	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
Clarkson (2019)	6MWT	Neutral	Neutral	Neutral	Neutral	Serious (-1)	Moderate
Zhao (2019)	Fatigue	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	PCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	MCS	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Zhang (2019)	SBP	Neutral	Serious (-1)	Neutral	Neutral	Neutral	Moderate
	DBP	Neutral	Serious (-1)	Neutral	Serious (-1)	Neutral	Low
	BMI	Serious (-1)	Neutral	Neutral	Neutral	Neutral	Moderate

Huang (2019)	Kt/V	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	SBP	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	DBP	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	MCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	VO _{2peak}	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
Heiwe (2011)	Aerobic capacity	Neutral	Neutral	Neutral	Neutral	Serious (-1)	Moderate
	Muscle strength	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	Walking capacity	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	SBP	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	DBP	Neutral	Neutral	Neutral	Neutral	Neutral	High
Heiwe (2014)	Aerobic capacity	Neutral	Neutral	Neutral	Serious (-1)	Not reported (-1)	Low
	DBP	Neutral	Neutral	Neutral	Serious (-1)	Not reported (-1)	Low
	SBP	Neutral	Serious (-1)	Neutral	Serious (-1)	Not reported (-1)	Very low
	Muscle strength	Serious (-1)	Neutral	Neutral	Serious (-1)	Not reported (-1)	Very low
	Walking capacity	Neutral	Neutral	Neutral	Serious (-1)	Not reported (-1)	Low
Matsuzawa (2017)	VO _{2peak}	Neutral	Neutral	Neutral	Neutral	Neutral	High
	6MWT	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Neutral	Very low
	Muscle strength	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Smart (2011)	VO _{2peak}	Neutral	Serious (-1)	Neutral	Neutral	Serious (-1)	Low
Bogataj	6MWT	Serious (-1)	Serious (-1)	Neutral	Not reported (-1)	Not reported (-1)	Very low


(2020)	VO _{2peak}	Very serious (-2)	Serious (-1)	Neutral	Not reported (-1)	Not reported (-1)	Very low
	STS 10	Neutral	Serious (-1)	Neutral	Not reported (-1)	Serious (-1)	Very low
Sheng (2014)	Kt/V	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Neto (2018)	STS60	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
	PCS	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
Ferrari (2019)	Muscle strength	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	Kt/V (AE)	Neutral	Serious (-1)	Neutral	Serious (-1)	Neutral	Low
	Kt/V (RT)	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak} (COM)	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	VO _{2peak} (AE)	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT (RT)	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	6MWT(AE)	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
Wyngaert (2018)	DBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
	SBP	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Wyngaert (2018)	DBP	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low

	VO _{2peak}	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Neutral	Very low
	BMI	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
Oguchi (2018)	VO _{2peak}	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	HRQoL	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Ju (2020)	HGS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Neutral	Very low
	Symptom/problem (KDQoL)	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
	effects of kidney disease (KDQoL)	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
	burden of kidney disease (KDQoL)	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low

Abbreviation: AE = aerobic exercise; RT = resistance training; COM = combine; VO_{2peak} = peak oxygen uptake; HRQoL = health-related quality of life; DBP = diastolic blood pressure; SBP = systolic blood pressure; PCS = physical component summary; MCS = mental component summary; 6MWT = 6 minutes walk test; STS 10 = sit to stand 10 test; STS 30 = sit to stand 30 test; STS 60 = sit to stand 60 test; TUGT = timed up and go test; BMI = body mass index; SMD = standardized mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; SF-36 = short form-36; KDQoL = kidney disease quality of life;

Very serious mean the included studies existed two or more high risk of bias in terms of randomization, blinding, allocation concealment, completeness of result data, or selective reporting, or $75\% \leq I^2 \leq 100\%$.

Serious mean the included studies existed two or more high risk of bias in terms of randomization, blinding, allocation concealment, completeness of result data, or selective reporting, or $50\% \leq I^2 < 75\%$, or the included study sample size < 400, asymmetric funnel plot or less than 9 studies included.



Supplemental Figures S1

peer review only



PRISMA 2020 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page 4-5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Page 4
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page 5
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 5
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page 4-5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 5
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page 5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page 5-6
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Page 4-5
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page 5
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	None
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Not applicable
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	None
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	None
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	None
Certainty	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page 6



PRISMA 2020 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Location where item is reported
assessment			
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 6
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Page 6
Study characteristics	17	Cite each included study and present its characteristics.	Page 6
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Page 6
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Page 18-32
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Not applicable
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Not applicable
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Not applicable
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	None
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Page 6
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Page 6
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 10
	23b	Discuss any limitations of the evidence included in the review.	Page 12
	23c	Discuss any limitations of the review processes used.	Page 12
	23d	Discuss implications of the results for practice, policy, and future research.	None
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 2
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 2
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	None
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 1
Competing interests	26	Declare any competing interests of review authors.	Page 1
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	Page 1



PRISMA 2020 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

For peer review only

BMJ Open

Therapeutic effects of exercise interventions for patients with chronic kidney disease: an umbrella review of systematic reviews and meta-analyses

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054887.R2
Article Type:	Original research
Date Submitted by the Author:	19-Jul-2022
Complete List of Authors:	Zhang, Fan; Long Hua Hospital, Department of Nephrology Bai, Yan; Shanghai University of Traditional Chinese Medicine, Longhua Clinical Medical College Zhao, Xing; Shanghai University of Traditional Chinese Medicine, Longhua Clinical Medical College Huang, Liuyan; Shanghai University of Traditional Chinese Medicine Wang, Weiqiong; Long Hua Hospital, Blood Purification Centre Zhou, Wenqin; Long Hua Hospital, Department of Nursing Zhang, Huachun; Long Hua Hospital, Department of Nephrology
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Rehabilitation medicine, Evidence based practice
Keywords:	Nephrology < INTERNAL MEDICINE, Rehabilitation medicine < INTERNAL MEDICINE, Chronic renal failure < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Therapeutic effects of exercise interventions for patients with chronic kidney**
2 **disease: an umbrella review of systematic reviews and meta-analyses**

3 Title page

4 Fan Zhang¹, Yan Bai², Xing Zhao², Liuyan Huang¹, Weiqiong Wang³, Wenqin Zhou⁴,
5 Huachun Zhang⁴

6 1 Department of Nephrology, Longhua Hospital Shanghai University of Traditional
7 Chinese Medicine, ShangHai, 200032, China.

8 2 Longhua Clinical Medical College, Shanghai University of Traditional Chinese
9 Medicine, Shang Hai, 200032, China.

10 3 Blood Purification Centre, Longhua Hospital Shanghai University of Traditional
11 Chinese Medicine, ShangHai, 200032, China.

12 4 Department of Nursing, Longhua Hospital Shanghai University of Traditional
13 Chinese Medicine, ShangHai, 200032, China.

14 **Key words:** Exercise, chronic kidney disease, systematic review, meta-analyses

15 **Running Head:** Exercise for chronic kidney disease

16 **First author**

17 Fan Zhang, Department of Nephrology, No. 725, Wan Ping Nan Road, Xuhui District,
18 Shanghai, 200032, P.R. China E-mail: fan_zhang1993@163.com

19 **Corresponding author**

20 Huachun Zhang, Department of Nursing, No. 725, Wan Ping Nan Road, Xuhui District,
21 Shanghai, 200032, P.R. China, E-mail: lhlky@163.com

22

1 ABSTRACT

2 **Objective** To conduct an overview of meta-analyses evaluating the impact of exercise
3 interventions on improving health outcomes in patients with chronic kidney disease
4 (CKD).

5 **Design** An umbrella review of systematic review and meta-analyses of intervention
6 trials was performed.

7 **Data sources** PubMed, Web of Science, Embase, and the Cochrane Database of
8 Systematic Reviews were searched from inception to March 9th, 2021, for relevant
9 articles.

10 **Eligibility criteria for selecting studies** Eligible meta-analyses compared the effects
11 of usual care with and without exercise in CKD patients. Health outcomes included
12 those related to cardiovascular risk factors, physical fitness, dialysis-related symptoms,
13 dialysis adequacy, and health-related quality of life. Systematic reviews and meta-
14 analyses that included fewer than three RCTs or fewer than 100 participants were
15 excluded from the analysis.

16 **Results** A total of 31 eligible systematic reviews and meta-analyses were included that
17 assessed 120 outcomes. For physical fitness, there was a moderate effect size for
18 cardiorespiratory fitness, muscle strength, and body composition and small effect size
19 for muscle endurance. The effect sizes for cardiovascular risk factors, dialysis-related
20 symptoms, and health-related quality of life outcomes were small. According to the
21 Grading of Recommendations Assessment, Development, and Evaluation framework,
22 most outcomes were low or very low quality.

23 **Conclusion** Exercise appears to be a safe way to affect concomitant cardiovascular risk
24 factors, such as blood pressure, improve physical fitness and health-related quality of
25 life, and reduce dialysis-related symptoms in CKD patients.

26 **Keywords:** Exercise, Chronic Kidney Disease, Systematic Review, Meta-Analyses

27 **PROSPERO registration number** CRD42020223591.

28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Strengths and limitations of this study**

2 1) A strength of this study is to comprehensively summarize the systematic review and
3 meta-analysis of exercise interventions on the spectrum of chronic kidney disease.

4 2) Methodological quality of the included reviews was assessed using standardized
5 measures.

6 3) The limitation of this overview is that language bias may exist in this review because
7 the search strategy was limited to English.

8 4) Another limitation was that most studies were based on hemodialysis-dependent
9 chronic kidney disease.
10
11

1 INTRODUCTION

2 Chronic kidney disease (CKD) is a long-term condition characterized by the gradual
3 loss of renal function over time.[1] In the past 30 years, the mortality attributed to CKD
4 increased by 41.5%, a percentage rate that exceeds several cancers and cardiovascular
5 diseases.[2] With the increasing incidence of hypertension, diabetes, and obesity, this
6 number will continue to rise.[3, 4] CKD patients experience a high symptom burden
7 with progressively impaired physical performance, leading to decreased kidney
8 function, lower health-related quality of life (HRQOL), increased risk of cardiovascular
9 events, and increased all-cause mortality.[5, 6]

10 With an increasing number of patients with CKD living longer, the effectiveness and
11 accessibility of their health services have never been more critical. Renal rehabilitation
12 is a multifaceted intervention program. Rehabilitation consists of exercise interventions,
13 diet control, fluid management, and psychological support to alleviate physical/mental
14 deficiencies caused by kidney disease and renal replacement therapy to improve disease
15 prognosis and prolong life expectancy.[7] Since exercise is the core of renal
16 rehabilitation, there is an increasing number of systematic reviews and meta-analyses
17 investigating the influence of exercise on health outcomes in CKD patients.[8]

18 Data from large cohort studies show that mortality risk was lower for regular (equal to
19 or more than once/week) versus non-regular (less than once/week) exercisers [adjusted
20 hazard ratio (HR)=0.73, 95% confidence interval (CI): 0.69–0.78], and mortality risk
21 tended to decrease as exercise frequency increased (HR_{for participants who exercised once/week} =
22 0.82, 95% CI: 0.73–0.91; HR_{for those who exercised 6–7 times/week} = 0.69, 95% CI: 0.63–0.76)
23 and patients who exercised daily had lower mortality risk (HR = 0.84, 95% CI: 0.74–
24 0.96) than patients exercising once/week.[9] Based on data from 41 randomized
25 controlled trials (RCT), Heiwe et al. reported practical improvements in aerobic
26 capacity, muscular function, and walking capacity in CKD patients after exercise, [10]
27 indicators that are the core of frailty. [11] In other words, exercise is an essential non-
28 pharmacological strategy to improve frailty symptoms in CKD patients, the latter being
29 a significant cause of sedentary behavior in such population. [12] Because of this, some
30 researchers and guidelines recommend that healthcare providers prescribe exercise for
31 CKD patients.[13-16] However, the results of meta-analyses of exercise in CKD
32 patients are inconsistent.

33 This umbrella review aims to assess the therapeutic effects of exercise on
34 cardiovascular risk factors, physical fitness, dialysis-related symptoms, dialysis
35 adequacy, and HRQOL in CKD patients, summarized in systematic reviews and meta-
36 analyses.

1 Requisite data were extracted independently by two independent authors into a
2 standardized format that included: 1) author, 2) publication year, 3) stage of CKD, 4)
3 the number of included studies and participants, 5) exercise type, 6) exercise mode
4 (intradialytic or interdialytic), 7) standardized mean difference (SMD) or mean
5 difference (MD) with corresponding 95% CI for each outcome, 8) *P*-values, 9) *I*² values,
6 and 10) exercise-related adverse events.

7 **Risk of bias assessment**

8 A Measurement Tool to Assess Systematic Reviews-2 (AMSTAR-2) was used to assess
9 the risk of bias among the included systematic reviews.[19] This checklist contains 16
10 items, and each item was answered with a "yes" (1 point), "partial yes" (0.5 points), or
11 "no" (0 points). The percentage score for each study was calculated using the total score
12 as the numerator and the highest score of 16 points as the denominator. A meta-analysis
13 scoring $\geq 80\%$ was classified as high quality, 40-79% as medium quality, and those
14 scoring $< 40\%$ as low quality.[20] Two authors performed the risk of bias assessment
15 independently, and discussions resolved the disagreement.

16 **Data analysis**

17 The summary effect size from each meta-analysis was analyzed qualitatively based on
18 the SMD and its 95% CI for each outcome. If they were not presented as SMD in the
19 original meta-analysis, Review Manager V.5.3 was used to convert SMD outcomes. If
20 data could not be converted into SMD, we contacted the authors of the meta-analysis
21 for the data. Effects were considered small (SMD < 0.50), moderate (SMD from 0.50
22 to 0.79), and large (SMD ≥ 0.80).[21] *I*² values were interpreted as follows: $\leq 25\%$
23 indicate low heterogeneity, $25\% < I^2 \leq 50\%$ indicate mild heterogeneity, $50\% < I^2 \leq 75\%$
24 indicate moderate heterogeneity, and $> 75\%$ indicate high heterogeneity.[22]

25 The level of evidence for each meta-analysis was evaluated using the Grading of
26 Recommendations Assessment, Development, and Evaluation (GRADE) system.[23]
27 The quality of evidence was assessed using five domains: risk of bias, inconsistency,
28 indirectness, imprecision, and publication bias. Beginning with an initial score of 4
29 points, the score for each of these five domains was reduced accordingly: "not reported
30 (-1)", "serious (-1)", "very serious (-2)", or "neutral (0)". Studies were rated as high (4
31 points), moderate (3 points), low (2 points), or very low (≤ 1 point) using the GRADE
32 system. The GRADE assessment was conducted independently by two authors. Any
33 differences were resolved by discussion or adjudication by a third author. The incidence
34 of adverse events was based on the number of reported divided by the patients in the
35 exercise group.

36 **RESULTS**

1 **Characteristics of the meta-analyses**

2 The search identified 2305 potential articles, of which 648 were duplicates. After
3 reading the title and abstract, 1598 papers were excluded, and 28 were excluded after
4 full-text review resulting in 31 final studies. [10, 24-53] The PRISMA flowchart of
5 study inclusion is illustrated in **Figure 1**. The reasons for excluded articles are listed in
6 **Supplementary Table S2**.

7 **Figure 1 Flowchart of literature screening.**

8 Legend: CDSR = Cochrane Database of Systemic Review

9
10 The 31 included systematic reviews and meta-analyses were published from September
11 2011 through March 2021. The number of included studies assessed in the articles
12 ranged from 3 to 24, with a mean of 8 studies. The study sample sizes ranged from 106
13 to 874 participants, with a mean of 304. The characteristics of the included meta-
14 analyses are shown in **Supplement Table S3**. SMD data from four papers could not be
15 obtained from the authors, and the data of their effect size was presented as MD.[29,
16 30, 40, 46]

17 Scores based on AMSTAR-2 ranged from 34.4% to 100.0%, with an average score of
18 68.0%. Seven (22.6%) systematic reviews were rated high quality, while 23 (74.2%)
19 were rated medium quality, and just one (0.3%) was rated low quality (**Supplement**
20 **Table S4**).

21 Of the GRADE evidence quality of the 120 outcomes, 1.7% (2 / 120) reported evidence
22 of high quality, 17.5% (21 / 120) reported evidence of moderate quality, 20.0%
23 (24 / 120) reported evidence of low quality, and 60.8% (73 / 120) reported evidence of
24 very low quality (**Supplement Table S5**).

25 **Blood pressure**

26 There were 25 meta-analyses (reported in 13 articles) investigating the effect of
27 exercise on cardiovascular risk factors (systolic and diastolic blood pressure) in CKD
28 patients. [10, 27, 30, 33, 34, 40, 41, 43, 46-49, 52] Of which, the number of studies
29 ranged from 3 to 12 with a mean of 314 participants (range from 198 to 514) were
30 included in each meta-analysis (**Table 1**).

31 The effect of exercise on systolic blood pressure was investigated in 13 meta-analyses
32 with a mild heterogeneity (average $I^2 = 36.1\%$), [10, 27, 30, 33, 34, 40, 41, 43, 46-49,
33 52] and six reported a positive statistically significant outcome. [30, 33, 41, 43, 49, 52]
34 Of the 13 meta-analyses, nine reported a small effect size, [10, 27, 33, 34, 41, 43, 47,
35 48, 52] and one reported moderate.[49] GRADE assessment of quality indicated the

1 overall evidence as being very low (10 meta-analyses[10, 27, 30, 33, 41, 43, 46-49]),
2 low (two meta-analyses[34, 40]), and moderate (one meta-analysis[52]).

3 The effect of exercise on diastolic blood pressure was investigated in 12 meta-analyses
4 with a mild heterogeneity (average $I^2=49.1\%$),[10, 27, 30, 33, 34, 40, 41, 43, 46-48, 52]
5 and 2 reported a positive statistically significant outcome.[41, 43] Of the 12 meta-
6 analyses, nine reported small effect sizes [10, 27, 33, 34, 41, 43, 47, 48, 52], and all
7 were graded as low or very low quality of evidence.

8 **Cardiorespiratory fitness**

9 There were 34 meta-analyses (reported in 21 articles) that investigated the effects of
10 exercise on cardiorespiratory fitness in CKD patients using a peak oxygen uptake (18
11 of 34), a 6-minute walk test (14 of 34), or aerobic capacity (2 of 34). The meta-analyses
12 included a mean of nine studies (ranging from 5 to 20) and a mean of 330 participants
13 (ranging from 179 to 504) (**Table 2**).

14 The effect of exercise on peak oxygen consumption was investigated in 18 meta-
15 analyses (reported in 17 articles) with a mild heterogeneity (average $I^2=42.2\%$),[24, 25,
16 27, 28, 30, 32, 34, 37, 38, 40, 41, 43, 44, 49, 50, 54] and 16 reported positive statistically
17 significant outcomes. [24, 25, 28, 30, 32, 34, 37, 38, 40, 41, 43, 44, 47, 49, 50] Of the
18 18 meta-analyses, three reported a low effect size,[27, 39, 50] nine reported a moderate
19 effect size[25, 28, 32, 34, 37, 41, 43, 44, 49] and three reported a large effect size.[24,
20 38, 47] GRADE assessment of quality indicated the overall evidence as being very low
21 (9 meta-analyses[25, 27, 28, 30, 32, 37, 43, 47, 49]), low (8 meta-analyses[24, 34, 38-
22 41, 44, 50]), and high (one meta-analysis[37]). A meta-analysis that included
23 kidney transplant recipients found no statistically significant difference in the SMD of
24 the exercise group (0.38; 95% CI, -0.06 to 0.82; $P=0.09$).[39]

25 The effect of exercise on the 6-minute walk test was investigated in 14 meta-analyses
26 (reported in 13 articles) with a mild heterogeneity (average $I^2=44.9\%$),[25, 28-30, 32,
27 34, 36-38, 40, 41, 43, 51] and 13 reported positive statistically significant outcomes.[25,
28 28-30, 32, 34, 36-38, 41, 43, 51] Of the 14 meta-analyses, two reported a small effect
29 size,[25, 28] five reported a moderate effect size,[36, 37, 41, 43, 51] and three reported
30 a large effect size.[32, 34, 38] GRADE assessment of quality indicated the overall
31 evidence as being very low (eight meta-analyses[25, 30, 32, 34, 38, 40, 43]), low (four
32 meta-analyses[28, 37, 41, 51]), and moderate (two meta-analyses[29, 36]). In addition,
33 the meta-analysis by Heiwe et al. (2014) showed that regular exercise had significant
34 beneficial effects on aerobic capacity. [10, 33]

35 **Muscle strength**

1 Ten meta-analyses (reported in nine articles) investigated the effects of exercise on
2 muscle strength in CKD patients with a low heterogeneity (average $I^2 = 19.1\%$). [10, 26,
3 32, 33, 35-38, 51] The meta-analyses included a mean of seven studies (ranging from
4 3 to 12) and a mean of 252 participants (ranging from 115 to 385) (**Table 3**).

5 Muscle strength was measured using handgrip strength and lower limb muscle strength.
6 For patients in 8 of 10 meta-analyses, exercise resulted in statistically significant
7 improvements in muscle strength. [10, 32, 33, 35-37, 51] Of the 10 meta-analyses, three
8 reported a small effect size, [36, 38, 51] five reported a moderate effect size, [10, 32, 33,
9 35, 36] and two reported a large effect size, [26, 37] GRADE assessment of quality
10 indicated the overall evidence as being very low (six meta-analyses [10, 32, 33, 35, 37,
11 38]) and low (four meta-analyses [26, 36, 51]).

12 **Muscle endurance**

13 Nine meta-analyses (reported in 8 articles) investigated the effects of exercise on
14 muscle endurance with a mild heterogeneity (average $I^2 = 29.4\%$). [10, 25, 33, 36, 38,
15 40, 43, 51] An average of 238 participants (ranging from 106 to 461) from 5 studies
16 (ranging from 3 to 7) were included in the meta-analysis (**Table 4**).

17 Muscle endurance was measured using a sit-to-stand test, timed up and go test, and
18 walking capacity exercise. Pooled effect estimates from all nine meta-analyses
19 suggested a beneficial effect of exercise on muscle endurance in CKD patients. Seven
20 of the nine meta-analyses reported power to detect a statistically significant effect. [25,
21 33, 36, 38, 43, 51] Two meta-analyses reported moderate effect size, and 5 reported
22 small effect size. GRADE assessment of quality indicated the overall evidence as being
23 very low (seven meta-analyses [25, 33, 36, 38, 40, 43, 51]), low (one meta-analyses [36])
24 and moderate (one meta-analyses [10]).

25 **Body composition**

26 Four meta-analyses consisting of 9 studies (ranging from 4 to 13) and a mean of 335
27 participants (ranging from 166 to 466) included body mass index as an outcome. [27,
28 47, 49, 52] There was a low heterogeneity (average $I^2 = 12.0\%$) among the study
29 outcomes (**Table 5**).

30 Three of the four meta-analyses showed a positive statistically significant impact on
31 body mass index using exercise interventions in CKD patients. [47, 49, 52] Small effect
32 size was reported in all meta-analyses. GRADE assessment of quality indicated the
33 overall evidence as being very low (one meta-analysis), low (two meta-analyses [47,
34 49]), and moderate (one meta-analysis [52]).

35 **Dialysis-related symptoms**

1
2
3
4 1 Nine meta-analyses (reported in seven articles) investigated the effect of exercise on
5 2 dialysis-related symptoms in CKD patients.[30, 31, 34, 41, 43, 45, 53] Each meta-
6 3 analysis included a mean of seven studies (ranging from 3 to 12 studies) and a mean of
7 4 239 participants (ranging from 139 to 370). (**Table 6**).

8
9
10 5 Fatigue was measured using the Rhoten Fatigue Scale, Visual Analogue Scale, and
11 6 Hemodialysis Patients Fatigue Scale. The effect of exercise on fatigue was investigated
12 7 in 2 meta-analyses with a low heterogeneity (average $I^2=23.5\%$).[45, 53] The two meta-
13 8 analyses revealed a statistically significant effect of exercise on fatigue. Although the
14 9 meta-analyses reported large effect size, the quality of evidence was low[45] or very
15 10 low[53] according to GRADE criteria.

16
17
18
19
20 11 Just one meta-analysis investigated the effects of exercise on restless legs syndrome in
21 12 CKD patients.[45] The results showed that pooled effect estimated for restless legs
22 13 syndrome with statistically significant but considerable average heterogeneity
23 14 ($I^2 = 87.0\%$). According to GRADE criteria, the overall evidence for this outcome was
24 15 very low.

26 16 **Dialysis adequacy**

27
28
29
30 17 Dialysis adequacy was measured using the value of Kt/V. Six meta-analyses (reported
31 18 in 5 articles) investigated the effects of exercise on Kt/V in CKD patients with a mild
32 19 heterogeneity (average $I^2 = 25.7\%$).[30, 31, 34, 41, 43] Comprehensive effect estimates
33 20 from all the six meta-analyses with Kt/V outcomes showed that exercise had a
34 21 beneficial effect. In three of the six meta-analyses, 3 reported a small effect size[34, 41,
35 22 43], and one reported large effect size.[31] According to GRADE criteria, all meta-
36 23 analyses were rated as very low-quality evidence (**Table 6**).

38 24 **Health-related quality of life**

39
40
41
42
43 25 Twenty-nine meta-analyses (reported in 13 articles) investigated the effect of exercise
44 26 on HRQOL in CKD patients.[26, 28, 32, 34, 35, 37, 39-43, 51, 53] Among them, nine
45 27 meta-analyses assessed the physical and mental subscale of the Short-Form Health
46 28 Survey-36.[28, 32, 34, 37, 41-43, 51, 53] Each meta-analysis included an average of 6
47 29 studies (ranging from 3 to 10) and 311 participants (ranging from 167 to 562). The
48 30 included meta-analyses had moderate heterogeneity (average $I^2 = 51.0\%$) (**Table 7**).

49
50
51
52
53 31 Of the 29 meta-analyses, a comprehensive effect estimate of the 28 meta-analyses
54 32 shows that exercise is beneficial to the HRQOL of CKD patients, but only 12 of 29
55 33 meta-analyses reported a statistically significant outcome.[28, 34, 37, 39, 41-43, 53]
56 34 There were 13 of 29 meta-analyses reporting a small effect size, [28, 32, 34, 37, 41, 43,
57 35 51, 53] 4 were moderate,[32, 37, 39, 41] and 6 were large.[26, 35, 42] According to

1 GRADE criteria, the overall of evidence for HRQOL was rated as very low (20 meta-
2 analyses[32, 35, 37, 39-43, 53]) or low (nine meta-analyses[26, 28, 34, 41, 51, 53]).

3 **Adverse events**

4 Six meta-analyses reported exercise-related adverse events.[26, 28, 38, 41, 43, 44] Of
5 the adverse effects, the most commonly reported were hypotension and cramping.
6 Overall, the incidence of adverse events was approximately 0.3%.

7 **DISCUSSION**

8 **Summary of main results**

9 Several meta-analyses have been published on exercise interventions in CKD
10 patients.[55] The findings of these meta-analyses should be assessed to determine if the
11 evidence is consistent among the studies. This umbrella review included 31 eligible
12 articles involving 120 separate meta-analyses investigating the effect of exercise on the
13 health outcomes in CKD patients. There was low- or very low-quality evidence for
14 moderate beneficial effects of exercise on cardiorespiratory fitness, muscle strength,
15 and body composition. In addition, there was very low-quality evidence for minor
16 beneficial effects of exercise on muscle endurance, cardiovascular risk factors, dialysis-
17 related symptoms, and HRQOL. Few adverse events related to exercise indicate that
18 exercise is safe for CKD patients.

19 **Interpretation of study effects**

20 Cardiovascular disease is a frequent complication of CKD and is the leading cause of
21 death in CKD patients.[56] Hypertension is an important modifiable risk factor for
22 cardiovascular diseases and progressive renal dysfunction in CKD patients.[57] The
23 present overview showed that exercise has a small to moderate effect on blood pressure
24 (SMD: -0.75 to 0.04 for systolic blood pressure and SMD: -0.47 to 0.04 for diastolic
25 blood pressure); it is an appealing strategy for blood pressure control in CKD patients.
26 However, the dose effects of exercise in the context of the cardiovascular health of
27 CKD patients should be considered. A recent cohort study found that 7.5-15 metabolic
28 equivalent hours per week (MET-h/week) was associated with the lowest risk of
29 cardiovascular events.[58] Regrettably, the benefit of exercise on cardiovascular risk
30 factors cannot be determined because there are an insufficient number of conclusive
31 studies that assess exercise effects on overall cardiovascular health. In a systematic
32 review by Heiwe et al., a meta-analysis including two trials found that exercise
33 improved cardiovascular function in patients with CKD, as reflected in the standard
34 deviation of all normal RR intervals and left ventricular mass index.[10] Furthermore,

1 a recent randomized controlled trial published by Graham-Brown indicated that
2 intradialytic exercise could reduce left ventricular mass and is safe, deliverable, and
3 well-tolerated.[59] Although the GRADE evidence was low, exercise should be
4 recommended for CKD patients, particularly those comorbid with cardiovascular
5 disease. Future randomized controlled exercise trials need to focus more on the role of
6 exercise in cardiovascular events in patients with CKD.

7 Physical fitness is necessary for participation in activities of daily living. The exercise
8 provided the best results in improving cardiorespiratory fitness and muscle strength in
9 CKD patients, with more than half of the meta-analyses reporting moderate or large
10 effect sizes, regardless of the quality of evidence. Cardiorespiratory fitness is
11 considered a significant independent predictor of mortality, and muscle strength is an
12 essential indicator of physical performance in CKD patients.[60] It is well known that
13 aerobic exercise is the "gold standard" for cardiorespiratory rehabilitation[61] and
14 resistance training for muscle strength improvement.[62] However, a combination of
15 aerobic and resistance exercises may have a more profound effect on CKD patients
16 based on the current review. Meta-analyses by Andrade et al. showed that combined
17 training benefits cardiorespiratory fitness in CKD patients.[24]

18 Both sarcopenia and obesity have increased mortality risk and progression to end-stage
19 renal disease in CKD patients.[63] Unlike patients receiving dialysis, treatment
20 requirements for predialysis CKD patients are based on maintaining a "healthy weight"
21 and preventing or attenuating obesity.[14] In this overview, the effectiveness of
22 exercise for body mass index was supported by four analyses with small effect sizes
23 and moderate quality of evidence. Based on the results, exercise may contribute to
24 lower body mass index in CKD patients. However, additional studies are needed to
25 confirm the benefits of exercise programs for reducing sarcopenia and weight.

26 CKD population experience multiple symptoms that affect the patient's prognosis and
27 HRQOL.[64] Patients who received dialysis treatment commonly reported restless legs
28 syndrome, fatigue, and inadequate dialysis due to kidney function deterioration and
29 dialysis-related side effects.[65, 66] These symptoms affect sleep and daily activities
30 and impose considerable psychological distress and economic burden.[67] An
31 increasing number of researchers have investigated the role of exercise as an important
32 non-pharmacological strategy for preventing and/or treating symptoms. [68, 69] The
33 results of a small number of meta-analyses suggested the beneficial effect of exercise
34 on dialysis adequacy (SMD: 0.19 to 2.21) and improving restless legs syndrome (SMD:
35 -1.79) and fatigue symptoms (SMD: -0.97 to -0.85). Nevertheless, the efficacy of
36 exercise in CKD patients for preventing dialysis-related symptoms awaits new clinical
37 evidence.

1
2
3
4 1 With similar results obtained in another overview that included chronic disease,[70]
5 2 results from this overview demonstrated minor beneficial effects of exercise on
6 3 HRQOL, irrespective of the evidence level in CKD patients. Improved HRQOL is vital
7 4 because most of the population reported poor health and well-being due to diet
8 5 restriction, weakness, and dialysis treatment.[71] The consistent health benefits of
9 6 exercise in this overview demonstrated that exercise could be a strategy to improve the
10 7 poor long-term prognosis in CKD patients.

11 8 Several meta-analyses reported exercise-related adverse events. Based on the reported
12 9 adverse events, we calculate that only three adverse events occurred per 1000 CKD
13 10 patients. The low incidence of adverse events indicated that the benefits of exercise in
14 11 CKD patients outweigh its potential risks and most reflected typical response to
15 12 exercise (e.g., muscle soreness). However, most meta-analyses only included
16 13 intradialytic exercise for hemodialysis patients in their assessments. Exercises during
17 14 hemodialysis are usually performed under the supervision of a healthcare worker to
18 15 ensure safety.[72] It has been reported that all patients with CKD are at risk for
19 16 cardiovascular events (e.g., arrhythmias, myocardial ischemia) during exercise.
20 17 Therefore, medical screening should be performed before exercise to determine which
21 18 patients may be at increased risk for cardiovascular accidents. [73] In addition, special
22 19 attention should be paid to dry weight and blood pressure in patients with hemodialysis-
23 20 dependent CKD to avoid excessive volume loading or dehydration, which may increase
24 21 the risk associated with exercise. [60]

22 **Implications for clinical**

23 23 Taken together, there is good reason to recommend exercise for improving prognosis
24 24 in CKD patients. Evidence from most randomized controlled trials increased
25 25 confidence in the findings of this umbrella review. Because most of the meta-analyses
26 26 assessed in this study did not detail the exercises instituted, it is difficult to make
27 27 recommendations about the type of exercise that would be the most beneficial for CKD
28 28 patients. Although exercise's effect sizes on improving CKD patients' health prognosis
29 29 were generally moderate, these effects may bring some clinical benefit to patients
30 30 experiencing impaired function or symptom distress. Despite numerous meta-analyses
31 31 providing only low or very low-quality evidence, similar beneficial effects of exercise
32 32 were reported by meta-analyses of randomized controlled trials with different grades of
33 33 evidence. Remarkably, a recently published trial found that a 6-month intradialytic
34 34 exercise program effectively reduces healthcare costs.[74] Overall, exercise should be
35 35 integrated into the care of CKD, but the overall benefit of exercise to CKD is still
36 36 debatable.

1 **Limitations**

2 This overview has several limitations. First, most meta-analyses included in this review
3 involve hemodialysis patients, limiting the results' extrapolation to other CKD stages.
4 Second, improvement of flexibility in CKD patients was not investigated. Flexibility is
5 an important component of physical fitness that impacts muscular injury.[75] The
6 evidence for the efficacy of exercise on flexibility improvement is insufficient for a
7 systematic review or meta-analysis. Third, since the search strategy was limited to
8 English, this review may have language bias. It is unknown whether meta-analyses
9 published in other languages would affect the results of our study. Fourth, the results
10 may be had been influenced by an overlap in the original studies. Fifth, the accuracy of
11 the MD data cannot be guaranteed. Sixth, subgroup analyses of different types of
12 exercise were not performed as described in the published protocol because most of the
13 included meta-analyses did not detail the exercises. Seventh, both body composition
14 and cardiovascular risk factors are common terms. However, the inclusion of studies
15 was limited, so this review focused only on body mass index and blood pressure, and
16 more evidence is still needed for the effects of other assessment metrics.

17 **CONCLUSION**

18 In CKD patients, exercise improves muscle strength, endurance, body composition, and
19 HRQOL. At the same time, exercise decreases blood pressure and dialysis-related
20 symptoms in CKD patients. However, the quality of the evidence was considered low
21 or very low for all outcomes indicating that we have low certainty evidence to support
22 the findings above. More rigorous study is still needed in the future. Nevertheless, given
23 the health benefits of physical activity, exercise should be integrated into renal care for
24 a patient with any stage of CKD.

25 **Contributors**

26 FZ and LYH conceived and designed the review. YB and XZ searched databases,
27 extracted the data, and conducted the statistical analysis. WQZ revised the manuscript.
28 WQW and HCZ provided technical support. All authors had read and approved the final
29 manuscript and agreed on its submission.

30 **Ethics approval statement**

31 Ethics approval is not required as no private information from individuals is collected.

32 **Dissemination**

33 The results will be published in a peer-reviewed journal or disseminated in relevant

1 conferences.

2 **Funding** This study was supported by Longhua Hospital Shanghai University of
3 Traditional Chinese Medicine (Grant number: Y21026).

4 **Competing interest statement** None declared.

5 **Data availability statement** All data relevant to the study are included in the article or
6 uploaded as supplementary information.

7 **Patient consent for publication** Not required.

8 **Provenance and peer review** Not commissioned; externally peer reviewed.

9 REFERENCES

- 10 1. Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D,
11 Fouque D, Heine GH, Jager KJ *et al*: **The systemic nature of CKD**. *Nat Rev*
12 *Nephrol* 2017, **13**(6):344-358.
- 13 2. **Global, regional, and national burden of chronic kidney disease, 1990-2017:**
14 **a systematic analysis for the Global Burden of Disease Study 2017**. *Lancet*
15 2020, **395**(10225):709-733.
- 16 3. Yang C, Gao B, Zhao X, Su Z, Sun X, Wang HY, Zhang P, Wang R, Liu J,
17 Tang W *et al*: **Executive summary for China Kidney Disease Network (CK-**
18 **NET) 2016 Annual Data Report**. *Kidney Int* 2020, **98**(6):1419-1423.
- 19 4. Cheng HT, Xu X, Lim PS, Hung KY: **Worldwide Epidemiology of Diabetes-**
20 **Related End-Stage Renal Disease, 2000-2015**. *Diabetes Care* 2020.
- 21 5. Roshanravan B, Robinson-Cohen C, Patel KV, Ayers E, Littman AJ, de Boer
22 IH, Ikizler TA, Himmelfarb J, Katznel LI, Kestenbaum B *et al*: **Association**
23 **between physical performance and all-cause mortality in CKD**. *J Am Soc*
24 *Nephrol* 2013, **24**(5):822-830.
- 25 6. Wang XH, Mitch WE: **Mechanisms of muscle wasting in chronic kidney**
26 **disease**. *Nat Rev Nephrol* 2014, **10**(9):504-516.
- 27 7. Hoshino J: **Renal Rehabilitation: Exercise Intervention and Nutritional**
28 **Support in Dialysis Patients**. *Nutrients* 2021, **13**(5):1444.
- 29 8. Wilund KR, Viana JL, Perez LM: **A Critical Review of Exercise Training in**
30 **Hemodialysis Patients: Personalized Activity Prescriptions Are Needed**.
31 *Exerc Sport Sci Rev* 2020, **48**(1):28-39.
- 32 9. Tentori F, Elder SJ, Thumma J, Pisoni RL, Bommer J, Fissell RB, Fukuhara S,
33 Jadoul M, Keen ML, Saran R *et al*: **Physical exercise among participants in**
34 **the Dialysis Outcomes and Practice Patterns Study (DOPPS): correlates**
35 **and associated outcomes**. *Nephrol Dial Transplant* 2010, **25**(9):3050-3062.
- 36 10. Heiwe S, Jacobson SH: **Exercise training in adults with CKD: a systematic**
37 **review and meta-analysis**. *Am J Kidney Dis* 2014, **64**(3):383-393.
- 38 11. Wong L, Duque G, McMahon LP: **Sarcopenia and Frailty: Challenges in**

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 **Mainstream Nephrology Practice.** *Kidney Int Rep* 2021, **6**(10):2554-2564.
- 2 12. Rampersad C, Darcel J, Harasemiw O, Brar RS, Komenda P, Rigatto C, Prasad
3 B, Bohm C, Tangri N: **Change in Physical Activity and Function in Patients
4 with Baseline Advanced Nondialysis CKD.** *Clin J Am Soc Nephrol* 2021,
5 **16**(12):1805-1812.
- 6 13. March DS, Graham-Brown MP, Young HM, Greenwood SA, Burton JO:
7 **'There is nothing more deceptive than an obvious fact': more evidence for
8 the prescription of exercise during haemodialysis (intradialytic exercise) is
9 still required.** *Br J Sports Med* 2017, **51**(18):1379.
- 10 14. **Clinical Practice Guideline: Exercise and Lifestyle in Chronic Kidney
11 Disease**
12 [[https://renal.org/sites/renal.org/files/Exercise%20and%20Lifestyle%20in%20
13 CKD%20clinical%20practice%20guideline33_v4_FINAL_0.pdf](https://renal.org/sites/renal.org/files/Exercise%20and%20Lifestyle%20in%20CKD%20clinical%20practice%20guideline33_v4_FINAL_0.pdf)]
- 14 15. Yamagata K, Hoshino J, Sugiyama H, Hanafusa N, Shibagaki Y, Komatsu Y,
15 Konta T, Fujii N, Kanda E, Sofue T *et al*: **Clinical practice guideline for renal
16 rehabilitation: Systematic reviews and recommendations of exercise
17 therapies in patients with kidney diseases.** *Renal Replacement Therapy* 2019,
18 **5**.
- 19 16. Deschamps T: **Let's programme exercise during haemodialysis
20 (intradialytic exercise) into the care plan for patients, regardless of age.** *Br
21 J Sports Med* 2016, **50**(22):1357-1358.
- 22 17. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle
23 P, Stewart LA: **Preferred reporting items for systematic review and meta-
24 analysis protocols (PRISMA-P) 2015: elaboration and explanation.** *Bmj*
25 2015, **350**:g7647.
- 26 18. Zhang F, Wang H, Huang L, Zhang H: **Therapeutic effects of exercise
27 interventions for patients with chronic kidney disease: protocol for an
28 overview of systematic reviews and meta-analyses of clinical trials.** *BMJ
29 Open* 2021, **11**(2):e043011.
- 30 19. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell
31 P, Welch V, Kristjansson E *et al*: **AMSTAR 2: a critical appraisal tool for
32 systematic reviews that include randomised or non-randomised studies of
33 healthcare interventions, or both.** *Bmj* 2017, **358**:j4008.
- 34 20. Grgic J, Grgic I, Pickering C, Schoenfeld BJ, Bishop DJ, Pedisic Z: **Wake up
35 and smell the coffee: caffeine supplementation and exercise performance-
36 an umbrella review of 21 published meta-analyses.** *Br J Sports Med* 2020,
37 **54**(11):681-688.
- 38 21. Cohen J: **Quantitative methods in psychology: A power primer.**
39 *Psychological Bulletin* 1992, **112**:115-159.
- 40 22. Higgins JP, Thompson SG, Deeks JJ, Altman DG: **Measuring inconsistency
41 in meta-analyses.** *Bmj* 2003, **327**(7414):557-560.
- 42 23. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH,
43 Harbour RT, Haugh MC, Henry D *et al*: **Grading quality of evidence and
44 strength of recommendations.** *Bmj* 2004, **328**(7454):1490.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 24. Andrade FP, Rezende PS, Ferreira TS, Borba GC, Muller AM, Rovedder PME: **Effects of intradialytic exercise on cardiopulmonary capacity in chronic kidney disease: systematic review and meta-analysis of randomized clinical trials.** *Sci Rep* 2019, **9**(1):18470.
- 2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25. Bogataj S, Pajek M, Pajek J, Buturovic Ponikvar J, Paravlic A: **Exercise-Based Interventions in Hemodialysis Patients: A Systematic Review with a Meta-Analysis of Randomized Controlled Trials.** *J Clin Med* 2019, **9**(1).
26. Cheema BS, Chan D, Fahey P, Atlantis E: **Effect of progressive resistance training on measures of skeletal muscle hypertrophy, muscular strength and health-related quality of life in patients with chronic kidney disease: a systematic review and meta-analysis.** *Sports Med* 2014, **44**(8):1125-1138.
27. Chen G, Gao L, Li X: **Effects of exercise training on cardiovascular risk factors in kidney transplant recipients: a systematic review and meta-analysis.** *Ren Fail* 2019, **41**(1):408-418.
28. Chung YC, Yeh ML, Liu YM: **Effects of intradialytic exercise on the physical function, depression and quality of life for haemodialysis patients: a systematic review and meta-analysis of randomised controlled trials.** *J Clin Nurs* 2017, **26**(13-14):1801-1813.
29. Clarkson MJ, Bennett PN, Fraser SF, Warmington SA: **Exercise interventions for improving objective physical function in patients with end-stage kidney disease on dialysis: a systematic review and meta-analysis.** *Am J Physiol Renal Physiol* 2019, **316**(5):F856-f872.
30. Ferrari F, Helal L, Dipp T, Soares D, Soldatelli A, Mills AL, Paz C, Tenorio MCC, Motta MT, Barcellos FC *et al*: **Intradialytic training in patients with end-stage renal disease: a systematic review and meta-analysis of randomized clinical trials assessing the effects of five different training interventions.** *J Nephrol* 2020, **33**(2):251-266.
31. Ferreira GD, Bohlke M, Correa CM, Dias EC, Orcy RB: **Does Intradialytic Exercise Improve Removal of Solutes by Hemodialysis? A Systematic Review and Meta-analysis.** *Arch Phys Med Rehabil* 2019, **100**(12):2371-2380.
32. Gomes Neto M, de Lacerda FFR, Lopes AA, Martinez BP, Saquetto MB: **Intradialytic exercise training modalities on physical functioning and health-related quality of life in patients undergoing maintenance hemodialysis: systematic review and meta-analysis.** *Clin Rehabil* 2018, **32**(9):1189-1202.
33. Heiwe S, Jacobson SH: **Exercise training for adults with chronic kidney disease.** *Cochrane Database Syst Rev* 2011(10):Cd003236.
34. Huang M, Lv A, Wang J, Xu N, Ma G, Zhai Z, Zhang B, Gao J, Ni C: **Exercise Training and Outcomes in Hemodialysis Patients: Systematic Review and Meta-Analysis.** *Am J Nephrol* 2019, **50**(4):240-254.
35. Ju H, Chen H, Mi C, Chen Y, Zuang C: **The Impact of Home-Based Exercise Program on Physical Function of Chronic Kidney Disease Patients: A Meta-Analysis of Randomized Controlled Trials.** *Physikalische Medizin, Rehabilitationsmedizin, Kurortmedizin* 2020, **30**(02):108-114.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 36. Lu Y, Wang Y, Lu Q: **Effects of Exercise on Muscle Fitness in Dialysis Patients: A Systematic Review and Meta-Analysis.** *Am J Nephrol* 2019, **50(4):291-302.**
- 2
3
4 37. Matsuzawa R, Hoshi K, Yoneki K, Harada M, Watanabe T, Shimoda T, Yamamoto S, Matsunaga A: **Exercise Training in Elderly People Undergoing Hemodialysis: A Systematic Review and Meta-analysis.** *Kidney Int Rep* 2017, **2(6):1096-1110.**
- 5
6
7
8 38. Nakamura K, Sasaki T, Yamamoto S, Hayashi H, Ako S, Tanaka Y: **Effects of exercise on kidney and physical function in patients with non-dialysis chronic kidney disease: a systematic review and meta-analysis.** *Sci Rep* 2020, **10(1):18195.**
- 9
10
11
12 39. Oguchi H, Tsujita M, Yazawa M, Kawaguchi T, Hoshino J, Kohzuki M, Ito O, Yamagata K, Shibagaki Y, Sofue T: **The efficacy of exercise training in kidney transplant recipients: a meta-analysis and systematic review.** *Clin Exp Nephrol* 2019, **23(2):275-284.**
- 13
14
15
16 40. Pei G, Tang Y, Tan L, Tan J, Ge L, Qin W: **Aerobic exercise in adults with chronic kidney disease (CKD): a meta-analysis.** *Int Urol Nephrol* 2019, **51(10):1787-1795.**
- 17
18
19 41. Pu J, Jiang Z, Wu W, Li L, Zhang L, Li Y, Liu Q, Ou S: **Efficacy and safety of intradialytic exercise in haemodialysis patients: a systematic review and meta-analysis.** *BMJ Open* 2019, **9(1):e020633.**
- 20
21
22 42. Salhab N, Karavetian M, Kooman J, Fiaccadori E, El Khoury CF: **Effects of intradialytic aerobic exercise on hemodialysis patients: a systematic review and meta-analysis.** *J Nephrol* 2019, **32(4):549-566.**
- 23
24
25 43. Sheng K, Zhang P, Chen L, Cheng J, Wu C, Chen J: **Intradialytic exercise in hemodialysis patients: a systematic review and meta-analysis.** *Am J Nephrol* 2014, **40(5):478-490.**
- 26
27
28 44. Smart N, Steele M: **Exercise training in haemodialysis patients: a systematic review and meta-analysis.** *Nephrology (Carlton)* 2011, **16(7):626-632.**
- 29
30 45. Song YY, Hu RJ, Diao YS, Chen L, Jiang XL: **Effects of Exercise Training on Restless Legs Syndrome, Depression, Sleep Quality, and Fatigue Among Hemodialysis Patients: A Systematic Review and Meta-analysis.** *J Pain Symptom Manage* 2018, **55(4):1184-1195.**
- 31
32
33 46. Thompson S, Wiebe N, Padwal RS, Gyenes G, Headley SAE, Radhakrishnan J, Graham M: **The effect of exercise on blood pressure in chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials.** *PLoS One* 2019, **14(2):e0211032.**
- 34
35
36
37 47. Vanden Wyngaert K, Van Craenenbroeck AH, Van Biesen W, Dhondt A, Tanghe A, Van Ginckel A, Celie B, Calders P: **The effects of aerobic exercise on eGFR, blood pressure and VO₂peak in patients with chronic kidney disease stages 3-4: A systematic review and meta-analysis.** *PLoS One* 2018, **13(9):e0203662.**
- 38
39
40
41
42 48. Wu X, Yang L, Wang Y, Wang C, Hu R, Wu Y: **Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic**

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 **kidney disease: a systematic review and meta-analysis.** *Clin Rehabil* 2020,
2 **34(7):851-865.**
- 3 49. Yamamoto R, Ito T, Nagasawa Y, Matsui K, Egawa M, Nanami M, Isaka Y,
4 Okada H: **Efficacy of aerobic exercise on the cardiometabolic and renal**
5 **outcomes in patients with chronic kidney disease: a systematic review of**
6 **randomized controlled trials.** *J Nephrol* 2021, **34(1):155-164.**
- 7 50. Yang H, Wu X, Wang M: **Exercise Affects Cardiopulmonary Function in**
8 **Patients with Chronic Kidney Disease: A Meta-Analysis.** *Biomed Res Int*
9 2017, **2017:6405797.**
- 10 51. Zhang F, Zhou W, Sun Q, Zhai Y, Zhang Y, Su H, Wang Z: **Effects of**
11 **intradialytic resistance exercises on physical performance, nutrient intake**
12 **and quality of life among haemodialysis people: A systematic review and**
13 **meta-analysis.** *Nurs Open* 2021, **8(2):529-538.**
- 14 52. Zhang L, Wang Y, Xiong L, Luo Y, Huang Z, Yi B: **Exercise therapy**
15 **improves eGFR, and reduces blood pressure and BMI in non-dialysis CKD**
16 **patients: evidence from a meta-analysis.** *BMC Nephrol* 2019, **20(1):398.**
- 17 53. Zhao QG, Zhang HR, Wen X, Wang Y, Chen XM, Chen N, Sun Y, Liu H, Lu
18 PJ: **Exercise interventions on patients with end-stage renal disease: a**
19 **systematic review.** *Clin Rehabil* 2019, **33(2):147-156.**
- 20 54. **!!! INVALID CITATION !!! .**
- 21 55. Clyne N, Anding-Rost K: **Exercise training in chronic kidney disease-effects,**
22 **expectations and adherence.** *Clin Kidney J* 2021, **14(Suppl 2):ii3-ii14.**
- 23 56. Webster AC, Nagler EV, Morton RL, Masson P: **Chronic Kidney Disease.**
24 *Lancet* 2017, **389(10075):1238-1252.**
- 25 57. Cheung AK, Chang TI, Cushman WC, Furth SL, Ix JH, Pecoits-Filho R,
26 Perkovic V, Sarnak MJ, Tobe SW, Tomson CRV *et al*: **Blood pressure in**
27 **chronic kidney disease: conclusions from a Kidney Disease: Improving**
28 **Global Outcomes (KDIGO) Controversies Conference.** *Kidney Int* 2019,
29 **95(5):1027-1036.**
- 30 58. Kuo CP, Tsai MT, Lee KH, Lin YP, Huang SS, Huang CC, Tseng WC, Tarng
31 DC: **Dose-response effects of physical activity on all-cause mortality and**
32 **major cardiorenal outcomes in chronic kidney disease.** *Eur J Prev Cardiol*
33 2021.
- 34 59. Graham-Brown MPM, March DS, Young R, Highton PJ, Young HML,
35 Churchward DR, Dungey M, Stensel DJ, Bishop NC, Brunskill NJ *et al*: **A**
36 **randomized controlled trial to investigate the effects of intra-dialytic**
37 **cycling on left ventricular mass.** *Kidney International* 2021.
- 38 60. Zelle DM, Klaassen G, van Adrichem E, Bakker SJ, Corpeleijn E, Navis G:
39 **Physical inactivity: a risk factor and target for intervention in renal care.**
40 *Nat Rev Nephrol* 2017, **13(3):152-168.**
- 41 61. Mezzani A, Hamm LF, Jones AM, McBride PE, Moholdt T, Stone JA,
42 Urhausen A, Williams MA: **Aerobic exercise intensity assessment and**
43 **prescription in cardiac rehabilitation: a joint position statement of the**
44 **European Association for Cardiovascular Prevention and Rehabilitation,**

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 **the American Association of Cardiovascular and Pulmonary**
2 **Rehabilitation and the Canadian Association of Cardiac Rehabilitation.**
3 *Eur J Prev Cardiol* 2013, **20**(3):442-467.
- 4 62. Chan D, Cheema BS: **Progressive Resistance Training in End-Stage Renal**
5 **Disease: Systematic Review.** *Am J Nephrol* 2016, **44**(1):32-45.
- 6 63. Androga L, Sharma D, Amodu A, Abramowitz MK: **Sarcopenia, obesity, and**
7 **mortality in US adults with and without chronic kidney disease.** *Kidney Int*
8 *Rep* 2017, **2**(2):201-211.
- 9 64. Weisbord SD, Fried LF, Arnold RM, Fine MJ, Levenson DJ, Peterson RA,
10 Switzer GE: **Prevalence, severity, and importance of physical and emotional**
11 **symptoms in chronic hemodialysis patients.** *J Am Soc Nephrol* 2005,
12 **16**(8):2487-2494.
- 13 65. Flythe JE, Hilliard T, Castillo G, Ikeler K, Orazi J, Abdel-Rahman E, Pai AB,
14 Rivara MB, St Peter WL, Weisbord SD *et al*: **Symptom Prioritization among**
15 **Adults Receiving In-Center Hemodialysis: A Mixed Methods Study.** *Clin J*
16 *Am Soc Nephrol* 2018, **13**(5):735-745.
- 17 66. Gregg LP, Bossola M, Ostrosky-Frid M, Hedayati SS: **Fatigue in CKD:**
18 **Epidemiology, Pathophysiology, and Treatment.** *Clin J Am Soc Nephrol*
19 2021.
- 20 67. Flythe JE, Dorough A, Narendra JH, Forfang D, Hartwell L, Abdel-Rahman E:
21 **Perspectives on symptom experiences and symptom reporting among**
22 **individuals on hemodialysis.** *Nephrol Dial Transplant* 2018, **33**(10):1842-
23 1852.
- 24 68. Metzger M, Abdel-Rahman EM, Boykin H, Song MK: **A Narrative Review of**
25 **Management Strategies for Common Symptoms in Advanced CKD.** *Kidney*
26 *Int Rep* 2021, **6**(4):894-904.
- 27 69. Johansen KL: **The Promise and Challenge of Aerobic Exercise in People**
28 **Undergoing Long-Term Hemodialysis.** *Clin J Am Soc Nephrol* 2021,
29 **16**(4):505-507.
- 30 70. Fuller JT, Hartland MC, Maloney LT, Davison K: **Therapeutic effects of**
31 **aerobic and resistance exercises for cancer survivors: a systematic review**
32 **of meta-analyses of clinical trials.** *Br J Sports Med* 2018, **52**(20):1311.
- 33 71. Amir N, Tong A, McCarthy H, Howell M: **Trajectories of quality of life in**
34 **chronic kidney disease: a novel perspective of disease progression.** *Nephrol*
35 *Dial Transplant* 2021.
- 36 72. Parker K: **Intradialytic Exercise is Medicine for Hemodialysis Patients.** *Curr*
37 *Sports Med Rep* 2016, **15**(4):269-275.
- 38 73. Smart NA, Williams AD, Levinger I, Selig S, Howden E, Coombes JS, Fassett
39 RG: **Exercise & Sports Science Australia (ESSA) position statement on**
40 **exercise and chronic kidney disease.** *J Sci Med Sport* 2013, **16**(5):406-411.
- 41 74. March DS, Hurt AW, Grantham CE, Churchward DR, Young HML, Highton
42 PJ, Dungey M, Bishop NC, Smith AC, Graham-Brown MPM *et al*: **A Cost-**
43 **Effective Analysis of the CYCLE-HD Randomized Controlled Trial.**
44 *Kidney International Reports.*

- 1
2
3 1 75. Fuhrmann I, Krause R: **Principles of exercising in patients with chronic**
4 **kidney disease, on dialysis and for kidney transplant recipients.** *Clin*
5 **2**
6 **3** *Nephrol* 2004, **61 Suppl 1**:S14-25.
7
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4

For peer review only

Table 1 Summary of the effect of exercise on cardiovascular risk factor in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD or MD (95% CI)	Effect size	P	I ²	GRADE
SBP										
Pei (2019)	RCT/quasi-RCT	Mixed	12(514)	AE	-	MD:-2.91 (-6.68, 0.87)	-	0.13	40.0%	⊕⊕○○
Wu (2020)	RCT/quasi-RCT	Predialysis	3 (204)	AE+RT	-	SMD:-0.19(-0.46,0.08)	Small	0.16	50.0%	⊕○○○
Chen (2019)	RCT	KTRs	5(198)	Mixed	-	SMD:0.18(-0.10,0.46)	Small	0.21	0.0%	⊕○○○
Pu (2019)	RCT	HD	7(287)	Mixed	Intradialytic	SMD:-0.28(-0.52,-0.05)	Small	0.02	0.0%	⊕○○○
Yamamoto (2021)	RCT	Predialysis	10(392)	AE	-	SMD:-0.75(-1.24,-0.26)	Moderate	0.003	80.3%	⊕○○○
Thompson (2019)	RCT	Predialysis	10(335)	Mixed	-	MD:-4.30(-9.00,0.40)	-	N.P.	50.4%	⊕○○○
Zhang (2019)	RCT	Predialysis	14(463)	Mixed	-	SMD:-0.41(-0.70,-0.11)	Small	0.007	55.0%	⊕⊕⊕○
Huang (2019)	RCT	HD	7(260)	Mixed	Mixed	SMD:-0.17(-0.41,0.08)	Small	0.18	8.0%	⊕⊕○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	9(347)	Mixed	-	SMD:0.25(0.04,0.47)	Small	0.02	0.0%	⊕○○○
Heiwe (2014)	RCT	HD	10(312)	Mixed	-	SMD:0.04(-0.34,0.41)	Small	0.8	58.0%	⊕○○○
Sheng (2014)	RCT	HD	7(296)	Mixed	Intradialytic	SMD:-0.27(-0.50,-0.04)	Small	0.02	0.0%	⊕○○○
Ferrari (2019)	RCT	HD	10(332)	AE	Intradialytic	MD:-10.07(16.35,-3.78)	-	0.002	44.0%	⊕○○○
Wyngaert (2018)	RCT	Predialysis	8(269)	AE	-	SMD:0.08(-0.58,0.74)	Small	0.81	84%	⊕○○○
DBP										
Pei (2019)	RCT/quasi-RCT	Mixed	12(514)	AE	-	MD:-1.11 (-3.41, 1.20)	-	0.35	0.0%	⊕⊕○○
Wu (2020)	RCT/quasi-RCT	Predialysis	4 (194)	AE+RT	-	SMD:-0.47(-1.10,0.15)	Small	0.14	70.0%	⊕○○○
Chen (2019)	RCT	KTRs	5(198)	Mixed	-	SMD:0.04(-0.45,0.52)	Small	0.89	59.0%	⊕○○○
Pu (2019)	RCT	HD	7(287)	Mixed	Intradialytic	SMD:-0.32(-0.55,-0.08)	Small	0.008	42.0%	⊕○○○
Thompson (2019)	RCT	Predialysis	8(303)	Mixed	-	MD:-1.18(-4.76,2.40)	-	N.P.	60.5%	⊕○○○

Zhang (2019)	RCT	Predialysis	12(399)	Mixed	-	SMD:-0.31(-0.71,0.08)	Small	0.12	70.0%	⊕⊕○○
Huang (2019)	RCT	HD	7(260)	Mixed	Mixed	SMD:-0.23(-0.69,0.24)	Small	0.34	68.0%	⊕○○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	11(419)	Mixed	-	SMD:0.16(-0.04,0.36)	Small	0.11	40.0%	⊕○○○
Heiwe (2014)	RCT	HD	10(212)	Mixed	Mixed	SMD:0.17(-0.16,0.49)	Small	0.3	45.0%	⊕⊕○○
Sheng (2014)	RCT	HD	7(296)	Mixed	Intradialytic	SMD:-0.24(-0.47,-0.01)	Small	0.04	52.1%	⊕○○○
Ferrari (2019)	RCT	HD	10(334)	AE	Intradialytic	MD:-2.96(-7.71,1.78)	-	0.22	0.0%	⊕○○○
Wynngaert (2018)	RCT	Predialysis	7(237)	AE	-	SMD-0.09(-0.78,0.59)	Small	0.79	83%	⊕○○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; DBP = diastolic blood pressure; SBP = systolic blood pressure; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; GRADE = Grading of Recommendations Assessment, Development, and Evaluation; N.P. = no report.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Table 2 Summary of the effect of exercise on cardiopulmonary fitness in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD or MD (95% CI)	Effect size	P	I ²	GRADE
VO _{2peak}										
Pei (2019)	RCT/quasi-RCT	Mixed	17(464)	AE	-	MD:2.08(1.10,3.05)	-	<0.001	25.0%	⊕⊕○○
Nakamura (2020)	RCT/cross-over	Predialysis	10(401)	Mixed	-	SMD:0.88(0.53,1.23)	Large	<0.001	56.0%	⊕⊕○○
Chen (2019)	RCT	KTRs	6(202)	Mixed	-	SMD:0.33(-0.02,0.69)	Small	0.06	27.0%	⊕○○○
Andrade (2019)	RCT	HD	5(201)	AE+RT	Intradialytic	SMD:1.01(0.71,1.30)	Large	<0.001	0.0%	⊕⊕○○
Chung (2016)	RCT	HD	6(238)	Mixed	Intradialytic	SMD:0.55(0.18,0.92)	Moderate	0.003	52.9%	⊕○○○
Pu (2019)	RCT	HD	10(400)	Mixed	Intradialytic	SMD:0.57(0.23,0.90)	Moderate	<0.001	59.0%	⊕⊕○○
Yamamoto (2021)	RCT	Predialysis	10(365)	AE	-	SMD:0.54(0.29,0.78)	Moderate	<0.001	24.6%	⊕○○○
Yang (2017)	RCT	Mixed	5(179)	Mixed	-	SMD:0.33(0.03,0.63)	Small	0.003	47.0%	⊕⊕○○
Huang (2019)	RCT	HD	10(371)	Mixed	Mixed	SMD:0.73(0.52,0.95)	Moderate	<0.001	71.0%	⊕⊕○○
Matsuzawa (2017)	RCT	HD	18(582)	Mixed	Mixed	SMD:0.62(0.38,0.87)	Moderate	<0.001	49.0%	⊕⊕⊕⊕
Smart (2011)	RCT	HD	8(365)	Mixed	Mixed	SMD:0.75(0.39,1.11)	Moderate	<0.001	60.0%	⊕⊕○○
Bogataj (2020)	RCT	HD	20(504)	Mixed	Mixed	SMD:0.58(0.32,0.85)	Moderate	<0.001	57.4%	⊕○○○
Sheng (2014)	RCT	HD	7(310)	Mixed	Intradialytic	SMD:0.53(0.30,0.76)	Moderate	<0.001	36.0%	⊕○○○
Neto (2018)	RCT	HD	10(394)	Mixed	Intradialytic	SMD:0.60(0.15,1.04)	Moderate	0.008	76.0%	⊕○○○
Ferrari (2019)	RCT	HD	5(201)	AE+RT	Intradialytic	MD:5.41(4.03,6.79)	-	<0.001	0.0%	⊕○○○
Ferrari (2019)	RCT	HD	7(248)	AE	Intradialytic	MD:2.07(0.42,3.72)	-	<0.001	0.0%	⊕○○○
Wyngaert (2018)	RCT	Predialysis	11(325)	AE	-	SMD:0.99(0.49,1.48)	Large	<0.001	74.0%	⊕○○○
Oguchi (2018)	RCT	KTRs	4(182)	Mixed	-	SMD:0.38(-0.06,0.82)	Small	0.09	45.0%	⊕⊕○○
6MWT										

Pei (2019)	RCT/quasi-RCT	Mixed	8 (496)	AE	-	MD:0.04 (-0.52, 0.59)	-	0.90	86.0%	⊕○○○
Nakamura (2020)	RCT/cross-over	Predialysis	5(392)	Mixed	-	SMD:1.04(0.17,1.90)	Large	0.02	92.0%	⊕○○○
Lu (2019)	RCT	Dialysis	11(300)	Mixed	Mixed	SMD:0.52(0.31,0.72)	Moderate	<0.001	39.0%	⊕⊕⊕○
Chung (2016)	RCT	HD	4(127)	Mixed	Intradialytic	SMD:0.44(0.09,0.80)	Small	0.015	0.0%	⊕⊕○○
Zhang (2021)	RCT	HD	8(299)	RT	Intradialytic	SMD:0.52(0.28,0.75)	Moderate	<0.001	18.7%	⊕⊕○○
Pu (2019)	RCT	HD	7(219)	Mixed	Intradialytic	SMD:0.57(0.30,0.84)	Moderate	<0.001	0.0%	⊕⊕○○
Clarkson (2019)	RCT	Dialysis	18(744)	Mixed	-	MD:33.64(23.74,43.54)	-	<0.001	0.0%	⊕⊕⊕○
Huang (2019)	RCT	HD	7(205)	Mixed	Mixed	SMD:1.01(0.26,1.76)	Large	0.008	83.0%	⊕○○○
Matsuzawa (2017)	RCT	HD	10(326)	Mixed	Mixed	SMD:0.58(0.24,0.93)	Moderate	<0.001	53.0%	⊕⊕○○
Bogataj (2020)	RCT	HD	19	Mixed	Mixed	SMD:0.44(0.21,0.67)	Small	<0.001	49.6%	⊕○○○
Sheng (2014)	RCT	HD	4(146)	Mixed	Intradialytic	SMD:0.58(0.23,0.93)	Moderate	<0.001	89.7%	⊕○○○
Neto (2018)	RCT	HD	6(158)	Mixed	Intradialytic	SMD:0.96(0.11,1.80)	Large	0.03	82.0%	⊕○○○
Ferrari (2019)	RCT	HD	6(211)	RT	Intradialytic	MD:68.5(29.05,107.96)	-	<0.001	36.0%	⊕○○○
Ferrari (2019)	RCT	HD	6(188)	AE	Intradialytic	MD:64.98(43.86,86.11)	-	<0.001	0.0%	⊕○○○
Aerobic capacity										
Heiwe (2011)	RCT/quasi-RCT	Mixed	24(847)	Mixed	-	SMD:-0.56(-0.70,-0.42)	Moderate	<0.001	12.0%	⊕○○○
Heiwe (2014)	RCT	HD	21(374)	Mixed	Mixed	SMD:-0.80(-1.02,-0.58)	Large	<0.001	0.0%	⊕⊕○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; VO_{2peak} = peak oxygen uptake; 6MWT = 6 minutes walk test; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Table 3 Summary of the effect of exercise on muscle strength in CKD patients

Author(year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD or MD(95% CI)	Effect size	P	I ²	GRADE
Cheema (2014)	RCT	Predialysis	7(249)	RT	-	SMD:1.15(0.80,1.49)	Large	0.161	35.0%	⊕⊕○○
Nakamura (2020)	RCT/cross-over	Predialysis	4(119)	Mixed	-	SMD:0.35(-0.03,0.73)	Small	0.07	7.0%	⊕○○○
Lu (2019)	RCT	Dialysis	5(234)	Mixed	Mixed	SMD:0.59(0.20,0.98)	Moderate	0.003	52.0%	⊕⊕○○
Lu (2019)	RCT	Dialysis	7(224)	Mixed	Mixed	SMD:0.47(0.20,0.74)	Small	<0.001	0.0%	⊕⊕○○
Zhang (2021)	RCT	HD	6(300)	RT	Intradialytic	SMD:0.35(0.12,0.58)	Small	0.003	41.6%	⊕⊕○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	9(358)	Mixed	-	SMD:-0.52(-0.73,-0.31)	Moderate	<0.001	0.0%	⊕○○○
Heiwe (2014)	RCT	HD	12(385)	Mixed	Mixed	SMD:-0.56(-0.77,-0.35)	Moderate	<0.001	0.0%	⊕○○○
Matsuzawa (2017)	RCT	HD	9(281)	Mixed	Mixed	SMD:0.94(0.67,1.21)	Large	<0.001	10.0%	⊕○○○
Neto (2018)	RCT	HD	9(250)	Mixed	Intradialytic	SMD:0.61(0.39,0.83)	Moderate	<0.001	58.9%	⊕○○○
Ju (2020)	RCT	Mixed	3(115)	Mixed	-	SMD:0.52(0.14,0.89)	Moderate	0.007	0.0%	⊕○○○

Abbreviation: RCT = randomized controlled trial; RT = resistance training; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Table 4 Summary of the effect of exercise on muscle endurance in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcome	SMD or MD (95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
Lu (2019)	RCT	Dialysis	3(193)	Mixed	Mixed	STS 10	MD:-4.69(-9.01,-0.38)	-	0.028	72.2%	⊕○○○
Bogataj (2020)	RCT	HD	5(461)	Mixed	-	STS 10	SMD:-0.55(-1.00,-0.09)	Moderate	0.019	71.6%	⊕○○○
Lu (2019)	RCT	Dialysis	6(240)	Mixed	Mixed	STS 30	SMD:0.43(0.17,0.69)	Small	0.001	2.0%	⊕⊕○○
Zhang (2021)	RCT	HD	5(164)	RT	Intradialytic	STS 30	SMD:0.42(0.11,0.74)	Small	0.008	0.0%	⊕○○○
Sheng (2014)	RCT	HD	3(106)	Mixed	Intradialytic	STS 60	SMD:0.71(0.31,1.12)	Moderate	<0.001	0.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	5(445)	AE	-	STS 60	MD:2.08(1.1,3.05)	-	0.98	82.0%	⊕○○○
Nakamura (2020)	RCT/cross-over	Predialysis	3(170)	Mixed	-	TUGT	SMD:-0.42(-0.73,-0.11)	Small	0.007	0.0%	⊕○○○
Heiwe (2011)	RCT/quasi-RCT	Mixed	7(191)	Mixed	-	Walking capacity	SMD:-0.48(-0.79,-0.17)	Small	0.003	2.0%	⊕○○○
Heiwe (2014)	RCT	HD	7(174)	Mixed	Mixed	Walking capacity	SMD:-0.33(-0.67,0.01)	Small	0.06	16.0%	⊕⊕⊕○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; STS 10 = sit to stand 10 test; STS 30 = sit to stand 30 test; STS 60 = sit to stand 60 test; TUGT = timed up and go test; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Table 5 Summary of the effect of exercise on body composition in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	SMD (95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
Chen (2019)	RCT	KTRs	4(166)	Mixed	-	SMD:0.02(-0.28,0.33)	Small	0.89	0.0%	⊕○○○
Yamamoto (2021)	RCT	Predialysis	10(414)	AE	-	SMD:-0.19(-0.38,-0.00)	Small	0.026	0.0%	⊕⊕○○
Zhang (2019)	RCT	Predialysis	13(466)	Mixed	-	SMD:-0.21(-0.39,-0.03)	Small	0.02	0.0%	⊕⊕⊕○
Wyngaert (2018)	RCT	Predialysis	9(294)	AE	-	SMD:-0.36(-0.60,-0.13)	Small	0.002	48.0%	⊕⊕○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; SMD = standardized mean difference; KTRs = kidney transplant recipients;;GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Table 6 Summary of the effect of exercise on dialysis-related symptoms in CKD patients

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcomes	SMD or MD(95% CI)	Effect size	<i>P</i>	<i>I</i> ²	GRADE
Ferreira (2019)	RCT/quasi-RCT	HD	10(346)	AE	Intradialytic	Kt/V	SMD:2.21(1.17,3.25)	Large	<0.001	92.0%	⊕○○○
Pu (2019)	RCT	HD	10(301)	Mixed	Intradialytic	Kt/V	SMD:0.29(0.06,0.52)	Small	0.01	0.0%	⊕○○○
Huang (2019)	RCT	HD	8(257)	Mixed	Mixed	Kt/V	SMD:0.19(-0.06,0.43)	Small	0.14	0.0%	⊕○○○
Sheng (2014)	RCT	HD	7(233)	Mixed	Intradialytic	Kt/V	SMD:0.27(0.01,0.53)	Small	0.04	0.0%	⊕○○○
Ferrari (2019)	RCT	HD	12(370)	AE	Intradialytic	Kt/V	MD:0.08(0.0,0.15)	-	0.04	56.0%	⊕○○○
Ferrari (2019)	RCT	HD	6(220)	RT	Intradialytic	Kt/V	MD:0.10(0.0,0.2)	-	0.06	6.0%	⊕○○○
Song (2018)	RCT	HD	4(141)	Mixed	Mixed	RLS	SMD:-1.79(-2.21,-1.37)	Large	<0.001	87.0%	⊕○○○
Song (2018)	RCT	HD	3(139)	Mixed	Mixed	Fatigue	SMD:-0.85(-1.20,-0.50)	Large	<0.001	0.0%	⊕○○○
Zhao (2019)	RCT	Dialysis	3(141)	Mixed	-	Fatigue	SMD:-0.97(-1.32,-0.62)	Large	<0.001	47.0%	⊕⊕○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; RLS = Restless Legs Syndrome; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.

Table 7 Summary of the effect of exercise on health-related quality of lives in CKD patients


Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcomes	SMD or MD (95% CI)	Effect size	P	I ²	GRADE
Salhab (2019)	RCT	HD	5(282)	AE	Intradialytic	PCS	SMD:1.82(-0.92,4.55)	Large	0.19	98.0%	⊕○○○
Chung (2016)	RCT	HD	6(229)	Mixed	Intradialytic	PCS	SMD:0.46(0.20,0.73)	Small	<0.001	1.90%	⊕⊕○○
Zhang (2021)	RCT	HD	7(297)	RT	Intradialytic	PCS	SMD:0.23(-0.00,0.46)	Small	0.055	0.0%	⊕⊕○○
Pu (2019)	RCT	HD	10(320)	Mixed	Intradialytic	PCS	SMD:0.57(0.14,1.01)	Moderate	0.01	70.0%	⊕○○○
Zhao (2019)	RCT	Dialysis	5(186)	Mixed	-	PCS	SMD:0.31(0.02,0.61)	Small	0.04	46.0%	⊕⊕○○
Huang (2019)	RCT	HD	7(263)	Mixed	Mixed	PCS	SMD:0.34(0.09,0.59)	Small	0.007	27.0%	⊕⊕○○
Matsuzawa (2017)	RCT	HD	9(264)	Mixed	Mixed	PCS	SMD:0.53(0.52,0.82)	Moderate	<0.001	19.0%	⊕○○○
Sheng (2014)	RCT	HD	7(256)	Mixed	Intradialytic	PCS	SMD:0.30(0.05,0.55)	Small	0.02	39.5%	⊕○○○
Neto (2018)	RCT	HD	7(187)	Mixed	Intradialytic	PCS	SMD:0.50(-0.19,1.18)	Moderate	0.16	62.0%	⊕○○○
Salhab (2019)	RCT	HD	5(282)	AE	Intradialytic	MCS	SMD:1.02(0.31,1.73)	Large	0.005	75.0%	⊕○○○
Chung (2016)	RCT	HD	5(193)	Mixed	Intradialytic	MCS	SMD:0.23(-0.05,0.52)	Small	0.109	0.0%	⊕⊕○○
Zhang (2021)	RCT	HD	7(297)	RT	Intradialytic	MCS	SMD:0.13(-0.10,0.36)	Small	0.082	46.5%	⊕⊕○○
Pu (2019)	RCT	HD	8(219)	Mixed	Intradialytic	MCS	SMD:0.19(-0.09,0.46)	Small	0.18	30.0%	⊕⊕○○
Zhao (2019)	RCT	Dialysis	5(186)	Mixed	-	MCS	SMD:0.30(-0.20,0.80)	Small	0.24	64.0%	⊕○○○
Huang (2019)	RCT	HD	7(263)	Mixed	Mixed	MCS	SMD:0.27(0.02,0.51)	Small	0.03	0.0%	⊕⊕○○
Matsuzawa (2017)	RCT	HD	8(228)	Mixed	Mixed	MCS	SMD:0.14(-0.15,0.42)	Small	0.34	10.0%	⊕○○○
Sheng (2014)	RCT	HD	5(167)	Mixed	Intradialytic	MCS	SMD:0.14(-0.16,0.43)	Small	0.37	14.8%	⊕○○○
Neto (2018)	RCT	HD	7(185)	Mixed	Intradialytic	MCS	SMD:0.39(-0.19,0.98)	Small	0.19	50.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	6(522)	AE	-	Physical function (SF-36)	MD:8.36(-1.24,17.95)	-	0.09	76.0%	⊕○○○

Pei (2019)	RCT/quasi-RCT	Mixed	7(562)	AE	-	Physical role (SF-36)	MD:14.65(1.47,27.84)	-	0.03	78.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	6(447)	AE	-	Social function (SF-36)	MD:8.24(-1.09,17.58)	-	0.08	85.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	6(513)	AE	-	Pain (SF-36)	MD:5.94(1.65,10.23)	-	0.007	49.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	7(562)	AE	-	General health (SF-36)	MD:8.90(2.48,15.32)	-	0.007	71.0%	⊕○○○
Pei (2019)	RCT/quasi-RCT	Mixed	6(542)	AE	-	Mental health (SF-36)	MD:7.30(-0.94,15.54)	-	0.08	84.0%	⊕○○○
Cheema (2014)	RCT	Predialysis	6 (223)	RT	-	HRQOL	SMD:0.83(0.51,1.16)	Large	0.226	27.8%	⊕⊕○○
Oguchi (2018)	RCT	KTRs	4(179)	Mixed	-	HRQOL	SMD:0.54(0.02,1.07)	Moderate	0.04	58.0%	⊕○○○
Ju (2020)	RCT	Mixed	3 (387)	Mixed	-	Symptom/problem (KDQOL)	SMD:1.92(-1.06,4.90)	Large	0.21	99.0%	⊕○○○
Ju (2020)	RCT	Mixed	3 (387)	Mixed	-	Effects of kidney disease (KDQOL)	SMD:-3.69(-8.56,1.19)	Large	0.14	99.0%	⊕○○○
Ju (2020)	RCT	Mixed	3 (387)	Mixed	-	Burden of kidney disease (KDQOL)	SMD:1.04 (-0.75,2.82)	Large	0.26	98.0%	⊕○○○

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; COM = combine; HRQOL = health-related quality of life; PCS = physical component summary; MCS = mental component summary; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; SF-36 = Short-Form Health Survey-36; KDQOL = kidney disease quality of life; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.

Mixed means aerobic exercise combined with resistance training.



Figures 1 Flowchart of literature screening.

CDSR = Cochrane Database of Systemic Review

Supplementary Table S1 The detailed search strategy

Databases	#	Search strategy
Pubmed	1	"renal insufficiency, chronic"[MeSH Terms]
	2	"chronic renal insufficiency"[Title/Abstract] or "chronic kidney insufficiency"[Title/Abstract] or "chronic kidney disease"[Title/Abstract] or "chronic renal disease"[Title/Abstract]
	3	"CKD"[Title/Abstract] or "CKF"[Title/Abstract] or "CRD"[Title/Abstract] or "CRF"[Title/Abstract]
	4	"end-stage kidney"[Title/Abstract] or "end-stage renal"[Title/Abstract] or "endstage kidney"[Title/Abstract] or "endstage renal"[Title/Abstract]
	5	"ESRD"[Title/Abstract] or "ESRF"[Title/Abstract] or "ESKD"[Title/Abstract] or "ESKF"[Title/Abstract]
	6	"Renal Replacement Therapy"[MeSH Terms]
	7	"dialysis"[Title/Abstract]
	8	"hemodialysis"[Title/Abstract] or "haemodialysis"[Title/Abstract] or "hemodiafiltration"[Title/Abstract] or "haemodiafiltration"[Title/Abstract] or "HD"[Title/Abstract]
	9	"PD"[Title/Abstract]
	10	"renal transplantation"[Title/Abstract] or "kidney grafting"[Title/Abstract] or "kidney transplantation"[Title/Abstract]
	11	"KTRs"[Title/Abstract]
	12	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
	13	"Exercise"[MeSH Terms]
	14	"Exercise Movement Techniques"[MeSH Terms]
	15	"Exercise Therapy"[MeSH Terms]
	16	"Sports"[MeSH Terms]
	17	"train"[Title/Abstract] or "physical activity"[Title/Abstract] or "exercise"[Title/Abstract]
	18	#13 or #14 or #15 or #16 or #17
	19	"Systematic Review"[Publication Type] or "Systematic Reviews as Topic"[MeSH Terms]
	20	"meta analysis"[Publication Type] or "Meta-Analysis as Topic"[MeSH Terms]

	21	"Systematic Review"[Title/Abstract] or "system review"[Title/Abstract] or "data pooling"[Title/Abstract] or "meta"[Title/Abstract]
	22	#19 or #20 or #21
	23	#12 and #18 and #22
CDSR	1	MeSH descriptor: [Kidney Diseases] explode all trees
	2	("chronic kidney disease") or ("chronic renal disease") or ("chronic kidney failure") or ("chronic renal failure"):ti,ab,kw
	3	(CKF or CKD or CRF or CRD):ti,ab,kw
	4	("end-stage kidney") or ("end-stage renal") or ("endstage kidney") or ("endstage renal"):ti,ab,kw
	5	ESRD or ESRF or ESKD or ESKF:ti,ab,kw
	6	MeSH descriptor: [Renal Replacement Therapy] explode all trees
	7	dialysis:ti,ab,kw
	8	(hemodialysis or haemodialysis or hemodiafiltration or haemodiafiltration or HD):ti,ab,kw
	9	PD:ti,ab,kw
	10	("renal transplantation") or ("kidney grafting") or ("kidney transplantation"):ti,ab,kw
	11	KTRs:ti,ab,kw
	12	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
	13	MeSH descriptor: [Exercise] explode all trees
	14	MeSH descriptor: [Exercise Movement Techniques] explode all trees
	15	MeSH descriptor: [Exercise Therapy] explode all trees
	16	MeSH descriptor: [Sports] explode all trees
	17	(train or ("physical activity") or exercise):ti,ab,kw
	18	#13 or #14 or #15 or #16 or #17
	19	MeSH descriptor: [Meta-Analysis as Topic] explode all trees
	20	MeSH descriptor: [Systematic Reviews as Topic] explode all trees
	21	("systematic review") or ("system review") or ("data pooling") or (meta):ti,ab,kw
	22	#19 or #20 or #21

	23	#12 and #18 and #22
Embase	1	'kidney disease'/exp
	2	('chronic kidney disease' or 'chronic renal disease' or 'chronic kidney failure' or 'chronic renal failure'):ti,ab,kw
	3	(CKF or CKD or CRF or CRD):ti,ab,kw
	4	('end-stage kidney' or 'end-stage renal' or 'endstage kidney' or 'endstage renal'):ti,ab,kw
	5	(ESRD or ESRF or ESKD or ESKF):ti,ab,kw
	6	'renal replacement therapy'/exp
	7	'dialysis':ti,ab,kw
	8	(hemodialysis or haemodialysis or hemofiltration or haemofiltration or hemodiafiltration or haemodiafiltration or HD):ti,ab,kw
	9	PD:ti,ab,kw
	10	('renal transplantation' or 'kidney grafting' or 'kidney transplantation'):ti,ab,kw
	11	KTRs:ti,ab,kw
	12	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
	13	'exercise'/exp
	14	'physical activity'/exp
	15	'sport'/exp
	16	(train or 'physical activity' or exercise):ti,ab,kw
	17	#13 or #14 or #15 or #16
	18	'systematic review (topic)'/exp or 'systematic review'/exp
	19	'meta analysis (topic)'/exp or 'meta analysis'/exp
	20	('systematic review' or 'system review' or 'data pooling' or meta):ti,ab,kw
	21	#18 or #19 or #20
	22	#12 and #17 and #21
Web of Science	1	TS: ("chronic kidney disease" or "chronic renal disease" or "chronic kidney failure" or "chronic renal failure" or CKD or CRD or CKF or CRF)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	2	TS: ("end-stage kidney" or "end-stage renal" or "endstage kidney" or "endstage renal" or ESKD or ESKF or ESRD or ESRF)
	3	TS: ("renal replacement therapy" or dialysis or hemodialysis or haemodialysis or hemofiltration or haemofiltration or hemodiafiltration or haemodiafiltration or HD or PD)
	4	TS: ("renal transplantation" or "kidney grafting" or "kidney transplantation" or KTRs)
	5	#1 or #2 or #3 or #4
	6	TS: (train or exercise or "physical activity")
	7	TS: ("systematic review" or "system review" or "data pooling" or meta)
	8	#1 and #2 and #3 and #4 and #5

Supplementary Table S2 The characteristic of excluded studies

Studies	Reasons for exclusion
Nantakool et al (2020)	Non predefine outcome
Sawant et al (2014)	Non predefine outcome
Smart et al (2014)	Duplicate literature
Barcellos et al (2015)	Meta-analysis was not conducted
Yang et al (2020)	Non predefine outcome
Young et al (2018)	Included cases<100
Phan et al (2015)	Duplicate literature
Molsted et al (2019)	Included cases<100
Segura et al (2010)	Non-English
Ferreira et al (2020)	Non predefine outcome
Koufaki et al (2013)	Meta-analysis was not conducted
Smart et al (2012)	Abstracts
Howden et al (2012)	Meta-analysis was not conducted
Calella et al (2019)	Meta-analysis was not conducted
Singh et al (2005)	Meta-analysis was not conducted
Cardoso et al (2020)	Non predefine outcome
Villanego et al (2020)	Non-English
Medeiros et al (2017)	Intervention did not fit
Macdonald et al (2009)	Meta-analysis was not conducted
Wen et al (2019)	Non predefine outcome
Yang et al (2015)	Non predefine outcome
Thangarasa et al (2018)	Included cases<100
Chan et al (2016)	Meta-analysis was not conducted

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Johansen et al (2010)	Intervention did not fit
Thompson et al (2020)	Correction for published paper
Bakaloudi et al (2020)	Meta-analysis was not conducted
Kirkman et al (2019)	Meta-analysis was not conducted
Afsar et al (2018)	Meta-analysis was not conducted

For peer review only

Supplementary Table S3 The basic characteristics of the included meta-analyses

Author (year)	Design	Stage of CKD	k (n)*	Exercise type	Mode	Outcomes	SMD or MD(95% CI)	Effect size	P	I ²	GRADE
Pei (2019)	RCT/quasi-RCT	Mixed	17(464)	AE	-	VO _{2peak}	MD:2.08 (1.1,3.05)	-	<0.001	25.0%	Low
			5 (445)			STS 60	MD:2.08 (1.1,3.05)	-	0.98	82.0%	Very low
			8 (496)			6MWT	MD:0.04 (-0.52, 0.59)	-	0.9	86.0%	Very low
			12(514)			SBP	MD:-2.91 (-6.68, 0.87)	-	0.13	40.0%	Low
			12(514)			DBP	MD:-1.11 (-3.41, 1.20)	-	0.35	0.0%	Low
			6(522)			Physical function (SF-36)	MD:8.36(-1.24,17.95)	-	0.09	76.0%	Very low
			7(562)			Physical role (SF-36)	MD:14.65(1.47,27.84)	-	0.03	78.0%	Very low
			6(447)			Social function (SF-36)	MD:8.24(-1.09,17.58)	-	0.08	85.0%	Very low
			6(513)			Pain (SF-36)	MD:5.94(1.65,10.23)	-	0.007	49.0%	Very low
			7(562)			General health (SF-36)	MD:8.90(2.48,15.32)	-	0.007	71.0%	Very low
6(542)	Mental health (SF-36)	MD:7.30(-0.94,15.54)	-	0.08	84.0%	Very low					
Ferreira (2019)	RCT/quasi-RCT	HD	10(346)	AE	Intradialytic	Kt/V	SMD:2.21(1.17,3.25)	Large	<0.001	92.0%	Very low
Cheema (2014)	RCT	Predialysis	7(249)	RT	-	Muscle Strength	SMD:1.15 (0.80-1.49)	Large	0.161	35.0%	Low
			6(223)			HRQoL	SMD:0.83(0.51-1.16)	Large	0.226	27.8%	Low
Wu (2020)	RCT/quasi-RCT	Predialysis	3(204)	AE+RT	-	SBP	SMD:-0.19(-0.46,0.08)	Small	0.16	50.0%	Very low
			4(194)			DBP	SMD:-0.47(-1.10,0.15)	Small	0.14	70.0%	Very low

Nakamura (2020)	RCT/cross-over	Predialysis	10(401)	Mixed	-	VO _{2peak}	SMD:0.88(0.53,1.23)	Large	<0.001	56.0%	Low
			4(119)			Muscle Strength	SMD:0.35(-0.03,0.73)	Small	0.07	7.0%	Very low
			5(392)			6MWT	SMD:1.04(0.17,1.90)	Large	0.02	92.0%	Very low
			3(170)			TUGT	SMD:-0.42(-0.73,-0.11)	Small	0.007	0.0%	Very low
Lu (2019)	RCT	Dialysis	11(300)	Mixed	Mixed	6MWT	MD:67.6(49.93,85.26)	-	<0.001	30.6%	Moderate
			3(193)			STS 10	MD:-4.69(-9.01,-0.38)	-	0.028	72.2%	Very low
			5(234)			HGS	MD:5.35(3.34,7.37)	-	<0.001	0.3%	Low
			7(224)			Muscle strength	MD:3.67(1.37,5.97)	-	0.020	38.6%	Low
			6(240)			STS 30	MD:2.43(0.91,3.96)	-	0.002	21.2%	Low
Chen (2019)	RCT	KTRs	5(198)	Mixed	-	SBP	SMD:0.18(-0.10,0.46)	Small	0.21	0.0%	Very low
			5(198)			DBP	SMD:0.04(-0.45,0.52)	Small	0.89	59.0%	Very low
			4(166)			BMI	SMD:0.02(-0.28,0.33)	Small	0.89	0.0%	Very low
			6(202)			VO _{2peak}	SMD:0.33(-0.02,0.69)	Small	0.06	27.0%	Very low
Song (2018)	RCT	HD	4(141)	Mixed	Mixed	RLS	SMD:-1.79(-2.21,-1.37)	Large	<0.001	87.0%	Very low
			3(139)			Fatigue	SMD:-0.85(-1.20,-0.50)	Large	<0.001	0.0%	Very low
Salhab (2019)	RCT	HD	5(282)	AE	Intradialytic	PCS	SMD:1.82(-0.92,4.55)	Large	0.19	98.0%	Very low
			5(282)			MCS	SMD:1.02(0.31,1.73)	Large	0.005	75.0%	Very low
Andrade (2019)	RCT	HD	5(201)	AE+RT	Intradialytic	VO _{2peak}	SMD:1.01(0.71,1.30)	Large	<0.001	0.0%	Low
Chung (2016)	RCT	HD	4(127)	Mixed	Intradialytic	6MWT	SMD:0.44(0.09,0.80)	Small	0.015	0.0%	Low
			6(238)			VO _{2peak}	SMD:0.55(0.18,0.92)	Moderate	0.003	52.9%	Very low
			6(229)			PCS	SMD:0.46(0.20,0.73)	Small	<0.001	1.90%	Low
			5(193)			MCS	SMD:0.23(-0.05,0.52)	Small	0.109	0.0%	Low
Zhang (2021)	RCT	HD	8(299)	RT	Intradialytic	6MWT	SMD:0.52(0.28,0.75)	Moderate	<0.001	18.7%	Very low
			5(164)			STS 30	SMD:0.42(0.11,0.74)	Small	0.008	0.0%	Very low

			6(300)			HGS	SMD:0.35(0.12,0.58)	Small	0.003	41.6%	Very low
			7(297)			PCS	SMD:0.23(-0.00,0.46)	Small	0.055	0.0%	Very low
			7(297)			MCS	SMD:0.13(-0.10,0.36)	Small	0.082	46.5%	Very low
Pu (2019)	RCT	HD	10(301)	Mixed	Intradialytic	Kt/V	SMD:0.29(0.06,0.52)	Small	0.01	0.0%	Very low
			10(400)			VO _{2peak}	SMD:0.57(0.23,0.90)	Moderate	<0.001	59.0%	Low
			7(219)			6MWT	SMD:0.57(0.30,0.84)	Moderate	<0.001	0.0%	Low
			10(320)			PCS	SMD:0.57(0.14,1.01)	Moderate	0.01	70.0%	Very low
			8(219)			MCS	SMD:0.19(-0.09,0.46)	Small	0.18	30.0%	Low
			7(287)			SBP	SMD:-0.28(-0.52,-0.05)	Small	0.02	0.0%	Very low
			7(287)			DBP	SMD:-0.32(-0.55,-0.08)	Small	0.008	42.0%	Very low
Yamamoto (2021)	RCT	Predialysis	10(392)	AE	-	SBP	SMD:-0.75(-1.24,-0.26)	Moderate	0.003	80.3%	Very low
			10(365)			VO _{2peak}	SMD:0.54(0.29,0.78)	Moderate	<0.001	24.6%	Very low
			10(414)			BMI	SMD:-0.19(-0.38,-0.00)	Small	0.026	0.0%	Low
Thompson (2019)	RCT	Predialysis	10(335)	Mixed	-	SBP	MD:-4.3(-9.0,0.4)	-	N.P.	50.4%	Very low
			8(303)			DBP	MD:-1.18(-4.76,2.40)	-	N.P.	60.5%	Very low
Yang (2017)	RCT	Mixed	4(150)	Mixed	-	VO _{2peak}	SMD:0.33(0.03,0.63)	Small	0.003	47.0%	Low
Clarkson (2019)	RCT	Dialysis	18(744)	Mixed	-	6MWT	MD:33.64(23.74,43.54)	-	<0.001	0.0%	Moderate
Zhao (2019)	RCT	Dialysis	3(141)	Mixed	-	Fatigue	SMD:-0.97(-1.32,-0.62)	Large	<0.001	47.0%	Low
			5(186)			PCS	SMD:0.31(0.02,0.61)	Small	0.04	46.0%	Low
			5(186)			MCS	SMD:0.30(-0.20,0.80)	Small	0.24	64.0%	Very low
Zhang (2019)	RCT	Predialysis	14(463)	Mixed	-	SBP	SMD:-0.41(-0.70,-0.11)	Small	0.007	55.0%	Moderate
			12(399)			DBP	SMD:-0.31(-0.71,0.08)	Small	0.12	70.0%	Low
			13(466)			BMI	SMD:-0.21(-0.39,-0.03)	Small	0.02	0.0%	Moderate

Huang (2019)	RCT	HD	8(257)	Mixed	-	Kt/V	SMD:0.19(-0.06,0.43)	Small	0.14	0.0%	Very low
			7(260)			SBP	SMD:-0.17(-0.41,0.08)	Small	0.18	8.0%	Low
			7(260)			DBP	SMD:-0.23(-0.69,0.24)	Small	0.34	68.0%	Very low
			7(205)			6MWT	SMD:1.01(0.26,1.76)	Large	0.008	83.0%	Very low
			7(263)			PCS	SMD:0.34(0.09,0.59)	Small	0.007	27.0%	Low
			7(263)			MCS	SMD:0.27(0.02,0.51)	Small	0.03	0.0%	Low
			10(371)			VO _{2peak}	SMD:0.73(0.52,0.95)	Moderate	<0.001	71.0%	Low
Heiwe (2011)	RCT/quasi-RCT	Mixed	24(847)	Mixed	-	Aerobic capacity	SMD:-0.56(-0.70,-0.42)	Moderate	<0.001	12.0%	Moderate
			9(358)			Muscle strength	SMD:-0.52(-0.73,-0.31)	Moderate	<0.001	0.0%	Low
			7(191)			Walking capacity	SMD:-0.48(-0.79,-0.17)	Small	0.003	2.0%	Low
			9(347)			SBP	SMD:0.25(0.04,0.47)	Small	0.02	0.0%	Low
			11(419)			DBP	SMD:0.16(-0.04,0.36)	Small	0.11	40.0%	High
Heiwe (2014)	RCT	HD	21(374)	Mixed	-	Aerobic capacity	SMD:-0.80(-1.02,-0.58)	Large	<0.001	0.0%	Low
			10(212)			DBP	SMD:0.17(-0.16,0.49)	Small	0.3	45.0%	Low
			10(312)			SBP	SMD:0.04(-0.4,0.41)	Small	0.8	58.0%	Very low
			10(385)			Muscle strength	SMD:-0.56(-0.77,-0.35)	Moderate	<0.001	0.0%	Very low
			7(174)			Walking capacity	SMD:-0.33(-0.67,0.01)	Small	0.06	16.0%	Low
Matsuzawa (2017)	RCT	HD	18(582)	Mixed	-	VO _{2peak}	SMD:0.62(0.38,0.87)	Moderate	<0.001	49.0%	High
			10(326)			6MWT	SMD:0.58(0.24,0.93)	Moderate	<0.001	53.0%	Low
			9(281)			Muscle strength	SMD:0.94(0.67,1.21)	Large	<0.001	10.0%	Very low
			9(264)			PCS	SMD:0.53(0.52,0.82)	Moderate	<0.001	19.0%	Very low
			8(228)			MCS	SMD:0.14(-0.15,0.42)	Small	0.34	10.0%	Very low
Smart (2011)	RCT	HD	8(365)	Mixed	-	VO _{2peak}	SMD:0.75(0.39,1.11)	Moderate	<0.001	60.0%	Low
Bogataj	RCT	HD	19(571)	Mixed	-	6MWT	SMD:0.44(0.21,0.67)	Small	<0.001	49.6%	Very low

(2020)			20(504)			VO _{2peak}	SMD:0.58(0.32,0.85)	Moderate	<0.001	57.4%	Very low
			5(461)			STS 10	SMD:-0.55(-1.00,-0.09)	Moderate	0.019	71.6%	Very low
Sheng (2014)	RCT	HD	7(233)	Mixed	Intradialytic	Kt/V	SMD:0.27(0.01,0.53)	Small	0.040	0.0%	Very low
			7(310)			VO _{2peak}	SMD:0.53(0.30,0.76)	Moderate	<0.001	36.0%	Very low
			7(256)			PCS	SMD:0.30(0.05,0.55)	Small	0.02	39.5%	Very low
			5(167)			MCS	SMD:0.14(-0.16,0.43)	Small	0.37	14.8%	Very low
			4(146)			6MWT	SMD:0.58(0.23,0.93)	Moderate	<0.001	89.7%	Very low
			7(296)			DBP	SMD:-0.24(-0.47,-0.01)	Small	0.04	52.1%	Very low
			7(296)			SBP	SMD:-0.27(-0.50,-0.04)	Small	0.02	0.0%	Very low
			3(106)			STS 60	SMD:0.71(0.31,1.12)	Moderate	<0.001	0.0%	Very low
Neto (2018)	RCT	HD	10(394)	Mixed	Intradialytic	VO _{2peak}	SMD:0.60(0.15,1.04)	Moderate	0.008	76.0%	Very low
			7(187)			PCS	SMD:0.50(-0.19,1.18)	Moderate	0.16	62.0%	Very low
			7(185)			MCS	SMD:0.39(-0.19,0.98)	Small	0.19	50.0%	Very low
			6(158)			6MWT	SMD:0.96(0.11,1.80)	Large	0.03	82.0%	Very low
			9(250)			Muscle strength	SMD:0.61(0.39,0.83)	Moderate	<0.001	58.9%	Very low
Ferrari (2019)	RCT	HD	12(370)	AE	Intradialytic	Kt/V	MD:0.08(0,0.15)	-	0.04	56.0%	Low
			6(220)	RT		Kt/V	MD:0.1(0,0.2)	-	0.06	6.0%	Very low
			5(201)	COM		VO _{2peak}	MD:5.41(4.03,6.79)	-	<0.001	0.0%	Low
			7(248)	AE		VO _{2peak}	MD:2.07(0.42,3.72)	-	<0.001	0.0%	Very low
			6(211)	RT		6MWT	MD:68.5(29.05,107.96)	-	<0.001	36.0%	Low
			6(188)	AE		6MWT	MD:64.98(43.86,86.11)	-	<0.001	0.0%	Low
			10(332)	AE		SBP	MD:-10.07(16.35,-3.78)	-	0.002	44.0%	Low
			10(334)	AE		DBP	MD:-2.96(-7.71,1.78)	-	0.22	0.0%	Low
Wyngaert (2018)	RCT	Predialysis	8(269)	AE	-	SBP	SMD:0.08(-0.58,0.74)	Small	0.81	84%	Very low
			7(237)	AE		DBP	SMD:-0.09(-0.78,0.59)	Small	0.79	83%	Very low

			11(325)			VO _{2peak}	SMD:0.99(0.49,1.48)	Large	<0.001	74.0%	Very low
			9(294)			BMI	SMD:-0.36(-0.60,-0.13)	Small	0.002	48.0%	Low
Oguch (2018)	RCT	KTRs	4(182)	Mixed	-	VO _{2peak}	SMD:0.38(-0.06,0.82)	Small	0.09	45.0%	Low
			4(179)			HRQoL	SMD:0.54(0.02,1.07)	Moderate	0.04	58.0%	Very low
Ju (2020)	RCT		3 (115)	Mixed	-	HGS	SMD:0.52(0.14,0.89)	Moderate	0.007	0.0%	Very low
			3 (387)			Symptom/problem (KDQoL)	SMD:1.92(-1.06,4.90)	Large	0.21	99.0%	Very low
			3 (387)			Effects of kidney disease (KDQoL)	SMD:-3.69(-8.56,1.19)	Large	0.14	99.0%	Very low
			3 (387)			Burden of kidney disease (KDQoL)	SMD:1.04 (-0.75,2.82)	Large	0.26	98.0%	Very low

Abbreviation: RCT = randomized controlled trial; AE = aerobic exercise; RT = resistance training; COM = combine; VO_{2peak} = peak oxygen uptake; HRQoL = health-related quality of life; DBP = diastolic blood pressure; SBP = systolic blood pressure; PCS = physical component summary; MCS = mental component summary; 6MWT = 6 minutes walk test; STS 10 = sit to stand 10 test; STS 30 = sit to stand 30 test; STS 60 = sit to stand 60 test; TUGT = timed up and go test; RLS = Restless Legs Syndrome; BMI = body mass index; SMD = standardized mean difference; MD = mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; SF-36 = short form-36; KDQoL = kidney disease quality of life; GRADE = Grading of Recommendations Assessment, Development, and Evaluation.

*Number of included studies and corresponding sample size.
Mixed means aerobic exercise combined with resistance training.

Supplementary Table S4 Results of the assessment of the methodological quality of the included meta-analyses using AMSTAR-2

Author	AMSTAR-2 Items																Score
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
Pei(2019)	√	×	√	○	√	√	×	√	√	×	√	×	×	×	√	×	53.1%
Ferreira(2019)	√	√	√	○	√	√	×	○	√	×	√	×	×	×	×	×	50.0%
Cheema(2014)	√	×	√	√	√	√	√	√	√	×	√	√	√	√	√	√	87.5%
Wu(2020)	√	√	√	○	√	√	×	√	√	×	√	√	√	√	√	√	84.4%
Nakamura(2020)	√	√	√	○	√	√	×	√	√	×	√	√	√	√	√	√	84.4%
Lu(2019)	√	×	√	○	√	×	×	○	○	×	√	×	×	×	√	√	46.9%
Chen(2019)	√	×	√	○	×	√	×	√	○	×	√	×	×	×	×	√	43.8%
Song(2018)	√	×	√	○	√	√	×	√	√	×	√	×	√	√	√	√	71.9%
Salhab(2021)	√	√	√	○	√	√	×	√	×	×	√	×	×	√	×	×	53.1%
Andrade(2019)	√	√	√	○	√	√	×	√	√	×	√	×	×	√	×	√	65.6%
Chung(2016)	√	×	√	○	√	√	√	√	√	×	√	√	√	√	√	×	78.1%
Zhang(2019)	√	×	√	○	√	√	×	√	√	×	√	×	√	√	√	×	65.6%
Pu(2019)	√	×	√	○	√	√	×	√	√	×	√	√	√	√	×	√	71.9%
Yamamoto(2021)	√	×	√	×	√	√	×	○	√	×	√	√	√	√	√	√	71.9%
Thompson(2019)	√	×	√	○	√	√	×	√	√	√	√	√	√	√	√	√	84.4%
Yang(2017)	√	×	√	○	√	√	×	○	√	×	√	√	√	√	√	√	75.0%
Clarkson(2019)	√	×	√	○	√	√	×	√	√	×	√	√	√	√	√	√	78.1%
Zhao(2019)	√	×	√	○	√	√	×	√	√	×	√	×	√	×	×	√	59.4%
Zhang(2019)	√	×	√	○	√	√	×	○	√	×	√	√	×	×	√	√	62.5%
Huang(2019)	√	√	√	○	√	√	×	√	√	×	√	√	×	×	√	√	71.9%
Heiwe(2011)	√	√	√	√	√	√	√	√	√	√	√	√	√	√	√	√	100.0%
Heiwe(2014)	√	√	√	○	√	√	√	√	√	×	√	×	√	√	×	√	78.1%

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Matsuzawa(2017)	√	√	√	○	√	√	×	√	√	×	√	×	×	√	√	√	71.9%
Smart(2011)	√	×	√	○	√	×	×	○	○	×	√	×	×	√	×	×	40.6%
Bogataj(2020)	√	×	√	○	√	×	×	√	√	×	√	√	×	√	×	√	59.4%
Sheng(2014)	√	×	√	○	√	√	√	√	√	×	√	×	×	√	√	×	65.6%
Neto(2018)	√	×	√	○	√	√	×	√	√	×	√	×	×	×	×	√	53.1%
Ferrari(2019)	√	√	√	○	√	√	√	√	√	×	√	√	√	√	√	√	90.6%
Wyngaert(2018)	√	√	√	○	√	√	×	√	√	×	√	√	√	√	√	√	84.4%
Oguchi(2018)	√	√	√	○	√	√	×	√	√	×	√	√	√	×	√	×	71.9%
Ju(2020)	√	×	√	○	×	×	×	√	√	×	√	×	×	×	×	×	34.4%

√ mean yes; ○ mean partial yes; ×mean no.

1. Did the research questions and inclusion criteria for the review include the components of PICO? 2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? 3. Did the review authors explain their selection of the study designs for inclusion in the review? 4. Did the review authors use a comprehensive literature search strategy? 5. Did the review authors perform study selection in duplicate? 6. Did the review authors perform data extraction in duplicate? 7. Did the review authors provide a list of excluded studies and justify the exclusions? 8. Did the review authors describe the included studies in adequate detail? 9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? 10. Did the review authors report on the sources of funding for the studies included in the review? 11. If meta-analysis was performed did the review authors use appropriate methods for statistical combination of results? 12. If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? 13. Did the review authors account for RoB in individual studies when interpreting/ discussing the results of the review? 14. Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? 15. If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? 16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?

Supplementary Table S5: Results of the assessment of the quality of evidence for each outcome of the included meta-analyses using GRADE

Author	Outcome	GRADE items					Quality of the evidence
		Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	
Pei (2019)	VO _{2peak}	Very serious (-2)	Neutral	Neutral	Neutral	Neutral	Moderate
	STS 60	Serious (-1)	Very serious (-2)	Neutral	Neutral	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Neutral	Serious (-1)	Very low
	SBP	Serious (-1)	Neutral	Neutral	Neutral	Not reported (-1)	Moderate
	DBP	Serious (-1)	Neutral	Neutral	Neutral	Not reported (-1)	Moderate
	Physical function (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	Physical role (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	Social function (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	Pain (SF-36)	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	General health (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
Mental health (SF-36)	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low	
Ferreira (2019)	Kt/V	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
Cheema (2014)	Muscle Strength	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	HRQoL	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Wu (2020)	SBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low

Nakamura (2020)	VO _{2peak}	Neutral	Serious (-1)	Neutral	Neutral	Serious (-1)	Moderate
	Muscle Strength	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Neutral	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	TUGT	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Lu (2019)	6MWT	Neutral	Neutral	Neutral	Serious (-1)	Neutral	Moderate
	STS 10	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	HGS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	Muscle strength	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	STS 30	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Chen (2019)	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	BMI	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Song (2018)	RLS	Serious (-1)	Serious (-1)	Neutral	Very serious (-2)	Serious (-1)	Very low
	Fatigue	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Salhab (2019)	PCS	Not reported (-1)	Serious (-1)	Neutral	Very serious (-2)	Serious (-1)	Very low
	MCS	Not reported (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Andrade (2019)	VO _{2peak}	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Chung (2019)	6MWT	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	VO _{2peak}	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	MCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
Zhang (2021)	6MWT	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	STS 30	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low

	HGS	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Pu (2019)	Kt/V	Serious (-1)	Neutral	Neutral	Serious (-1)	Not reported (-1)	Very low
	VO _{2peak}	Neutral	Serious (-1)	Neutral	Neutral	Not reported (-1)	Moderate
	6MWT	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	PCS	Neutral	Serious (-1)	Neutral	Serious (-1)	Not reported (-1)	Very low
	MCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Moderate
	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Yamamoto (2021)	SBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Very serious (-2)	Neutral	Neutral	Serious (-1)	Neutral	Very low
	BMI	Very serious (-2)	Neutral	Neutral	Neutral	Neutral	Low
Thompson (2019)	SBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Very serious (-2)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Yang (2017)	VO _{2peak}	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
Clarkson (2019)	6MWT	Neutral	Neutral	Neutral	Neutral	Serious (-1)	Moderate
Zhao (2019)	Fatigue	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	PCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	MCS	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Zhang (2019)	SBP	Neutral	Serious (-1)	Neutral	Neutral	Neutral	Moderate
	DBP	Neutral	Serious (-1)	Neutral	Serious (-1)	Neutral	Low
	BMI	Serious (-1)	Neutral	Neutral	Neutral	Neutral	Moderate

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Huang (2019)	Kt/V	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	SBP	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	DBP	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	MCS	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	VO _{2peak}	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
Heiwe (2011)	Aerobic capacity	Neutral	Neutral	Neutral	Neutral	Serious (-1)	Moderate
	Muscle strength	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	Walking capacity	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	SBP	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	DBP	Neutral	Neutral	Neutral	Neutral	Neutral	High
Heiwe (2014)	Aerobic capacity	Neutral	Neutral	Neutral	Serious (-1)	Not reported (-1)	Low
	DBP	Neutral	Neutral	Neutral	Serious (-1)	Not reported (-1)	Low
	SBP	Neutral	Serious (-1)	Neutral	Serious (-1)	Not reported (-1)	Very low
	Muscle strength	Serious (-1)	Neutral	Neutral	Serious (-1)	Not reported (-1)	Very low
	Walking capacity	Neutral	Neutral	Neutral	Serious (-1)	Not reported (-1)	Low
Matsuzawa (2017)	VO _{2peak}	Neutral	Neutral	Neutral	Neutral	Neutral	High
	6MWT	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Neutral	Very low
	Muscle strength	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Smart (2011)	VO _{2peak}	Neutral	Serious (-1)	Neutral	Neutral	Serious (-1)	Low
Bogataj	6MWT	Serious (-1)	Serious (-1)	Neutral	Not reported (-1)	Not reported (-1)	Very low

(2020)	VO _{2peak}	Very serious (-2)	Serious (-1)	Neutral	Not reported (-1)	Not reported (-1)	Very low
	STS 10	Neutral	Serious (-1)	Neutral	Not reported (-1)	Serious (-1)	Very low
Sheng (2014)	Kt/V	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	PCS	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
	DBP	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
Neto (2018)	STS60	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak}	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
	PCS	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	MCS	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low
Ferrari (2019)	Muscle strength	Neutral	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
	Kt/V (AE)	Neutral	Serious (-1)	Neutral	Serious (-1)	Neutral	Low
	Kt/V (RT)	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	VO _{2peak} (COM)	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	VO _{2peak} (AE)	Serious (-1)	Neutral	Neutral	Serious (-1)	Serious (-1)	Very low
	6MWT (RT)	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	6MWT(AE)	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	SBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
Wyngaert (2018)	DBP	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
	SBP	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Wyngaert (2018)	DBP	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Serious (-1)	Very low


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	VO _{2peak}	Serious (-1)	Very serious (-2)	Neutral	Serious (-1)	Neutral	Very low
	BMI	Serious (-1)	Neutral	Neutral	Serious (-1)	Neutral	Low
Oguchi (2018)	VO _{2peak}	Neutral	Neutral	Neutral	Serious (-1)	Serious (-1)	Low
	HRQoL	Serious (-1)	Serious (-1)	Neutral	Serious (-1)	Serious (-1)	Very low
Ju (2020)	HGS	Very serious (-2)	Neutral	Neutral	Serious (-1)	Neutral	Very low
	Symptom/problem (KDQoL)	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
	effects of kidney disease (KDQoL)	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low
	burden of kidney disease (KDQoL)	Very serious (-2)	Very serious (-2)	Neutral	Serious (-1)	Not reported (-1)	Very low

Abbreviation: AE = aerobic exercise; RT = resistance training; COM = combine; VO_{2peak} = peak oxygen uptake; HRQoL = health-related quality of life; DBP = diastolic blood pressure; SBP = systolic blood pressure; PCS = physical component summary; MCS = mental component summary; 6MWT = 6 minutes walk test; STS 10 = sit to stand 10 test; STS 30 = sit to stand 30 test; STS 60 = sit to stand 60 test; TUGT = timed up and go test; BMI = body mass index; SMD = standardized mean difference; HD = hemodialysis; KTRs = kidney transplant recipients; SF-36 = short form-36; KDQoL = kidney disease quality of life;

Very serious mean the included studies existed two or more high risk of bias in terms of randomization, blinding, allocation concealment, completeness of result data, or selective reporting, or $75\% \leq I^2 \leq 100\%$.

Serious mean the included studies existed two or more high risk of bias in terms of randomization, blinding, allocation concealment, completeness of result data, or selective reporting, or $50\% \leq I^2 < 75\%$, or the included study sample size < 400, asymmetric funnel plot or less than 9 studies included.



Supplemental Figures S1

peer review only



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page 4-5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Page 4
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page 5
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 5
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page 4-5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 5
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page 5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page 5-6
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Page 4-5
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page 5
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	None
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Not applicable
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	None
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	None
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	None
Certainty	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page 6



PRISMA 2020 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Location where item is reported
assessment			
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 6
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Page 6
Study characteristics	17	Cite each included study and present its characteristics.	Page 6
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Page 6
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Page 18-32
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Not applicable
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Not applicable
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Not applicable
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	None
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Page 6
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Page 6
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 10
	23b	Discuss any limitations of the evidence included in the review.	Page 12
	23c	Discuss any limitations of the review processes used.	Page 12
	23d	Discuss implications of the results for practice, policy, and future research.	None
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 2
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 2
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	None
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 1
Competing interests	26	Declare any competing interests of review authors.	Page 1
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	Page 1



PRISMA 2020 Checklist

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

For peer review only